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Abstract  
The family of Triggering Receptors Expressed on Myeloid Cells (TREM) contain 
novel activating receptors of the Ig super-family that are expressed on myeloid cells.  
TREM-1 is a transmembrane glycoprotein expressed on blood neutrophils and a 
subset of monocytes, but not on lymphocytes or other cell types and is upregulated by 
bacterial and fungal products. TREM-1 signaling potentiates the outcome of Toll-like 
Receptor (TLR) signaling. Blockade of TREM-1 prevents experimentally induced 
septic shock. In addition to the membrane-bound form, a soluble TREM-1 molecule 
(sTREM-1) exists that regulates membrane bound TREM-1 by competing against the, 
as yet, unknown natural TREM-1 ligand. sTREM-1 is detected at high levels during 
bacterial infection and asthma and is used as a predictive biomarker for severe 
inflammation. TREM-2 on, the other hand is not known to be secreted and the 
membrane bound form is reported to prevent TLR signaling and promote 
osteoclastogenesis.  The expression and function of TREM proteins during respiratory 
viral infection is not currently known.   
 
In this thesis we investigate the hypothesis that TREM-1 signaling contributes to 
excessive cytokine production during pulmonary viral infection in a murine model 
and that soluble TREM-1 and membrane bound TREM-2 proteins are anti-
inflammatory.  We show, for the first time, the following novel mechanisms that 
significantly increase our understanding of this important receptor family: 1) TREM-1 
is highly up-regulated during influenza and the subsequent release of sTREM-1 likely 
contributes to secondary bacterial super-infection, 2) Blockade of TREM-1 at the 
onset of viral infection significantly reduces the risk of secondary bacterial 
pneumonia and 3) TREM-2 expressing macrophages that appear during the resolution 
of influenza-induced inflammation display a regulatory phenotype that can reduce 
TLR responsiveness of inflammatory macrophages. Taken together, our data suggests 
that TREM-1 proteins represent a novel therapeutic target for the alleviation of 
influenza-induced pathology and that TREM-2 expression identifies a novel 
population of regulatory macrophages. 
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1. Introduction 
1.1 Influenza 
1.1.1 Epidemiology of influenza infection 
Influenza infection is an acute respiratory disease that is one of the most persistent 
and important infectious diseases to have afflicted mankind throughout the ages. This 
extremely variable virus is highly contagious and is an omnipresent threat to the 
population, regardless of age or gender. Influenza is a global dilemma inducing 
seasonal epidemics that can affect 10 to 20% of the population with ensuing 
morbidity and mortality. The worst 1918 Spanish influenza pandemic killed between 
20 and 40 million people and infected approximately half of the world’s population. 
 
The most recent influenza pandemic ‘swine flu’ started in early April 2009. A new 
influenza A (H1N1) virus emerged in California and Mexico, quickly spreading 
worldwide through human-to-human transmission (Scalera et al., 2009). According to 
data from the Centers for Disease Control and Prevention (CDC), the virus had 
infected at least 1 million individuals as of August 2009 (Finelli et al., 2009). By 
October 2009, 99% of circulating influenza viruses in the United States were H1N1. 
The trivalent seasonal influenza vaccines used in American do not provide protective 
immunity against the H1N1 virus (Zhu et al., 2009). In general, the pandemic H1N1 
develops as a mild infection primarily in children and young adults (Dunning et al., 
2010).  Initially the hospitalisation rates were 2-8 % but later moderated to 
approximately 1% in view of under-ascertainment of mild cases (Gilsdorf  et al., 2009 
and Jain S et al., 2009). The majority of pandemic influenza victims included 
children, younger adults, patients with underlying chronic lung conditions and 
pregnant women (Kwan-Gett et al., 2009). Both uncontrolled viral replication and an 
excessive host immune response may determinate the outcome (Dunning et al., 2010) 
 
1.1.2 Classification and structure 
Influenza virus is a member of the family Orthomyxoviridae, and can be classified 
into three genera, namely types A, B and C (Stephenson et al., 2002). Influenza A is 
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acknowledged to be the most prominent and severe, being responsible for the seasonal 
epidemics and the devastating pandemics that sporadically afflict mankind (Simonsen 
et al., 1998). Influenza B and C are not recognised to present the same threat as type 
A (Hilleman et al., 2002).  
Influenza is an enveloped, negative stranded RNA virus that is approximately 80-
120nm in size (Hilleman et al., 2002) (Fig 1.1). The outer envelope comprises of a 
lipid bilayer from which hemagglutinin (HA) and neuraminidase (NA) glycoproteins 
project. These outer membrane proteins are functionally essential to the viability and 
replication of the influenza virion. The HA protein is fundamental for binding and 
subsequent fusion to the host cell, whereas the NA protein fulfils a critical role in 
preventing viral aggregation and aiding release of viral particles from the host cell 
post-replication. NA has also been implicated in aiding the transport of the virion 
through the respiratory tract (Hilleman et al., 2002).  
 
Positioned within the viral envelope exists the matrix protein M1, which interacts 
with both the cell genome and the nuclear export factor and facilitates viral assembly 
(Lamb et al., 1996). Also located within the envelope is viral protein M2, which 
Figure 1.1 The structure of Influenza 
The exterior of the virus is composed of a lipid (fat) envelope covered with two 
types of protein molecules called surface antigens. The spikes are known as 
hemagglutinin (HA) and the mushrooms are known as neuraminidase (NA). Each 
hemagglutinin spike is made up of three entwined molecules while each 
neuraminidase mushroom is comprised of four entwined molecules.  
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forms an ion channel between the interior of the viral particle and its immediate 
environment, dictating the localised pH. Maintenance of a low pH is mandatory for 
several viral activities, such as HA synthesis and virion uncoating. The RNA genome 
of influenza consists of 8-segmented genes, containing the genetic information for 
expression of 10 viral proteins, each encased by nucleoprotein (NP) (Stephenson et 
al., 2002). In addition to the viral proteins already discussed, a further 3 proteins 
(PB2-, PB1- and PA-encoded proteins) form a transcriptase complex and there are 2 
non-structural proteins, NS1 and NEP, that govern post-transcription RNA control 
and viral assembly, respectively.  
1.1.3 Antigenic diversity of influenza: Antigenic drift and shift 
Influenza A is responsible for extensive illness in humans owing to the considerable 
antigenic variability that it displays enabling it to successfully evade the host’s 
neutralizing antibody repertoire. As discussed, influenza A expresses HA and NA on 
its surface. These glycoproteins are subject to extensive antigenic variation that is 
important for immune evasion and it is changes in these surface glycoproteins that are 
largely responsible for the observed epidemics and pandemics. There are to date at 
least 15 haemagglutinin subtypes and 9 neuraminidase subtypes. Widely circulating 
influenza strains within the human populace are restricted to 3 HA subtypes (H1-3) 
and 2 NA (N1-2), with the remaining subtypes being seen in viruses that persist 
within avian reservoirs.   
The antigenic variability that occurs within the influenza genome takes two forms: 
antigenic drift and antigenic shift. Antigenic drift occurs when genes encoding the 
surface glycoproteins undergo stepwise mutation, owing to the relatively low fidelity 
of the influenza RNA-specific RNA polymerase which lacks proof reading 5’-3’ 
exonuclease activity. These mutations may lead to attenuated or non viable influenza, 
but some may provide a survival advantage, which will be selected for and expand. If 
the surface glycoproteins are sufficiently different that the host’s antibodies are 
incapable of neutralizing it then the new strain is capable of causing disease, and 
frequently the observed seasonal epidemics. 
Antigenic shift is a far less frequent form of antigenic change but can lead to the 
devastating pandemics that occasionally plague mankind. Antigenic shift occurs when 
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two different viruses from distinct host’s co-infect a single host and exchange genetic 
information. The ensuing reassortment of viral genome segments results in a new 
virus that possesses elements from each of the two original strains. Again the resulting 
virus may be attenuated or non-viable, but it may also be highly virulent and 
potentially pathogenic due to expression of novel surface proteins derived from the 
animal host virus. In this scenario, the human host may possess little or no immunity 
to the novel surface proteins and the new variant can cause widespread disease 
through evasion of the host’s immune response.  
 
1.1.4 Replication cycle 
Transmission of influenza between individuals is via virus laden liquid droplets that 
are expelled when the infected patient coughs or sneezes (Julkunen et al., 2000). The 
primary sites of infection of the infective virions are the epithelial cells of the upper 
respiratory tract, but influenza also possesses a propensity for invading macrophages 
and other leukocytes within this localised area (Ronni et al., 1997). The virus has the 
potential to invade any cell that possesses a suitable receptor, notably those 
expressing a sialic acid containing cell surface glycoprotein. As previously discussed, 
attachment and fusion to the host cell is mediated through HA. HA exists as a native 
precursor termed HA0, which attaches the virion to cell surface receptors containing 
sialic acid, and is subsequently cleaved through the action of extracellular host 
proteases to yield HA1 and HA2 (Steinhauer et al., 2001). The virion is subsequently 
endocytosed to form an endosome with HA2 mediating the union between virus 
membrane and host cell. The low pH of the endosome induces a conformational 
change in the HA2 protein, culminating in enhanced proximity of viral and host cell 
membranes, and ultimately the fusion event (Lamb et al., 1996). Fusion subsequently 
leads to the liberation and nuclear import of viral nucleocapsids, which contains the 
crucial genetic code that dictates the amplification and generation of substantial viral 
progeny (Fig 1.2). 
The viral RNA genome, once translocated to the host nucleus, is transcribed by viral 
RNA polymerases resulting in the synthesis of viral mRNAs. The mRNAs are 
subsequently transported to the cytoplasm of the host cell where they are translated to 
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yield viral nucleoproteins and polymerases. The newly generated viral proteins are 
then re-directed towards the host nucleus where they assist in viral replication and 
further mRNA synthesis. This positive feedback loop greatly amplifies the quantity of 
viral RNA and proteins, which are subsequently packaged to form viral nucleocapsids 
that are exported from the nucleus before budding from the host plasma membrane to 
form active virions (Julkunen et al., 2000). Hence the virus envelope is derived from 
host cell plasma membrane. 
 
 
Figure 1.2 Influenza virus replication cycle.  
The virus is endocytosed after initial binding of the HA to host cell sialic acid 
receptors. Acidification of the cleaved HA facilitates approximation of viral and 
endosomal membranes and release of RNP. Transcription follows importation of 
RNPs into the nucleus. Assembly occurs at the apical surface of the host cell 
where budding and release occur. 
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1.1.5 Influenza driven pathology and susceptibility to a secondary 
bacterial infection  
Influenza is highly cytopathic virus and induces extensive tissue damage at the site of 
infection, with submucosal oedema and shedding of epithelial cells. It directly causes 
an alteration of tissue architecture following infection, with extensive cell death via 
cytolysis and apoptosis. Influenza is capable of subverting host cell function by 
suppressing host gene transcription and protein synthesis, whilst promoting viral 
replication and production of virion particles (Julkunen et al., 2001). Influenza can 
also induce apoptosis of the invaded host cells, with virion proteins such as NA and 
NS1 implicated in the regulation of the apoptotic program. 
 
Influenza infection induces a potent pro-inflammatory response, with an abundance of 
cytokines and chemokines being released from epithelial cells and leukocytes. The 
release of these soluble mediators is fundamental to the control and resolution of 
influenza infection, but also contributes to clinical and pathological manifestations. 
Mediators induced by influenza infection and correlated with increased illness and 
disease inducible TNF, IL-6, IL-8, IL-1α, IL-1β, IFN-α, and various chemokines such 
as MIP-1α (Hussell et al., 2001; Kozak et al., 1997 and Cook et al., 1995). The use of 
a neutralising antibody to TNF in a murine model of influenza induced pneumonia 
culminated in a significant reduction in lung pathology and prolonged survival 
(Hussell et al., 2001). Similar investigations with anti-serum injection have defined 
IFN-α and IL-1α as important mediators of the influenza induced fever (Kurokawa et 
al., 1996). Influenza infected IL-1β and IL-6 knock out mice fail to display the same 
elevation in body temperature (Kozak et al., 1995 and Kozak et al., 1997) and MIP-
1α knock out mice possess reduced mononuclear infiltrate and pulmonary edema 
(Cook et al., 1995).  
 
Both macrophages and neutrophils are recruited during influenza infection. Upon 
activation, they produce highly reactive superoxide species, cause extensive damage 
to lung epithelial cells and may in extremes lead to respiratory failure and death 
(Hoshino T et al., 2008). Treatment with superoxide dismutase (SOD), which breaks 
down superoxide, improves lung pathology and reduces lethality in influenza induced 
pneumonia (Suliman et al., 2001). Despite the fact that an efficient T cell response is 
  Chapter 1: Introduction 
27 
crucial to the resolution of many viral infections, over-exuberance leads to 
immunopathology, airway occlusion and significant injury to alveoli epithelia. 
Furthermore the substantial accumulation of both CD4+ and CD8+ T cells in the 
alveolar spaces and / or the interstitium, impedes efficient oxygen transfer and 
compromises lung function. 
 
All these influenza-induced effects may provide an advantage for the invasion of 
secondary pathogens. This idea is supported by data from the influenza pandemics of 
1918, 1957, and 1968, which suggests that most deaths during these periods probably 
resulted from secondary bacterial pneumonia (Morens et al., 2008). Secondary 
bacterial infections have been found in 4–24% of 2009 pandemic H1N1 patients 
(Louie et al., 2009 and Kumar et al., 2009) where Streptococcus pneumoniae, 
Staphtococcus aureus and Haemophilus influenzae are the most common (Seki et al., 
2007). Both in adults and children, influenza-bacterial co-infections are associated 
with severe pneumonia and raised mortality (Finelli L et al., 2008 and Reed et al., 
2009). Potential mechanisms for the increased susceptibility to post-influenza 
bacterial pneumonia are upregulation of adhesion molecules in respiratory epithelium, 
which provides benefit for bacterial adherence and invasion (McCullers et al., 2002); 
and the immunosuppressive microenvironment caused by influenza which allow 
outgrowth of bacterial (Speshock et al., 2007). Furthermore, resolution of 
inflammation can sometimes result in the innate immune response in the lung more 
suppressed than pre-infection state. (Hussell et al., 2009 and Snelgrove et al., 2008)  
 
1.2 Innate and Adaptive Immunity to Respiratory Infections 
The primary line of defence to micro-organisms entering the respiratory tract is the 
innate immune system. Pattern recognition receptors (PRRs) recognize microbe-
associated molecular patterns (MAMPs), as well as endogenous danger signals (e.g. 
microbial nucleic acids or components of, bacterial cell walls, extracellular ATP) that 
provide a fast but non-specific response to fight against foreign pathogens. 
Consequently, anti-microbial products are upregulated together with induced 
apoptosis of infected cells. PRR engagements result in the elevated production of 
cytokines and chemokines, which attract and activate cytotoxic effector cells, and 
antigen-presenting cells (APCs). The APCs subsequently initiate the pathogen 
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specific, adaptive immune response to effectively eliminate the pathogen and resolve 
infection.  
 
1.2.1 Pathogen recognition receptors: Toll like receptors (TLRs)  
PRRs are a family of cell surface and intracellular receptors, which recognise 
pathogens directly to initiate signalling cascades that culminate in an ‘appropriate’ 
innate immune response. Each PRR has the ability to detect a broad specificity of 
ligands that have a common structural motif or MAMPs, such as the regular patterns 
of lipids, matrix proteins, unmethylated dinucleotides, double stranded RNA or 
complex carbohydrates. These MAMPs are present on or within micro-organisms, but 
absent from host cells.  
 
Toll receptors were first identified in Drosophila and recognized fungal products 
during embryo dorsal–ventral polarity formation (Belvin et al., 1996). Toll-like 
receptors (TLR) in mammalian species was discovered later and the initial studies 
revealed TLR4 as a receptor for lipopolysaccharide (LPS) of Gram-negative bacteria 
in mice (Poltorak et al., 1998). There are 13 recognized extracellular and intracellular 
TLR receptors namely TLR 1 through 13 (Table 1.1). All of them are transmembrane 
receptors and expressed in various cellular compartment of immune cells like 
neutrophils, monocytes, macrophages, dendritic cells (Chang et al., 2008), NK cells 
(Smyth et al., 2006), T and B cells (Liu et al., 2010) as well endothelial cells (Fitzner 
et al., 2008), epithelial cells (Palladino et al., 2008), skin keratinocytes (Kurokawa et 
al., 2009), fibroblasts (Ospelt et al., 2010) and cancer cells (Szajnik et al., 2009). 
TLRs play an important role in the regulation of innate and adaptive immunity. 
 
The ligands for TLR are diverse and include cell wall components, bacterial genome 
DNA; viral, fungal and parasitic products; and synthetic analogs of natural products. 
Thus they can be used to recognize various pathogens to provoke inflammatory and 
innate effector responses and enhance adaptive immunity against pathogens (Inohara 
et al., 2005 and Meylan et al., 2006). In reality, the host is constantly exposed to TLR 
ligands and stress induced proteins especially at mucosal sites or lung and gut that if 
left unchecked, would result in chronic inflammation. TLR function and signalling 
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cascades are therefore tightly regulated during homeostasis and throughout ongoing 
innate inflammatory responses to limit host immunopathology.  
 
Based on the type of pathogens recognized, TLRs can be subdivided into two groups. 
One group recognizes PAMPs from extracellular pathogens and includes TLR1, 
TLR2, TLR4, and TLR6 found on the cell membrane that bind bacterial surface-
associated PAMPs. The second group recognizes PAMPs from intracellular pathogens 
and includes TLR3, TLR7, TLR8 and TLR9 detected intracellularly on endosomes 
and binds mainly to the nuclear acid PAMPs from viruses and bacteria. 
 
The activation of TLR signalling is triggered by ligation and receptor homo or hetero-
dimerization. TLR signalling cascades employ the myeloid differentiation factor 88 
(MyD88) and Toll/interleukin-1 receptor domain-containing protein (TIRAP) as 
adapter proteins to deliver signals (Fig 1.3). The Toll/interleukin-1 receptor (TIR) 
domains of MyD88 interact with TIR domain in the cytoplasmic tail of the activated 
TLR. This complex recruits and activates downstream kinases, such as IL-1 receptor 
associated kinases (IRAK) 1, 2 and 4 (O’Neill et al., 2009), leading to activation of 
tumour necrosis factor associated factor 6 (TRAF 6) through death domain 
interactions common to MyD88 and IRAKs. Subsequently, the activation of 
additional downstream kinases, including inhibitor of NF-κB (IκB) kinases (IKKs), 
results in the release of NF-κB from its inhibitory complex, allowing NF-κB to 
translocate to the nucleus and mediate inflammatory cytokine gene expression.  
 
Despite shared signalling adaptors between different TLRs, some specific adaptors 
are also utilised to organize pathogen specific immune responses. TRIF is only used 
by TLR3 and 4 to induce IFN-β synthesis through IRF-3 activation, a signalling 
pathway crucial for anti-viral immunity (Kawai et al., 2001 and Toshchakov et al., 
2002). Another example is in the TLR-4 pathway, where TRIF and TRAM adaptor 
proteins are used to activate IRF 3 (Beutler et al., 2006). Additional pathways also 
contribute to TLR function, such as Jun N terminal kinase (JNK) and the mitogen 
activated protein kinases (MAPKs) (Kumar et al., 2009). The detail mechanism of 
how TLR employ various combinations of adaptor signalling cascades to generate 
highly specific and complex immune response is a large filed of active investigation  
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TLRs Cell type expressed  Ligands 
TLR1 Myeloid cells, T and B cells, NK cells, 
endothelial cells, epithelial cells, 
keratinocytes 
Forms heterodimers with TLR2 for bacterial 
tri-acyl lipopeptide, OSP of Borrelia spp 
and other ligands 
TLR2 Myeloid cells, T cells, B cells, endothelial 
cells, epithelial cells, keratinocytes 
Peptidoglycan from Gram-positive bacteria, 
Mycoplasma lipopeptide LAM from 
Mycobacteria BCG, LTA, GXM and LPS  
TLR3 Myeloid cells, T cells, NK cells, endothelial 
cells, epithelial cells, keratinocytes, neurons 
Single-stranded viral RNA (ssRNA) and 
double-strand-RNA (dsRNA) 
TLR4 Myeloid cells, NK cells, mast cells, T cells, 
endothelial cells, epithelial cells, 
keratinocytes 
BCG, LPS, lipoteichoic acid, respiratory 
syncytial virus, fibronectin, heparin sulfate, 
fusion protein,  
TLR5 Myeloid cells, T cells, NK cells, endothelial 
cells, epithelial cells, keratinocytes 
Flagellin from Gram-positive or Gram-
negative bacteria 
TLR6 Myeloid cells, T cells, B cells, endothelial 
cells, epithelial cells, keratinocytes 
Mycoplasma di-acyl-lipopeptides, a 
peptidoglycan from Gram-positive bacteria 
and Zymosan from fungal cell wall 
TLR7 Myeloid cells, NK cells, endothelial cell, T 
cells, B cells 
ssRNA compounds, such as the 
imidazoquinolines 
TLR8 Myeloid cells, NK cells, endothelial cell  ssRNA 
TLR9 Myeloid cells, T and B cells, NK cells, 
endothelial and epithelial cells, 
keratinocytes  
Unmethylated CpG motifs found in 
microbial DNA 
TLR10 Myeloid cells, T and B cells, endothelial 
cell, epithelial cells 
Unknown, may interact with TLR2 
TLR11 macrophages, dendritic cells, and bladder 
epithelial cells 
component in the uropathogenic E. coli 
TLR12 Macrophages and bladder epithelial cells. Unknown 
TLR13 Macrophages and bladder epithelial cells. Unknown 
 
 
 
Table 1.1 Toll-like receptors (TLRs) and their principal ligands 
This table is derived from review (Lambiase et al., 2011). CpG cytidine-phosphate-
quannosine, GXM glucuronoxylomannan, HSP heat shock protein, LAM 
lipoarabinomannan, LPS lipopolysaccharide, LTA lipoteichoic acid, BCG Bacillus 
Calmette-Guerin, NK natural killer, OSP outer surface protein, HMGB1 high mobility 
group box1 
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Figure 1.3 TLR. The TLR signalling pathway 
TIRAP, toll-interleukin 1 receptor (TIR) domain containing adaptor protein; 
Myeloid differentiation primary response gene 88, MyD 88;  
IRAKM, IL1 receptor-associated kinase M; TOLLIP, Toll-interacting protein; 
TRIF, TIR-domain-containing adapter-inducing interferon-β; TRIF-related 
adaptor molecule, TRAM; TRAF, TNF receptor associated factor; TAK1,  
MAP3K transforming growth factor β activated kinase 1; JNK, c-jun kinase; AP-
1, activator protein 1 
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1.2.2. Regulation of TLR signalling in the immune system 
At mucosal surfaces, immune cells are continuously exposed to an array of TLR 
ligands. Thus, TLRs have to be inhibited to avoid breaking down immune 
homeostasis; which would lead to immunopathological conditions such as endotoxin 
shock and autoimmune responses (Foster et al., 2009). TLRs have regulatory 
mechanisms to control the timing, period and magnitude of its activation to generate 
sufficient immunity to eliminate pathogens and prevent overexuberant responses. 
Splice variants for adaptors or their related protein adaptors are involved in the 
negative regulation of TLRs (Carty et al., 2006). Alternatively spliced variants of both 
MyD88 and IRAK family members play a key role in negative feedback regulatory 
mechanisms (Janssens et al., 2002). Over expression studies of MyD88 short, an 
alternative spliced variant of MyD88 that lacks a domain critical for TLR and IRAK 4 
binding, inhibits IL-1 and LPS, but not TNF-α induced NF-κB activation (Janssens et 
al., 2002). 
Another inhibitory regulator is toll interacting protein (Tollip). This protein recruits to 
the TLR complex, by directly interacting with TLR2 and TLR4, preventing IRAK1 
phosphorylation, and inhibiting NF-κB activation (Zhang et al., 2002). Once 
phosphorylated, Tollop separates from the complex to overcome the negative 
regulation by Tollip. Tollip has a role in the naïve state of immune cells and to assist 
the termination of TLR-induced inflammation. A20 is another negative regulator 
induced by LPS stimulation in many cell types. Its enzymatic activity cleaves 
ubiquitin from TRAF 6, an essential modification for downstream signalling (Boone 
et al., 2004). A20-deficient mice develop spontaneous multiorgan inflammation and 
severe cachexia, highlighting the critical role of A20 in anti-inflammatory responses 
(Turer et al., 2008). As both pathways require TRAF 6, A20 can control both MyD88 
dependant and independent TLR signalling pathways. 
TLR signalling can be amplified or inhibited by other transmembrane proteins such as 
DAP12. Although DAP12 contains an immunoreceptor tyrosine-based activation 
motif (ITAM), it has been reported to deliver both positive and negative signalling, 
depending on the cooperating myeloid receptor found on macrophages and NK cells. 
Hamerman et aldescribe inhibition of proinflammatory cytokine responses to LPS, 
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CpG ODN and zymosan in macrophages (Hamerman et al., 2005); whilst Turnbull 
and colleagues indicate that DAP12 signaling augments lipopolysaccharide-mediated 
cytokine production (Turnbull et al., 2005). Finally, some cytokine receptors use 
MyD88 as part of their signalling pathway. IL-33 binds to ST2L on the surface of 
myeloid cell and recruits MyD88. It is possible that diversion of MyD88 airway from 
TLR contributes to the association of ST”L with Th1 cells and allergic response   
 
1.2.3 Macrophage subsets  
This thesis focuses predominantly macrophages that are essential cells of the innate 
immune system. In the respiratory tract of naïve mice, 95% airway cells are alveolar 
macrophages. They fulfil an important role in immune surveillance, recognizing 
invading pathogens and initiating microbicidal and inflammatory events necessary for 
the clearance of invading pathogens (Gordon et al., 2002). Alveolar macrophages have 
been reported to be derived both from precursors in peripheral blood (Matute-Bello et 
al. 2004) and from local proliferation (Sawyer et al., 1982; Bowden et al., 1984) and 
can be very long lived (Murphy et al., 2008).  
 
1.2.3.1 Alveolar macrophages  
Alveolar macrophages express an assortment of receptors that facilitate recognition 
and phagocytosis of microbial pathogens, such as Fc, complement, mannose receptor, 
Toll-like receptor and an array of scavenger receptors. Ingested pathogens are 
subsequently exposed to toxic mediators, such as reactive oxygen species (ROS) and 
proteases that can kill the engulfed micro-organism (Babior et al., 1999). Macrophages 
also secrete an array of other molecules that are anti-microbial including lysozyme, 
lactoferrin, and defensins which together confer resistance to an array of potential 
infective agents (Farnaud et al., 2003 and Oppenheim et al., 2003) 
 
At homeostasis states, the activity of macrophages is reduced by high levels of anti- 
inflammatory cytokines such as IL-10, produced by interstitial macrophages (Bonfield 
et al. 1995) or elevated expression of negative regulators, like CD200R in alveolar 
macrophages (Snelgrove et al., 2008).  
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Upon sufficient recognition of the pathogen, alveolar macrophages produce 
proinflammatory cytokines, such as IL-1β, IL-6, IL-8, IL-12, IFN-γ, and TNF-α, 
promoting inflammation and clearance of potential infections (Juarez et al., 2010). In 
addition, these cytokines enhance the secretion of chemokines and up-regulate 
adhesion molecules on the endothelia and epithelia, facilitating the recruitment of 
neutrophils and lymphocytes into the lung. Once the pathogen is eliminated, 
macrophages can also alter their phenotype to terminate inflammation.  
 
1.2.3.2. Classically and alternative activated macrophages  
The heterogeneity of macrophage is well recognized and each subset has a specific 
phenotype and function, Heterogeneity is influenced by microbial antigens, Th1 or 
Th2 effector T cells and their secretory cytokines (Elgert et al., 1998 and Munder et 
al., 1998). Dependent on the function and stimulus, macrophages can be classified as 
classically (M1) or alternatively (M2) activated macrophages.  Those in a type I 
cytokine environment (IFN-γ, TNF) or stimulated by microbial molecules (LPS, 
lipoproteins, dsRNA, lipoteichoic acid, etc) and endogenous “danger” signals (heat 
shock proteins), tend to become M1 macrophages. Upon activation, these 
macrophages produce elevated level of proinflammatory cytokines, such as TNF-α, 
IL-6, IL-12, but low level of IL-10 (Urban et al., 1986 and Verreck et al., 2004), and 
secrete reactive nitrogen and oxygen species (NO, peroxynitrite, hydrogen peroxide, 
superoxide). M1 macrophages play an important role in promoting inflammation, 
extracellular matrix destruction, and apoptosis (Bonnotte et al., 2001).  
 
Recent studies have found that stimulation with Th2 cytokines, especially IL-4 and 
IL-13, induce alternatively activation of macrophage (Gordon et al., 2003).  
Compared with M1 macrophages, M2 macrophage secrete less inflammatory 
cytokines and produce abundant amounts of anti-inflammatory molecules such as IL-
1 and TGF-β, thereby down-regulating inflammatory processes initiated by M1. This 
immunosuppressive effect is confirmed by studies shown that M2 can inhibit T-cell 
proliferation (Brys et al., 2005; Loke et al., 2000).  M2 macrophages are identified by 
secretion of Ym1 and RELM-α, the resistin-like secreted protein FIZZ1 and the 
growth factor IGF (insulin-like growth factor)-1, which play roles in repair and 
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healing, cell proliferation, and angiogenesis (Gordon et al., 2003). Consist with this, 
the M2 macrophage also produces the extracellular matrix (ECM) component 
fibronectin and TGF-β to induce the formation of ECM (Gratchev et al., 2001). 
Unlike M1 macrophage that produce reactive nitrogen by activating inducible nitric 
oxide synthase (iNOS), M2 macrophages induce the activity of arginase to generate l-
arginine to l-ornithine, l-proline, and polyamine to encourage fibroblast proliferation 
and collagen production (Gordon et al., 2003). Thus M2 macrophages are may play a 
crucial role in the repair of tissue damage and important to understand the underlying 
processes involved in the initiation and resolution of inflammatory processes (Naito et 
al. 1997 and Hume et al., 2008). 
 
1.2.4. Dendritic cells, neutrophils and NK cells 
Dendritic cells (DCs) are another important APC. They form a network in the 
submucosa of the nasopharynx, trachea and bronchial tree, where they constantly 
survey for invading pathogens or foreign material (Webb et al., 2005). These cell 
exhibit an enhanced capacity to present antigen as a result of their constitutive 
expression of several co-stimulatory molecules important in the activation of 
lymphocytes (Von Garnier et al., 2005). At the site of infection, naïve dendritic cells 
engulf and process pathogen for presentation, migrating to draining lymph nodes to 
present the epitopes to effector cells of the adaptive arm of the immune response 
(Lambrecht et al., 2001). 
 
Neutrophils are an essential component of the host’s armoury against many bacterial 
and other microbial infections of the lung. Neutrophils are recruited rapidly from the 
periphery to the site of infection in response to various stimuli, such as chemotactic 
proteins IL-8 and MIP-2 produced by lung macrophages and airway epithelial cells 
(Sibille et al., 1990 and Reynolds et al., 1983). Once at the infected site, neutrophils 
are activated by local pro-inflammatory cytokines. Neutrophils are strongly 
phagocytic and exhibit a higher propensity for ingesting and killing invading 
pathogens than macrophages (Papayannopoulos et al., 2009). They produce a number 
of pro-inflammatory cytokines such as TNF, IL-1, IL-6 and MIP-2, which augment 
and refine the response (Kumar et al., 2010). The infiltrations of neutrophils are 
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dominant within the affected areas of lungs following infection with highly 
pathogenic influenza (Narasaraju et al., 2009). The protective or pathogenic role of 
neutrophils during influenza infection is controversial with one study (Sakai et al., 
2000) showing their absence is beneficial but showing depletions increase lethality 
(Tate et al., 2009).  
 
Another important innate lymphocyte is the Natural Killer (NK) cell, which responds 
to a wide range of pathogens, including viruses, bacteria, and intracellular parasites 
(Yokoyama et al., 2004). Its killing activity was elevated shortly post influenza 
infection (Stein-Streilein et al., 1983) and the receptors expressed on NK cells, natural 
cytotoxicity receptors (NCR) NKp46 (NCR-1 in the mouse) and NKp44, are 
employed by NK cells to recognize hemagglutinins on various infected cells 
(Mandelboim et al., 2001 and Arnon  et al., 2001). After activation, NK cells exhibit 
enhanced cytotoxicity and production of inflammatory cytokines, such as IFNγ, 
TNFα, and MIP-1α (Tay et al., 1998 and Trinchieri et al., 1989). Depletion of NK 
cells by using GM1 or NK1.1 antibodies reveals its contribution to the control of 
influenza infection (Stein-Streilein et al., 1983 and Nogusa et al., 2008). This was 
consistent with study of the lethal case during H1N1 influenza outbreak, which 
reveals the impairment of NK cells response leading to uncontrolled viral spread and 
increased severity (Denney et al., 2010).  
 
1.2.5. Adaptive immunity against influenza 
This thesis is almost entirely related to innate immunity; however we will discuss 
adaptive immunity. To be able to resolve infection and develop pathogen-specific 
memory, an acquired specific immune response, comprising both cell mediated T cell, 
and humoral B cell, responses are established. Traditional CD4+ and CD8+ T cells 
recognize antigen Major Histocompatability Complex (MHC) complexes via a T cell 
receptor that possesses an α and a β chain.  
 
1.2.5.1. CD4 T cells 
CD4+ helper T cells exert their effector function primarily through the release of 
cytokines that activate and stimulate other cells. They also fulfil a significant role in 
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antibody production by providing a critical signal for B cell activation through the 
CD40-CD40L interaction. The T helper subset can be subdivided into two broad 
groups, namely Th1 and Th2, which are defined by the distinct cytokines expression 
profiles. Th1 derived cytokines (IL-2, IFN-, TNF- and GM-CSF) are responsible 
for predominantly cell-mediated immune responses to intracellular pathogens, 
whereas the Th2 (IL-4, IL-6, IL-10, IL-13 and IL-21) are important for antibody-
mediated humoral response that combats extracellular pathogens (Mosmann et al., 
1989 and Openshaw et al., 1995). In addition to Th1 and Th2 cells, another two CD4+ 
cell sub-populations Th17 and regulatory T cells (Tregs) were involved in regulation 
of the immune system response to viral infections. Th17 cells are characterized by the 
production of inflammatory cytokines such as IL-17, IL-21, and IL-26 (Brereton et 
al., 2011). Specifically, IL-21 was shown essential to maintain CD4+ and CD8+ T 
cell responses and efficient viral clearance during influenza infection (Heidi et al., 
2009). The generation and activity of Th17 were regulated by Treg cells, which are a 
subset of CD4+ T cells co-express CD25 and Foxp3 with naturally endowed immune-
suppressive activity (Rudensky et al., 2006 and Sakaguchi et al., 2008). This activity 
was generated by secretion and expression of various immune-suppressive molecules, 
which direct interacted with immune effector cells (Shevach et al., 2009). Recent data 
suggested that Treg cells can suppress innate immune-driven inflammation and 
influenza induced lung pathology in lymphocyte-deficient mice (Inês et al., 2010). 
CD4+ Th cells have a significant role in resolution of influenza infection, primarily 
via the delivery of signals to the main effectors. In addition to this role in the 
facilitation of humoral and cell mediated responses, they may also have a lesser role 
as cytolytic effectors (Hilleman et al., 2002).  
 
1.2.5.2. CD8 T cells 
Cytotoxic T cells are accomplished killers of infected and tumour cells, lysing 
infected cells via a perforin/granzyme dependent mechanism, which punches holes in 
the membrane of the cells or a Fas-dependent mechanism. In influenza infection, 
virus–specific CD8+ T-cells are amplified and activated at approximately day 3-4 
post infection (Hilleman et al., 2002). 2-3 days later, they migrate to the lungs and the 
infected airway epithelia, where they produce antiviral cytokines and lyse 
target/infected cells (Cerwenka et al., 1999). The target cells are recognized by CD8 
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cells through viral determinants such as conserved HA, NP and PB2 epitopes, 
subsequently lysed by exocytosis granules containing perforin and granzymes 
(Topham et al., 1997). All these data suggest that cytotoxic T cells confer a central 
role in resolution of viral infection via their cytopathic elimination of infected cells.  
 
1.2.5.3. NK T cells 
Natural Killer T (NKT) cells are a subset of T cells that are not restricted by classical 
MHC molecules. They produced excessive cytokines upon antigen recognition and 
share properties of both T cells and natural killer (NK) cells. The invariant NKT cells 
(iNKT) are characterized by the expression of an invariant T-cell receptor (TCR) α 
chain in combination with certain TCR-β chains (Matsuda et al., 2008). An elegant 
study by Ho et al demonstrates that invariant Natural killer T cells also contribute to 
influenza induced pathology (Ho et al., 2008). α-galactosylceramide is used to expand 
the NKT cells, which results in reduced viral titres in the lung and less influenza 
caused weight loss. During the early phase of infection, treated mice have a transient 
elevated innate immune response mediated by increased levels of cytokines (IL-12 
and IFN-c) and chemokines (MCP-1 and MIP-2). This is followed by fast resolution 
associated with enhanced levels of IL-4. This study supports the role of iNKT cells in 
viral clearance and resolving inflammation.   
 
1.3. TREMs 
1.3.1. The TREM family  
Triggering receptor expressed on myeloid cells (TREM) is a new family of receptors 
that is distantly related to NKp44 (Bouchon et al., 2000).  To data several family 
members have been identified and the cellular expression profile is show in Table 1.2. 
TREM-1 was first described in human monocytes and neutrophils (Bouchon et al., 
2000) and is highly evolutionarily conserved (Klesney-Tait et al., 2006) and its 
expression is upregulated by LPS stimulation (Li et al., 2011). The main role of 
TREM-1 is to amplify TLR mediated inflammatory responses.  In addition to the 
membrane bound form, a soluble form is also detected in the sera of septic patients 
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and sTREM-1 blocks the effect of cell associated TREM-1 and dampens TREM-1 
activation (Wong-Baeza et al., 2006).  
 
In contrast to the proinflammatory function of TREM-1, TREM-2 negatively 
regulates inflammation. Interestingly, both TREM-1 and 2 require DNAX activation 
protein 12 (DAP-12) as an adapter for signal transduction. TREM-2 is found on 
macrophages and monocytes and is associated with reduced TLR responses 
(Hamerman et al., 2005). We hypothesise that the development of overt inflammation 
will depend on the balance of TREM1 and TREM-2 on myeloid cell (Fig 1.4).  
 
Other members of the TREM family (Table 1.2) include TREM-3 to TREM-5, and 
TREM-like transcript (TREML)-4 (Allcock et al., 2003). These genes are clustered on 
human chromosome 6p21 and on mouse chromosome 17C3 (Bouchon et al., 2001a). 
TREM-4 is involved in the regulation of inflammation, neoplastic transformation, 
myeloid cell development, atherosclerosis, tumorigenesis, spermatogenesis, and 
microcirculation (Colonna et al., 2006).  The expression of TREM-5 on monocyte-
derived dendritic cells may affect dendritic cell function (Colonna et al., 2006). 
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Figure 1.4 The role of TREM protein in the inflammatory response 
TREM-1 enhances, and TREM-2 inhibits, TLR signalling thereby regulating the 
inflammatory responses. sTREM-1 may originate either by translation of an 
alternative splice form of TREM-1 or shedding of surface-expressed TREM-1 
molecules. sTREM-1 can capture the available ligand of TREM and therefore 
impair the TREM-1 signalling pathway.  
TREM, Triggering receptor expressed on myeloid cells; TLR, Toll-like receptor; 
sTREM, Soluble TREM; DAP12, DNAX activation protein 12;  LPS, 
Lipopolysaccharide  
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Members  Cell Type Technique Reference 
TREM-1 
Human peripheral blood 
CD14+ monocytes 
FACS, RT-PCR Gomez-Pina et al. (2007) 
 Neutrophils FACS; IF Fortin et al. (2007) 
 Lymph node macrophages FACS Schenk et al. (2005) 
 
Differentiated U937 (pre-
monocytic)  
RT-PCR Gingras et al. (2002) 
 
Blood monocytes and 
neutrophils 
FACS Wiersinga et al. (2007) 
TREM-2 
Human Immature monocyte 
derived DC 
FACS Bouchon et al. (2001b) 
 
THP-1 (monocyte) and U937 
(premonocyte) 
cells 
RT-PCR Allcock et al. (2003) 
 Microglia WB, FACS, CM Sessa et al. (2004) 
 
Peritoneal and bone marrow-
derived macrophages  
FACS Turnbull et al. (2006) 
 osteoclasts FACS Humphrey et al(2006). 
TREM-3 
macrophage cell lines 
(RAW264.7 and MT2) 
NB Chung D.Het al., (2002) 
TREM-4 myeloid cells RT-PCR Colonna, Met al., (2006) 
TREM-5 dendritic cells RT-PCR Colonna, Met al., (2006) 
TREML-3 
B cell line, macrophage cell 
line (U937) 
RT-PCR Allcock, R.J., (et al2003) 
TREML-4 
CD8 and dendritic cells 
macrophage 
RT-PCR Hemmi, Het al., (2009) 
 
 
Table 1.2 The cellular distribution of TREM proteins 
TREM proteins are found in a variety of cells using different methodology. The method 
used for discovery and the relevant reference are indicated. CM, confocal microscopy; 
FACS, fluorescence activated cell sorting; IF, immunofluoresence; NB, Northern blotting; 
RT-PCR, reverse transcriptase polymerase chain reaction; WB, Western blotting. 
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1.3.2. The TREM-1 signalling pathway  
TREM-1 is a cell surface transmembrane receptor that has been characterized in 
humans and mice and is expressed on neutrophils, monocytes and macrophages 
(Bouchon et al., 2000). It has a single extracellular immunoglobulin (Ig) ectodomain 
of the variable (V) type, a positively charged transmembrane region and a 
cytoplasmic tail with no apparent signalling motif (Kelker et al., 2004) and see Figure 
1.5). 
 
 
 
 
As the ligand for TREM-1 is unknown, an agonistic antibody was used to study the 
TREM-1 signalling pathway. After ligation with this antibody, the transmembrane 
domain of TREM-1 phosphorylates the immunoreceptor tyrosine-based activation 
motif (ITAM) of adaptor protein DAP-12. This causes phosphorylation on aspartate 
residue in ITAM, which leading to phosphorylation of protein tyrosine kinases Syk. 
Thereafter activated Syk mediates the activation of a downstream signalling cascade. 
Downstream signalling molecules include scaffolding molecules Lat; extracellular 
signal-related kinase (ERK); non-T cell activation linker (NTAL); kinase Akt, PLCγ, 
calcium and mitogen-activated protein kinases. The resultant effect on the cell is 
Figure 1.5 The molecular structure of TREM 
TREM-1 consist of : 1. Ectodomain 2. Transmembrane region with positive charge 
residue (mediate the complex formation with signalling adaptor) 3. Cytoplasmic tail 
which lacks signalling motif.  TREM-1 forms a complex with DAP12 to phosphorylate 
immunoreceptor tyrosine-based activation motifs (ITAM). Then it bind to Src 
homology 2 (SH2) domains of a protein tyrosine kinase (e.g., Syk), which mediates 
activation of downstream signalling pathways. 
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intracellular Ca
2+
 mobilization and rearrangement of the actin cytoskeleton. (Lanier et 
al., 2003). Upon co-stimulation with TLR-4, TREM-1 ligation results in a synergistic 
25 fold increase in TLR4 mediated pro-inflammatory cytokine and chemokine 
secretion (Bleharski et al., 2003).  
 
A monocyte cells line, U937, which ectopically expresses TREM-1, has yielded a 
better understanding of its signalling pathway. In this cell line, the knockdown of 
NTAL by RNA interference enhances TREM-1 induced ERK phosphorylation and 
production of TNF and IL-8 (Tessarz et al., 2007). It was also shown that TREM-1 
ligation causes phosphorylation of NTAL, which associates with growth factor 
receptor-bound protein 2 (Grb2), indicating a negative feedback mechanism for 
TREM-1 signalling by NTAL. Another outcome of TREM-1 ligation is the activation 
of CARD9/Bcl10 complex, which mediates activation of NF-kB (Hara et al., 2007). 
The NF-kB family is composed of a variety of homo and heterodimers made from 
five subunits: RelA(p65), p100/p50 (NFkB1), c-rel, RelB and p100/p52 (NFkB2) 
(Perkins et al., 2007). The nuclear level of RelA is significant increased by TREM-1 
ligation, but it is still under investigation whether other combinations of subunits are 
involved. Another downstream target, Bruton`s tyrosine kinase (Btk), is a positive 
regulator of TNF-α production upon TREM-1 stimulation (Tereza et al., 2011). Btk is 
a member of the Tec family of protein tyrosine kinases (PTKs), is involved in 
signalling via a variety of receptors including the B cell receptor (BCR), cytokine 
receptors and integrins (Lindvall et al., 2005). In the TREM-1 pathway, Btk is 
associated with the phosphorylation of the p65 subunit of NFκB and PLCγ which 
leads to TNF-α production and Ca2+ flux (Tereza et al., 2011). In RAW264.7 
macrophages, the downstream targets were identified by a combination of PCR-based 
arrays and RNA interference. 
  
Some aspects of monocyte TREM-1 signalling are shared in neutrophils, including 
phosphorylation of PLCγ and ERK1/2 (Fortin et al., 2007). However, the activation of 
kinases AKT, Lyn, Jak2, IRAK-1 and the transcription factors STAT5 and RelA may 
be specific responses to TREM-1 signalling in neutrophils (Fortin et al., 2007). Upon 
LPS stimulation with TREM-1 silencing, transcription of key proteins involved in the 
TLR4 signaling pathway are reduced, such as MyD88), CD14, inhibitor of kappa light 
chain gene enhancer in B cells (IkB-a) and p100. These studies support the function 
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of TREM-1 to amply inflammatory responses by increasing the availability of key 
proteins involved in TLR signalling and NF-kB activation.  
1.3.3. Regulation of TREM-1 expression 
The expression of TREM-1 is regulated by various factors including TLR ligands, 
intracellular kinases, inflammatory cytokines, pathogen products, and endogenous 
peptides. Membrane bound TREM-1 is significantly upregulated by various ligands 
for TLRs, including lipoteichoic acid (LTA) (TLR2), polyinosinic-polycytidylic acid 
(TLR3), and LPS (TLR4) (Bleharski et al., 2003 and Radsak et al., 2004). 
Furthermore, TREM-1 serves as an amplifier of the proinflammatory response by 
synergistically enhancing the production of pro-inflammatory cytokines in response to 
TLR stimulation (Bleharski et al., 2003).  
 
Several downstream products of TLR signalling, such as PGE2, have been identified 
as positive regulators of TREM-1(Murakami et al., 2007 and Zeng et al., 2007), as 
PGE2 treatment induces TREM-1 expression in macrophages (Bleharski et al., 2003). 
Accordingly, inhibiting the production of endogenous PGE2 by COX-1/2 inhibitors 
could significantly inhibit LPS-induced expression of mTREM-1. A 
phosphatidylinositol 3-kinase (PI3-kinase) inhibitor significantly suppresses the 
PGE2-mediated synthesis of TREM-1 in macrophages (Zeng et al., 2007). All these 
data suggest that TREM-1 expression is regulated by the cross-talk between the NF-
κB pathway and other kinase pathways, such as the PI3-kinase pathway (Perkins et 
al., 2007).  
 
On the other hand, the transcription factor PU.1 is known to block TREM-1 
expression in murine macrophages (Chen et al., 2008 and Zeng et al., 2007). After 
LPS stimulation of macrophages, the transcription factors PU.1, activator protein 1 
(AP-1) and RelA bind to the TREM-1 promoter (Zeng et al., 2007). This LPS induced 
expression of TREM-1 could be attenuated by pre-treatment of cells with NF-kB 
inhibitors; meanwhile gene silencing for PU.1 highly up-regulated TREM-1 in 
macrophages. This study demonstrates that expression of TREM-1 is dependent on 
activation of NF-kB, whereas PU.1 negatively regulates TREM-1 expression. 
Consistent with this finding, low TREM-1 expression and high levels of PU.1 are 
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detected in the nuclei of monocytes isolated from cystic fibrosis patients that succumb 
to numerous infections (del Fresno et al., 2008) 
 
In response to TLR stimulation, macrophages produce pro-inflammatory cytokines 
such as IL-1β and TNF-α, which induce the expression of TREM-1 (Chen et al., 
2008). This may due to the fact they utilize the same signalling adaptors such as 
serine-threonine innate immunity kinase (IRAK), TNFR-associated factor 6 (TRAF6), 
MAP kinases and NF-κB (Huang et al., 2003). 
 
Recently, two peptides LL-37 and Vasoactive intestinal peptide, have been described 
to have a regulatory effect on TREM-1 expression. LL-37 is a cationic antimicrobial 
peptide that can direct lyse bacteria through the permeabilization of cellular 
membranes (Lehrer et al., 1993). Its significant anti-staphylococcal activity 
contributes to protection of the mucosal surfaces of the upper airways against 
bacterial colonization (Bucki et al., 2010). It is produced as propeptide in neutrophils, 
monocytes and epithelial cells, then activated by extracellular cleavage in response to 
infection (Scott et al., 2002). Previous studies show that LL-37 inhibits inflammatory 
cytokine production in response to LPS and lipoteichoic acid (LTA) through the 
downregulation of p38 MAPK and NFκB signaling pathways (Molhoek et al., 2009 
and Pinheiro da Silva et al., 2009). LL-37 inhibits the expression of TREM-1 and 
strongly suppresses synergistic responses to TREM-1 and TLR4 and TLR2 
stimulation (Amatngalim et al., 2010). In contrast, vitamin D up-regulates both LL-37 
and TREM-1. This indicates that the regulatory effect of TREM-1 by LL-37 may be 
dependent on the peptide concentration and the composition of the media at the 
specific site in vivo. 
 
Vasoactive intestinal peptide (VIP) is a member of the secretin superfamily of 
peptides (Vaudry et al., 2000), that inhibits LPS-induced IL-12 and nitric oxide (NO) 
production by murine macrophages via a cAMP-dependent mechanism (Xin et al., 
1998 and Foster et al., 2005).  Treatment with VIP reduces the mRNA levels of 
TREM-1, but increases TREM-2 mRNA expression (Sun et al., 2011). VIP can 
therefore normalize the ratio of TREM-1 to TREM-2 (Ding et al., 2007) 
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Figure 1.6 The TREM-1 signal transduction pathway.  
Upon activation, TREM-1 uses DAP12 to initiate intracellular signalling to regulate 
the activity of NFκB. TREM-1 ligation also leads to the activation of the adaptors 
NTAL and Erk and NTAL can negatively regulate TREM signals by inhibiting 
Erk.The MyD88 pathway and STAT are utilized by TREM-1 to stimulate NF-κB.  
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1.3.4. Role of TREM-1 in infectious lung disease 
TREM-1 is implicated as an activator of the immune response in sepsis and infectious 
disease. Septic shock occurs in cases of bacteraemia, causing excessive inflammation, 
tissue damage, multi-organ failure, septic shock and eventually leading to death. The 
expression of TREM-1 is elevated on neutrophils and macrophages from infected 
tissues (Bouchon et al., 2001a). Enhanced productions of inflammatory cytokines are 
seen in monocytes co-stimulated with LPS and TREM-1 agonist antibody in vitro. In 
an in vivo murine model of sepsis, introduction of this agonist TREM-1 antibody 
produced double mortality rate (Gibot et al., 2004b). 
 
These data propose that inflammation during sepsis is regulated by TREM-1. This 
idea is supported by blocking TREM-1 using a chimeric protein composed of an Fc 
fragment and the extracellular portion of murine TREM-1. The administration of this 
antagonist protects septic mice from death and reduces inflammation (Bouchon et al., 
2001b). A similar effect is achieved with a synthetic peptide (LP17), that mimics the 
complementary determining region 3 and the ‘‘F’’ b strand of the extracellular 
domain of TREM-1 (Radaev et al., 2003).  LP17 impairs TREM-1 dimerization and 
inhibits TREM-1 by binding its natural ligand (Gibot et al., 2004b). LPS and TREM-
1 enhanced production of TNF and IL-1β is abolished by treatment with LP17. In vivo 
administration of LP17 leads to decreased plasma concentrations of several pro-
inflammatory cytokines and improves the survival rate in a murine model of sepsis 
(Gibot et al., 2004b).  
 
1.3.4.1. The Role of TREM-1 in bacterial infection 
One of the leading causes of sepsis is bacterial infection of the respiratory tract, such 
as streptococcus pneumoniae and pseudomonas aeruginosa. Elevated expression of 
TREM-1 is found on myeloid cells after both infections (Gibot et al., 2006; Wiersinga 
et al., 2007). In vitro, incubation with heat-inactivated Staphylococcus aureus, 
Pseudomonas aeruginosa, results in significantly increased levels of TREM-1 on 
neutrophils (Bouchon et al., 2001a). Studies demonstrate that TREM-1 plays an 
important role in modulating the production of TNF-α, IL-6 and MIP-2 and neutrophil 
infiltration by altering the dynamics of pulmonary IRAK-M expression during 
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pneumococcal pneumonia (Lagler et al., 2009). Experiments in a rat model of P. 
aeroginosa induced pneumonia demonstrate that LP17 decreases cellular infiltration, 
histological damage and levels of TNF, IL-1β and IL-6 both in BAL and plasma 
(Gibot et al., 2006). It also significant improves the survival rate.  
 
1.3.4.2. The role of TREM-1 in fungal and parasite infection    
TREM-1 is also important in other pulmonary infections caused by parasites and 
fungi. Schistosoma mansoni is a significant parasite of humans that causes 
inflammation of the skin or lung (Pearce et al., 2002). At the later phase of an 
infection they produce eggs with specific antigens that bind chemokines to inhibit 
their biological activity thereby regulating inflammation (Smith et al., 2005). One of 
these antigens is schistosoma egg antigens (SEA), which down-regulates expression 
of TREM-1 on macrophages in vitro (Cheng et al., 2011). Consistent with this 
finding, no significant increase in TREM-1 is observed at the later stages of infection 
(Cheng et al., 2011).  
 
Aspergillus fumigatus is a saprotrophic fungus that is widespread in nature. Long-term 
exposure to this fungus can cause airway hyperreactivity, peribronchial inflammation, 
and airway remodeling (Kauffman et al., 2000). In mouse model of A. fumigatus 
induced allergic airway disease, inhibition of TREM-1 activity results in the 
persistence of fungal material in the lung, enhances circulating IgE and induces 
profound lung inflammation and remodelling of the airways (Karen et al., 2011). 
These suggest that TREM-1 is critical for the clearance of A. fumigatus and the 
progression of lung disease.  
 
1.3.4.3. The role of TREM-1 in viral infection    
The only association between TREM-1 and viral infection to date is shown in studies 
on Marburg and Ebola viruses (Mhamadzadeh et al., 2006). Both are enveloped, 
nonsegmented, negative-stranded RNA viruses and are associated with high mortality 
rates during periodic outbreaks (de Wit et al., 2011). During viral infection, the 
dysregulated inflammation contributes to pathogenesis and TREM-1 is involved in the 
interaction between filoviruses and neutrophils (Mhamadzadeh et al., 2006). In 
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human neutrophils, TREM-1 directly binds the filoviral glycoprotein of Marburg 
viruses, downregulating its membrane expression and increasing its soluble form. 
LP17, a peptide mimic of the extracellular region of TREM-1, significant abrogates 
filoviral induced TNF-α and IL-1β production (Mhamadzadeh et al., 2006). These 
data demonstrate that TREM-1 plays a prominent role in the inflammatory responses 
to filovirus infections. 
 
1.3.5. The role of TREM1 in other inflammatory conditions in the 
lung 
TREM-1 has been characterized in other non-infectious inflammatory diseases in the 
lung, such as cystic fibrosis (CF). CF is a relatively common recessive, genetic 
disease resulting in frequent lung infections and prolonged inflammation leading to 
profound lung function alteration (Ratjen et al., 2009). On circulating monocytes from 
CF patients only a low level of TREM-1 is detected (del Fresno et al., 2008). The 
downregulated TREM-1 may contribute to the failure to organise a sufficient 
inflammatory response. Furthermore, an elevated level of the transcription factor 
PU.1 is expressed in these monocytes, which inhibits TLR-induced TREM-1 
upregulation (Zeng et al., 2007). Monocytes in cystic fibrosis patients have repressed 
TREM-1 expression by upregulation of PU.1, which causes desensitization of TLR 
responses. Restoring the expression of TREM-1 may improve TLR responsiveness 
and bacterial clearance. 
 
Upregulation of TREM-1 is also found on tumour-associated macrophages (TAMs) in 
the lung, but not on cancer cells (Ho CC et al., 2008). This upregulation is also 
observed on blood monocytes when co-cultured with lung cancer cells. Gene 
silencing of TREM-1 by shRNA in TAMs abolishs cancer cells invasiveness, whilst 
the activation of TREM-1 by agonist antibody induces metastasis (Ho CC et al., 
2008). These data imply that tumour progression may be assisted by TREM-1 
signalling.  
 
In addition, systemic inflammatory conditions such as mesenteric ischemia are also 
linked with TREM-1. Acute mesenteric ischemia (AMI) is a potentially fatal vascular 
emergency with overall mortality of 60% to 80% and is caused by a reduction in 
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intestinal blood flow (Victoni et al., 2010). Ischemia reperfusion causes systemic 
production of proinflammatory cytokines (TNF-α, IL-1β and IL-6) and activation of 
leukocytes, which leads to multiple organ failure and death. In a rat model of ischemia 
reperfusion, TREM-1 blockade, by administrating LP17, significantly reduces 
systemic inflammation, activation of hepatic NFκB, hemodynamic deterioration and 
bacterial translocation (Gibot et al., 2008).  
 
1.3.6. sTREM-1 as a biomarker for disease 
A soluble TREM-1 (sTREM-1), which only contains the extracellular domain of 
TREM-1, was first detected in BAL fluid of septic patients (Gibot et al., 2004b). The 
exact function of sTREM-1 is still not clear, however its structure makes it a potential 
competitor for membrane TREM-1. Thus, the presence of sTREM-1 may be a natural 
mechanism to control the magnitude of TREM-1 signaling. This is supported by data 
from models of murine septic peritonitis showing that an artificially generated 
sTREM-1 has a similar protective effect as inhibition of TREM-1 (Bouchon et al., 
2001b). Another important application of sTREM-1 is its use as an important 
predictor and diagnostic marker for sepsis and bacterial and fungal pneumonia (Gibot 
et al., 2004a). This will be examined in more detail in chapter 4, where the sTREM-1 
was evaluated in viral and bacterial co-infection.  
 
Due to the significant level of sTREM-1 found in the bronchoalveolar lavage (BAL) 
fluid in pneumonia (Richeldi et al., 2004) and in plasma in patients with sepsis, 
TREM-1 has become a promising diagnostic marker for these infections. It has been 
compared with other traditional markers, such as C-reactive protein (CRP) and 
procalcitonin (PCT). An initial study in 76 ICU patients with a suspicion of infection 
reveals that the plasma concentrations of CRP, PCT, and sTREM-1 were higher in 
infected patients than in those with noninfectious conditions. Compared with CRP and 
PCT, sTREM-1 exhibit higher sensitivity, specificity, positive and negative predictive 
(Gibot et al., 2004a). Furthermore in 44 neonates sTREM-1 was superior to CRP or 
immature to total neutrophil ratio in diagnosing severe bacterial infections (Chen et 
al., 2008). However two recent studies with 246 critically ill patients only show that 
sTREM-1 display sensitivity ranging from 49% to 70% and specificity of 60% to 79% 
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which was inferior to CRP or PCT (Latour-Perez et al., 2010 and Barati et al., 2010). 
Therefore the combined measurement of sTREM-1 with other markers performs 
better than each marker alone (Kofoed et al., 2007). 
 
The diagnostic value of sTREM-1 has also been extensively investigated in 
pulmonary infections. The levels of sTREM-1 in BAL fluid were disclosed by several 
reports as a marker of infectious pneumonia (Richeldi et al., 2003). Patients under 
mechanical ventilation have alveolar concentrations of sTREM-1 which were highly 
predictive of lung infection and performed as a better indicator than CRP and PCT in 
community acquired pneumonia and ventilator-associated pneumonia (Gibot et al., 
2004a). More recent work shows that sTREM-1 concentrations in BAL fluid are 
increased during bacterial or fungal pneumonias (Huh et al., 2008) and can be used to 
distinguish between aspiration pneumonia and pneumonitis (El Solh et al., 2008).  
 
In meningitis, distinguishing between a bacterial or viral cause is difficult as many 
patients have already received antibiotics. The level of sTREM-1 in the cerebrospinal 
fluid however discriminates between infectious and viral meningitis (Determann et 
al., 2006 and Bishara et al., 2007). Furthermore, measurement of sTREM-1 in urine is 
a valuable tool for the diagnosis of lower urinary tract infections (Determann et al., 
2007). The concentration of sTREM-1 is elevated in biologic fluids and tissues from 
patients with systemic inflammatory responses after multiple traumas (Philippe et al., 
2011), inflammatory bowel disease (Park et al., 2009), and in the synovial fluid of 
patients with rheumatoid arthritis (Collins et al., 2009). Chronic obstructive 
pulmonary disease (COPD) and pulmonary cancer also show a close association with 
sTREM-1 (Radsak et al., 2007). In a malignant tumour, the resultant enhanced innate 
immunity is a significant factor affecting its outcome. An elevated level of sTREM-1 
in malignant pleural effusions correlates with poor outcome, making sTREM-1 an 
independent predictor of patient survival (Ho CC et al., 2008) 
 
1.3.7. Source of sTREM-1 
The mechanism for the generation of sTREM-1 is not yet fully elucidated. There are 
two current hypotheses to account for the source of sTREM-1 (Fig 1.4). One proposes 
that it originates from proteolytic cleavage of membrane bound TREM-1 (Gibot et al 
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2004b), another suggests that sTREM-1 is produced by translation of alternative 
mRNA splice variant of TREM-1 (Begum et al 2004). This variant is detected in 
monocytes and CD34+ bone marrow cells and produces a protein devoid of both the 
transmembrane and cytoplasmic domains with a predicted molecular mass of 17.5 
kDa (Gingras et al., 2002). However sTREM-1 released from LPS stimulated 
monocytes has a mass of 27 kDa by Western blotting (Gibot et al., 2004b).  Our 
hypothesis regarding the mechanism of cleavage of sTREM-1 is discussed further in 
chapter 5 where we investigate the possible source to cleave TREM-1 during 
influenza infection.  
 
1.4. The TREM-2 receptor 
After initial identification as a TREM-1 homologue expressed on human monocyte-
derived dendritic cells (Bouchon et al., 2001b), TREM-2 was found on many myeloid 
cells, including macrophages, microglia, osteoclasts and dendritic cells (Colonna et 
al., 2003). The structure of TREM-2 is similar to TREM-1, containing three domains: 
an extracellular V-type immunoglobulin-like domain, a transmembrane region 
containing lysine residues with positive charge and a short cytoplasmic tail. Despite 
the fact that both TREM receptors employ DAP12 as signalling adaptor, TREM-2 is 
an inhibitor of inflammatory response. Activation of TREM-2 on macrophages may 
downregulate TLR signaling (Hamerman et al., 2005). Therefore, TREM-2 may 
counteract TREM-1 to induce a balanced inflammatory response. 
 
1.4.1. Negative signalling from TREM2 
The ligand for TREM-2 is not yet identified. After stimulation with an agonistic 
antibody, the transmembrane domain of TREM-2 phosphorylates the ITAM on 
DAP12, which recruits the tyrosine kinase SYK and leads to the activation of PI3K 
and MAPK (Bouchon et al., 2001b and Jiang et al., 2002). Other downstream events 
include ERK phosphorylation and Ca
2+
 mobilisation. Unlike TREM-1, TREM-2 
ligation does not induce the degradation of IkB-α and the subsequent nuclear 
translocation of NF-κB (Bouchon et al., 2001b). Initial work suggests that TREM-2 
suppresses macrophage TNF-α and IL-6 production and promotes an anti-
inflammatory state in microglia (Hamerman et al., 2006). Therefore, different 
  Chapter 1: Introduction 
53 
downstream signalling events must contribute to the resultant negative signals from 
TREM-2  
 
The regulatory effect of TREM-2 on TLR response is apparent in macrophages where 
gene silencing of TREM-2 results in increased production of TNF in response to the 
TLR2/6 ligand zymosan and the TLR9 ligand CpG (Hamerman et al., 2006). 
Consistant with this finding, BMDM from TREM-2 knockout mice secrete 
significantly more TNF and IL-6 in response to LPS than wild-type controls (Turnbull 
et al., 2006). A similar effect is also observed in microglia. Following co-culture with 
apoptotic neurons, microglia with overexpression of TREM-2 produce less TNF and 
inducible nitric oxide (iNOS) mRNA, whereas a modest increase in TNF and iNOS is 
observed after TREM-2 knockdown (Takahashi et al., 2005). All these data suggest 
TREM-2 acts as negative regulator of inflammation.  
 
The outcome of TREM-2 signalling may depend on the cell type. Following TREM-2 
activation of immature dendritic cells, CC chemokine receptor 7(CCR-7), CD40, 
CD86 and MHC class II are upregulated and dendritic cell maturation is induced 
(Bouchon et al., 2001b). These DCs were also resistant to apoptosis and chemotaxis 
towards macrophage inflammatory protein 3-β (MIP3-β) via upregulating CCR-7. 
However, TREM-2 signalling in microglia increases ERK1/2 phosphorylation and 
CCR7, but not CD86 or MHC class II expression (Takahashi et al., 2005). Moreover 
phagocytosis accompanied by a polarization and re-organization of F-actin in an 
ERK-dependent manner is also enhanced (Takahashi et al., 2005). The expression of 
CD86 and MHC II was also found elevated after TREM-1 activation. Despite the 
opposite effect on inflammatory responses by TREM-1 and TREM-2, some of the 
downstream effector genes activated are similar, which contributed to the difficulty in 
identifying their separate mode of action. 
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1.4.2. The role of TREM2 in infection 
TREM-2 is constitutively expressed by macrophage from in vitro culture systems. 
This expression reduces after LPS treatment of RAW 264.7, J774.2 macrophages, 
BMDM and microglia (Bouchon et al., 2001b; Turnbull et al., 2006; Piccio et al., 
2007). In vivo work on acute endotoxaemia also reveals that downregulation of 
TREM-2 in hepatic macrophages and endothelial cells may contribute to increased 
proinflammatory mediator production in the liver (Chen LC et al., 2008). In addition, 
other cytokines such as IFN-γ, IFN-α and IL-10 also suppress the expression of 
Figure 1.7 TREM2 signal transduction pathway.  
TREM-2 also employs DAP12 adaptor molecules to initiate its intracellular 
signalling. Activation of TREM-2 results in calcium mobilization via ERK and 
PI3K pathway.  
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TREM-2 (Kyung-Hyun et al., 2010). All these data suggest that during inflammation, 
suppressing TREM-2-mediated signals upregulates the host immune response by 
affecting functional responses of macrophages. 
 
The upregulation of TREM-2 may be closely linked with anti-inflammatory 
responses. In accordance with this hypothesis, TREM-2-transduced myeloid cells 
produce significant higher levels of IL-10 (Takahashi et al., 2007). Alternative 
activation of resident peritoneal macrophages by IL-4 leads to enhance TREM-2 
expression in vitro (Turnbull et al., 2006). This result was confirmed and extended in 
another paper which reported a link between TREM-2 signalling and wound healing 
(Hiroshi et al., 2008). Expression of TREM2 is observed in wound bed macrophages 
and TREM-2 knockout mice exhibit delayed and incomplete wound healing. 
Furthermore, macrophages from Trem2−/− mice display high levels of markers 
associated with classical macrophages such as inducible nitric oxide synthase, 
whereas the markers for alternative activated macrophage like arginase 1, Ym1 and 
mannose receptor are decreased compared to wild type mice. Thus TREM-2 is not 
only an inhibitor of TLR induced responses, but also enhances alternative macrophage 
activation.  Recent studies show constitutive expression of TREM-2 on hepatic 
macrophages and endothelial cells that is downregulated during acute endotoxemia 
which may contribute to increased proinflammatory mediator production (Chen et al., 
2008). TREM-2 may therefore terminate inflammation and initiate the tissue repair 
process (Whittaker et al., 2010).  
 
With respect to in vivo infection models, TREM-2 expression increases in the lung 
following Mycobacterium bovis infection of mice and this correlates with an increase 
in DAP-12 mRNA and protein expression (Aoki et al., 2004). There is evidence 
showing that TREM-2 can bind to bacteria. The inital report of Daws et al. suggests 
that murine TREM-2 recognises bacteria through a charge-dependent interaction 
(Daws et al., 2003). They found that membrane-expressed TREM-2 bound a variety 
of bacteria including Escherichia coli and Staphylococcus aureus, and that this 
binding was inhibited by LPS and other charged carbohydrates of bacterial origin. 
Recently, it has been proved that TREM-2 can alos promote phagocytosis of bacteria 
by macrophages (Elsa-Noah et al., 2009) and regulate the production of reactive 
oxygen species in response to Salmonella typhimurium by macrophages, (Charles et 
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al., 2008). TREM-2 also binds to N. gonorrhoeae through interactions with 
lipooligosaccharide (LOS) and Opa proteins. Binding of TREM-2 to whole bacteria 
paralleled its binding to LOS purified from them, suggesting that binding to LOS 
accounts for the majority of recognition of these bacteria by TREM-2 (David et al., 
2008). In addition, the expression of TREM-2 is detected on genitourinary epithelial 
cells driving pathogenesis of gonorrhea. All these suggest that TREM-2 act as a 
pattern recognition receptor to modulate innate immunity against gonococci. 
 
1.4.3. The role of TREM2 in osteoclastogenesis and 
neurodegeneration  
The function of TREM-2 was first revealed by studies in patients with Nasu–Hakola 
disease (Kondo et al., 2002). Nasu–Hakola disease is a rare, recessively inherited 
disease which develops as pathologic fractures of the extremities, demyelination of 
the central nervous system and rapid progression of dementia (Bianchin et al., 2004). 
In Nasu–Hakola disease, neurodegeneration in the brain is cased by overactivation of 
microglial cells that express high levels of TREM-2 among brain cells (Schmid et al. 
2002; Sessa et al. 2004).  
 
The association between TREM-2 and microglial activation is further demonstrated 
by inhibition studies.  In microglia, TREM-2 knockdown significantly enhances the 
transcriptions of inflammatory cytokines, the accumulation of apoptotic cell debris 
and neuronal damage (Takahashi et al., 2005). In addition, blockade of TREM2 
exacerbates brain pathology, whereas intravenous application of TREM2-rich stem 
cells facilitates brain repair in experimental autoimmune encephalomyelitis, the 
animal model of multiple sclerosis (Piccio et al. 2007). All these results suggest that 
TREM-2 plays an important role in mediating microglial phagocytosis of apoptotic 
neuronal membranes and is a promising therapeutic target to treat neurodegenerative 
diseases. 
 
Another important feature of Nasu-Hakola disease is abnormalities in bone 
remodeling and defective osteoclastogenesis (Paloneva et al., 2003). Isolated 
peripheral blood monocytes from patient with Nasu-Hakola disease fail to 
differentiate into osteoclasts and these immature osteoclasts exhibit impaired bone 
  Chapter 1: Introduction 
57 
resorptive activity (Cella et al., 2003). Two molecules associated with TREM-2, 
DAP12 and FcRγ, are essential costimulatory signal for RANKL-induced 
osteoclastogenesis (Koga et al., 2004 and Zou et al., 2007).  
 
1.5. Hypothesis and Aims  
This thesis is based on the hypothesis that early elevated TREM-1 expression may 
cause excessive innate inflammation during influenza infection, which defines 
pathology and susceptibility to subsequent bacterial infection. Further, following 
recovery from a severe infection, immune system in the lung is over-regulated while it 
healing. During this resolution phase, TREM-2 may be employed by the host to 
terminate the inflammatory response and initiate tissue repair.  
 
To address these we will ask the following questions  
1) What is the relative profile of TREM-1, TREM-2 and sTREM-1 in the lung during 
homeostasis and disease (influenza and influenza–bacterial confections).  
 
2) How do TREM-1 involved in the inflamed lung? What are the effects of TREM-1 
blockade by LP17 on the outcome of a lethal secondary Streptococcus 
pneumoniae infection induced in mice undergoing a primary influenza infection? 
 
3) How do TREM-2+ macrophage regulate the resolution from infection? What 
TREM-2+ macrophages behave throughout influenza infection and its effect on 
innate immunity? 
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2. Materials and Methods 
2.1 Mice and cells 
2.1.1 Mice 
8-12 week old female BALB/c mice were purchased from Harlan Olac Ltd (Bicester, 
UK). All mice were kept in pathogen-free conditions according to Home Office 
guidelines.  
2.1.2. Cell line 
The RAW 264.7 (TIB-71), a monocyte and macrophage cell line from BAL B/c 
source (purchased from ATCC), was cultured in Dulbecco's Modified Eagle Medium 
(DMEM) (from PAA), 10% foetal calf serum (FCS), 50U/ml penicillin, 50 mg/ml 
streptomycin and split every two or three days when  over 60% confluent according to 
supplier specification .  
 
MH-S, which is a continuous cell line of murine alveolar macrophages from BAL B/c 
source, was cultured in Roswell Park Memorial Institute medium (RPMI) 1640 Media 
, 10%  FCS, 50 U/ml penicillin, 50 mg/ml streptomycin and split 1:2 every two days 
or when confluent.  
 
2.1.3. In vitro stimulation of TREM-1 expression by TLR ligands 
To activate MH-S and RAW 264.7 cells through TREM-1, 2 x 10
5
  cells were 
cultured in 96-well flat-bottom plates, that were precoated with 10 µg/ml of an 
agonistic anti-TREM-1 monoclonal antibody (Clone 193015, R&D Systems) in the 
presence of: TLR2= LTA (5 ug/ml), TLR3= poly I:C (5 ug/ml), TLR4= LPS (10 
ng/ml), TLR7=poly U(1ug/ml) or TLR9= CpG (10 ug/ml). After 24 hour incubation 
at 37°C, the supernatants were collected and stored at –70°C until cytokine assays 
were performed. Cytokine concentrations were determined by Enzyme-linked 
immunosorbent assay (ELISA) (detection kits from BD Biosciences).  
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2.1.4. In vitro stimulation of sTREM-1 releasing  
To investigate the effects the factor stimulates the production of soluble TREM-1 
(sTREM-1). RAW 264.7 and MH-S cells were plated at 2 x 10
5
/ cells per well in 
triplicate and stimulated with 2.6x10
3
 plaque forming unit (PFU)  influenza viruses or 
diluted day 1 or day 2 Bronchoalveolar lavage (BAL) fluid from influenza infected 
mice. Following 4, 24 and 48 hour incubation, supernatants were removed and the 
concentration of sTREM-1 was detected by ELISA.  
 
When investigating the role of MMP-9 on sTREM-1 levels, 100 ng/ml MMP-9 
inhibitor (Merckchem) was added to BAL fluid before incubation with cells. RAW 
264.7 and MH-S cells were plated at 2 x 10
5
/ well in triplicate. Supernatants were 
removed at various time points and the concentration of sTREM-1 was determined by 
ELISA.  
 
Recombinant mouse MMP-9 (R&D Systems) was added to RAW 264.7 and MH-S 
cell culture medium at concentration from 100 ng/ml to 400 ng/ml. In some 
experiments, 500 ng/ml of recombinant Influenza A Virus H1N1 neuraminidase 
(R&D Systems) was also used to activate RAW and MH-S cells. As before, 
supernatants were removed at various time points and the concentration of sTREM-1 
was determinated by ELISA.  
2.1.5 Induction of TREM-2 cells  
For isolation of alveolar macrophage, BAL cells were harvested from naïve mouse 
and were sorted to 99% purity using an anti-CD11c antibody and a FACSAria (BD 
Biosciences). 5 x 10
6
 cells were cultured with 100 ng/ml or 500 ng/ml IL-4 for 72 
hours and the cells were stained with anti-TREM-2 antibody to check its expression 
(R&D).  
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2.2. Pathogen Stocks 
2.3.1 Influenza 
Recombinant influenza A strain X31 and A/PR8 were a kind gift from Dr Alan 
Douglas (National Institute for Medical Research, London, UK). X31 virus is H3N2 
type and A/ PR8 is H1N1 type.  
 
2.3.2 Bacteria  
Two bacteria were used in this thesis are Streptococcus pneumoniae and Haemophilus 
influenzae. Streptococcus pneumoniae strains used in this study were wild type 
isolates D39 (serotype 2) and Haemophilus influenzae strain Eagan is an encapsulated 
serotype b clinical isolate. 
2.4. Infection models  
2.3.1. Single infection 
Infectious agents were diluted in sterile phosphate buffered saline (PBS) and 
administered intranasally, in a volume of 50μl, to anesthetized mice by isoflurane and 
held in an upright position. For influenza alone infection, 2.6x10
3
 PFU was used and 
weight loss was monitored daily. For bacterial alone infection, 10
6
 colony forming 
unit (CFU) of each strain was used.  Mice were check daily.  
2.3.2. Co-infection 
In the co-infection model, 50 HA unit 2.6x10
3
 PFU of influenza virus (X31) were 
administered intranasally to anesthetized mice on day 0. S. pneumoniae or H. 
influenzae was given 7 days later at a dose of 10
6 
CFU. Following this secondary 
bacterial infection, the progression of pneumonia was monitored by weight and 
appearance overly sick mice (lost more than 25 % of original weight) were culled 
according to home office regulation.   
 
2.5. LP17 Treatment 
LP17 span the complementary determining region loop 3 of TREM-1, was chemically 
synthesized as a COOH terminally amidated peptide (Pepscan Systems). The peptide 
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(LQVTDSGLYRCVIYHPP) was obtained in >99% yield; was homogeneous after 
preparative purification, as confirmed by mass spectrometry and analytic reversed 
phase high performance liquid chromatography; and was endotoxin free. In addition, 
a sequence-scrambled peptide (TDSRCVIGLYHPPLQVY) was included as 
experimental control. All peptides were dissolved in LPS-free normal saline. 
 
100μg LP17 was administrated by intraperitoneal injection in a volume of a 100μl 
was at different time. Initially, the treatments were given daily from day 0 of 
influenza infection for 6 days. In experiments testing the delayed effect of the peptide, 
treatments were daily two days after influenza infection for therapeutic purpose or a 
single dose on the same day as bacterial challenge.  
 
2.6. Serum, Nasal Wash and Cell Recovery  
After terminal anesthesia, lungs of each mouse were flushed 6 times with 1.5ml 1mM 
Ethylenediaminetetraacetic acid (EDTA) in minimum essential medium (MEM) and 
placed in sterile tubes on ice. 100 µl BAL fluids from each mouse was centrifuged to 
remove contaminating cells and the supernatant and stored at –70°C for analysis of 
cytokines by ELISA and bacterial CFU assay. Lung tissue, spleen and lymph node 
were cut in small pieces and digested
 
for 30 min at 37°C with agitation with 0.14 
Wunsh unit of
 
Liberase III enzyme (Roche) in the presence of 50 µg/ml
 
of DNase 
(Roche) in DMEM containing
 
5% foetal calf serum (Invitrogen). A single cell 
suspension was obtained by passage through a 100µM sieve (BD labware, New 
Jersey, USA). The cell suspension was spun for 5 min at 1200rpm and red blood cells 
lysed by resuspending pellets in ACK buffer (0.15M ammonium chloride, 1M 
potassium hydrogen carbonate and 0.01mM EDTA, pH 7.2) for 3 minutes at room 
temperature before spinning (1200rpm 5 min) and washing with medium. Cell 
viability was assessed by trypan blue exclusion. In bacterial challenge experiment, the 
nasal cavity was flushed 200µl PBS and frozen at –70°C before ELISA analysis. One 
lobe of lung was stored at –70°C for PFU assay and analysis of cytokines by ELISA. 
Blood was first harvested by exsanguination via the femoral vessel and 50ul was 
taken for CFU assay. The remaining was centrifuged for 8 min at 8000 rpm. Isolated 
serum was stored at –70°C for analysis of cytokines.  
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2.7 Flow Cytometric Analysis  
2.7.1 Cell Surface Antigens 
Antibodies were purchased from R&D, eBioscience, BD Pharmingen (Heidelberg, 
Germany) except anti-CD200-FITC/PE and anti-CD200R-PE (Serotec UK, Oxford, 
UK) and diluted in PBS with 1%BSA and 0.005% sodium azide. The cells harvested 
from the BAL, lung, blood and lymph nodes were pelleted at 1000 x g for 5 minutes 
and resuspended in complete medium to a final concentration of 1 x 10
6
 cells/mL. 100 
μL of cells (1 x 105) were transferred to 96-well microplates (#3679; Corning), and 
following two washes in PBA. Cell suspensions
 
were stained for various surface 
markers and isotype controls (see table 2.1) in PBA for 45 min at 4°C, and then 
washed twice followed by fixated in
 
2% paraformaldehide PBS for 20 min at room 
temperature. Cells were then washed in PBA and data was acquired on a FACS 
Cantos II (BD Bioscience).  
 
The different cell types were characterized according
 
to their forward and side scatter 
profiles and selective expression of specific phenotypic markers. The different 
phenotypes were defined as follows: neutrophils (Ly6g
high
, CD11b
high
), macrophages
 
(CD11c
+
, F4/80
high
), T
 
lymphocytes (CD4
+
, CD8
+
) and activated T lymphocyte 
(OX40
+
 or CD45RB
-
).  The FACS data were analysed using Flowjo software (TriSatr 
US).  
 
2.7.2 Intracellular Cytokine Expression 
To detect intracellular cytokines, 10
6
 cells/ml were incubated with 50 ng/ml phorbol 
12-myristate 13-acetate (PMA), 500 ng/ml ionomycin (Calbiochem, Nottingham, 
UK), and 10mg/ml brefeldin A for 4-6 hours at 37
o
C. Cells were stained with anti-
CD4 and anti-CD8 and fixed as described above. After permeabilization with PBS 
containing 1 % saponin/1 % BSA/0.05 % azide (saponin buffer) for 10 min, cells 
were stained with anti-IFN-γ-FITC/PE, anti-TNF-FITC/PE, or PE-conjugated anti-IL-
4 diluted 1:50 in saponin buffer. 30 minutes later cells were washed once in saponin 
buffer and once in PBA followed by running on FACS Canto II. 
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Type of staining Cell markers used  
Conjugated  
fluorochrome 
Company 
T cells staining 
CD4 PE R&D Systems 
CD8 Prep R&D Systems 
OX40 Biotinylated +APC BD Bioscience  
CD200 PE BD Bioscience 
CD45RB FITC BD Bioscience 
Myeloid staining 
GR-1 PE R&D Systems 
CD11b PreP BD Bioscience 
IL-10 receptor APC eBioscience 
IL-4 receptor Biotinylated +APC R&D Systems 
TREM-1 APC/PE R&D Systems 
TREM-2 PE R&D Systems 
IgG2a (isotype for TREM-1) APC/PE BD Bioscience 
IgG2b (isotype for TREM-2) PE BD Bioscience 
CD11c APC BD Bioscience 
CD69 FITC BD Bioscience 
CD200R PE R&D Systems 
Ym-1 2
nd
 APC antibody  eBioscience 
Relm-α 2nd FITC antibody eBioscience 
F4/80 PEcy7 BD Bioscience 
CD86 APC BD Bioscience 
MHC II PE eBioscience 
CCR7 APC eBioscience 
CCR5 PEcy5 eBioscience 
CCR2 Pecy7 eBioscience 
TLR3 FITC eBioscience 
TLR4 PE eBioscience 
TLR7 APC eBioscience 
CD4 APC eBiosceince 
Intracellular CD8 FITC BD Bioscience 
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cytokine staining CD200 PE BD Bioscience 
IFNg PEcy5 BD Bioscience 
IL-4 PE BD Bioscience 
TNF PE BD Bioscience 
 
2.7.3 FACS sorting TREM-2+ macrophages  
IL-4 stimulated alveolar macrophage (describe as previously) were stained with 
CD11c-APC, F4/80-Pecy7 and TREM-2-PE antibodies for 40 min. Two populations, 
CD11C+TREM-2+ double positive cells and CD11C+ TREM-2 negative cells, were 
sorted by a fluorescence-activated cell sorter (FACSAria) with over 95% purity 
obtained. Isolated cells were washed with DMEM medium (with 10% FCS and P/S) 
and plated out for LPS (50ng/ml) stimulation. In addition, aliquots of 5 x 10
4
 cells 
were collected and were lysed in the RNA isolation reagent.  
2.8. Influenza-Specific Plaque Assay 
Lung homogenates were freeze thawed three times to physically disrupted with 
homogenizer to disrupt cells, centrifuged at 4000 g and supernatants titrated in 
doubling dilutions on Madine Darby canine kidney (MDCK) cell monolayers in flat 
bottomed 96 well plates. After incubation at room temperature for 3 hours, samples 
were over-layed with 1% methycellulose and incubated for 72 hours at 37°C. Cell 
monolayers were washed and incubated with anti-influenza antibody (Serotec) 
followed by anti-mouse-HRP (Dako) and infected cells were detected using 3-amino-
9-ethylcarbazole substrate. Infectious units were then enumerated by light microscopy 
and total plaque forming units per lung quantified (number of plaques × dilution 
factor × total volume of lung homogenate).  
 
2.9. Bacterial colony forming unit assay 
For the assessment of bacterial counts in the blood, airway, nasal cavity and lung, 5 µl 
of relevant biological fluids were collected from aseptically harvested tissues. 5 µl of 
blood were taken from the tail vein. Lung tissues were aseptically removed, 
homogenized through a 100 µm cell strainer in medium and spin down to collect 
Table. 2.1. All antibodies used in FACS staining. 
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supernatant. Nasopharyngeal lavage was obtained post mortem by flushing the 
nasopharynx through trachea and nares with PBS through a 20G canule inserted into 
the trachea. 100 µl of fluid were collected from the nares and used for plating. 
Bronchoalveolar lavage was collected by flushing the lungs once with 1 ml of PBS. 
They were for plating serial 10-folds dilutions on blood agar plates which made of 
columbia agar with 5% horse blood (Oxoid) and incubate for 18 hour at 37°C/5% 
CO
2
. 
 
2.10. Cytokine and albumin detection 
IL-4, sTREM-1, IFN-γ, and TNF in BAL fluid, and in some cases serum, were 
quantified using ELISA kits (Pharmingen, R&D and eBioscience). Briefly, microtiter 
plates (Nunc, Roskilde, Denmark) were coated with 100µl of capture antibody diluted 
in the recommended buffer overnight at 4°C.  After 5 washes with PBS containing 0.5 
% Tween-20, plates were blocked with 200 µl PBS containing 10 % FCS and left for 
1 hour at room temperature.  Samples and standards (diluted in PBS + 10 % FCS) 
were then incubated for a further 2 hours at room temperature.  After 5 washes, bound 
cytokine was detected using biotinylated antibodies pre-mixed with avidin-HRP 
followed by tetramethylbenzidine and hydrogen peroxidase.  Optical densities were 
read at 450 nm.  The concentration of cytokine in each sample was calculated from a 
standard curve. 
 
2.11. Macrophage co-culture stimulation  
FACS Aria-sorted naïve BALB/c alveolar macrophages (CD11 high) were cultured in 
the presence of 500ng/ml IL-4 for 72 hours, followed by further sorting based on the 
expression of TREM-2. TREM-2+ cells were cultured alone, with naïve macrophages 
or TREM-2- cells from the IL-4 cultures in the presence of 100ng/ml LPS. 2 x10
5
 
TREM-2+ cells were co-cultured with either 5 x10
5
 TREM-2– cells (ratio = 2: 5) or 5 
x10
5
 naïve cells (ratio = 2: 5). Control incubated the relevant amount of TREM-2+ 
macrophages were cultured alone. After 48 hours, supernatants were collected and the 
concentration of pro-inflammatory cytokines was assayed by ELISA.   
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FACS Aria-sorted resolved TREM-2 expressing macrophages were cultured alone or 
with naïve macrophage or TREM-2 negative cells in the presence of LPS. 2 x10
5
 
TREM-2+ cells were co-cultured with either 1 x10
6
 naïve macrophage (ratio = 2: 10) 
or 2 x10
5
 naïve cells (ratio = 1: 10) and relevant amount of TREM-2+ macrophages 
were cultured alone. After 48 hours, the concentration of pro-inflammatory cytokine 
was assayed by ELISA. The results are expressed as the mean of two experiments 
performed in triplicate for each condition. 
 
2.12. Adoptive transfer of TREM-2+ macrophage  
IL-4 stimulated airway macrophages were sorted on a FACS Aria based on gating 
around myeloid population and TREM-2 expression (purity of 96%). The cells were 
instilled intranasally into naïve mice. Normal airway macrophages or medium were 
administered into mice as control group. Day one after the transfer, all mice were 
infected with 50 HA units of influenza X31 and the weight loss was monitored. Mice 
were sacrificed on day 0, 3, 7 and BAL, and lungs were analyzed as described 
previously. 
 
2.13. Statistics  
All experiments were performed at least twice, analysing 5 individual mice per time 
point. Statistical significance was evaluated using the student t test, 2 tailed assuming 
unequal variance within the Minitab software program. The Bonferroni correction 
was applied where appropriate. 
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3.1 Introduction 
3.1.1. The TREM-1 signalling pathway   
Although the natural ligand for TREM-1 is unknown, the signalling pathway has been 
determined using an agonistic anti-TREM-1 antibody that induces the transmembrane 
region to phosphorylate the immunoreceptor tyrosine-based activation motifs (ITAM) 
of DAP 12. Conformational changes of DAP 12 result in phosphorylation of protein 
tyrosine kinases (Syk) by the ITAM, which activates downstream targets including 
scaffolding molecules Lat and NTAL; the kinase Akt, protein kinase C-θ, kinase C-θ, 
calcium and mitogen-activated protein kinases (MAPK). Their activation leads to 
intracellular Ca
2
+ mobilization and rearrangement of the actin cytoskeleton (Vivier et 
al., 2004 and Lanier et al., 2003). It has been show that the TREM-1 amplifies the 
TLR signalling; in the case of TLR4 this results in a 25 fold synergistic increase 
proinflammatory cytokine and chemokine secretion (Bleharski et al., 2003). 
3.1.2. The role of TREM in the immune system  
TREM-1 is involved in myeloid cell differentiation (Gingras et al., 2002) and is 
mainly found on murine and human neutrophils and monocytes (Bouchon et al., 
2000). TREM-1 expression is strongly enhanced upon stimulation with 
lipopolysaccharide (LPS) and serves as an amplifier of the proinflammatory response 
induced by TLR ligands (Radsak et al., 2004). Other in vitro studies show that 
stimulation of TREM-1 with the agonist antibody will induce the monocyte to 
increase intracellular Ca
2+
 and produce proinflammatory chemokines (MCP-1, MCP-
3, MIP-1) and cytokines (TNF-α)(Bleharski et al., 2003).  In neutrophils, triggering of 
TREM-1 induces the production of IL-8, lactoferrin (Bouchon et al., 2000) and 
reactive oxygen species (ROS) (Fortin et al., 2007); as well as rapid degranulation 
and phagocytosis (Radsak et al., 2004). 
 
The expression of TREM-1 is highly elevated in various inflammatory conditions 
including murine sepsis. During sepsis, TREM-1 upregulation was detected on 
monocytes, macrophages and neutrophils in the peritoneum and in peripheral blood 
and on splenic macrophages (Bouchon et al., 2001b). Increased TREM-1 expression 
is also described on monocytes from blood or in bronchoalveolar lavage (BAL) fluid 
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in melioidosis, which is an infectious disease caused by the Gram-negative bacterium, 
Burkholderia pseudomallei (Wiersinga et al., 2007). In vivo studies also implicate 
TREM-1 in bacterial infection. In a pig model of Salmonella enterica infection, 
expression of TREM-1 is induced 8 and 24 h post-infection (Ramanathan et al., 
2005). Based on these studies, it would be important to understand role TREM-1 in 
vivo during viral and bacterial infection to evaluate whether TREM-1 is a suitable 
therapeutic target.  
 
3.1.3. The soluble form of TREM-1 
In addition to the membrane-bound form expressed on the cell surface, a soluble 
TREM-1 (sTREM-1) is detected in mouse and human serum b et al., 2005). It only 
contains the extracellular part of TREM-1 and may block membrane bound TREM-1 
by competing for the unknown TREM-1 ligand. There are two hypotheses to account 
for the source of sTREM-1: one proposes that it originates from proteolytic cleavage 
of the membrane bound TREM-1 (Gibot et al., 2004b); the other hypothesis suggests 
that it is produced by translation of alternative mRNA splice variant of TREM-1 
(Begum et al., 2004).  
 
Due to the significant level of sTREM-1 found in BAL fluid in pneumonia (Richeldi 
et al., 2004) and plasma in patients with sepsis, TREM has become not only a 
diagnostic marker for these infections, but also a target for treatment. This idea is 
supported by the evidence from the mouse model of septic shock, which shows that 
the administration of a synthetic peptide (LP17), that mimics sTREM, can reduce the 
inflammatory response and augment survival (Gibot et al., 2004b). All these findings 
indicate that TREM-1 serves as an enhancer of innate immune responses and that 
sTREM-1 act as an inhibitory mechanism to switch off TREM-1 signalling.  
 
3.1.4. Hypothesis 
Based on these studies, it is likely that the TREM family will play a crucial role in 
regulating lung inflammatory disease during additional lung infection. TREM-1 acts 
as a potentiator and sTREM-1 as an inhibitor to modulate immune responses, which 
makes them potential targets to manipulate during the harmful overzealous 
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inflammatory response induced by influenza infection. Additionally, the observation 
that sTREM -1 is low in the absence of inflammation and rises with increasing 
inflammatory processes, makes it a promising biomarker for infective disease. By 
analysing the expression and regulation of TREM-1 during the course of infection, we 
can provide insights into unique parameters of these molecules and how they are 
manipulated by the pathogen. We will test that TREM-1 proteins are important for 
lung viral infection and potentiate secondary bacterial complications. 
 
3.1.5. Aims 
This chapter is based on the hypothesis that TREM-1 plays an important role in 
regulating immune homeostasis and the extent of inflammation in the lung during 
infection. Therefore, the following aims will be investigated to test this hypothesis:  
 
 To determine the expression profile of TREM-1 in the lung during 
homeostasis as well as during inflammation associated to influenza, bacterial, 
and influenza\bacterial dual infections. We anticipate that TREM-1 expression 
will be compartmentalized and cell type specific. 
 
 To correlate levels of sTREM-1 with the severity of infection. We will 
particularly analyse sTREM-1 expression during influenza infection, bacterial 
infection and co-infection  
 
 To compare the expression profile of membrane TREM-1 and soluble sTREM 
during different types of infection in different compartments. This 
comparative approach may reveal a distinct expression pattern of TREM 
molecules in the inflammatory response to influenza or co-infection. 
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3.2. Results 
3.2.1. TREM-1 expression on myeloid cells at homeostasis 
The respiratory tract is constantly exposed to inhaled particles, various antigens and 
microorganisms; therefore the innate immune response needs to be regulated to 
minimize collateral damage to lung tissue caused by unchecked inflammation. 
Myeloid cells are the essential building block of the early-induced response against 
viral infection and also mediate the link between the innate and adaptive immune 
system. They can be distinguished by cell surface expression of cell markers such as 
CD11c, CD11b, Ly6g and F4/80. Figure 3.1 shows representative FACS plots to 
assess neutrophils and macrophages in the airway. Dead cells, resting and activated 
lymphocyte were excluded based on size (forward) and granularity (side) scatter 
properties (Fig.3.1 A). The selected myeloid population was then examined for 
expression of CD11c, Ly6g and CD11b (Fig.3.1. B.C). The population with a high 
level of Ly6g and CD11b was defined as neutrophils (Fig.3.1.C) and the population 
with intermediated expression of CD11b and a high level CD11c was identified as 
airway macrophages. Notably that high levels of CD11c expression is a unique 
characteristic of airway macrophage as its expression is not observed on macrophages 
elsewhere or on those recruited to the airway during inflammation (Guth et al., 
2009).These myeloid cell populations were assayed for TREM-1 expression by 
staining with fluorescence conjugated antibody.  
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In naïve mice, more than of 95% the cell population in the airway are alveolar 
macrophages, which play a crucial role in maintaining immunological homeostasis 
(Upham et al., 1997 and Bilyk et al., 1995). Their main function is phagocytosis and 
sequestration of antigen from the immune system to avoid evoking an inflammatory 
(MacLean et al., 1996). Airway macrophages and neutrophils express low level of 
surface TREM-1 (Fig. 3.2.B&C). The expression of TREM-1 was also barely 
detectable on the uninflamed lung parenchyma macrophage and neutrophils (Fig. 3.2. 
E&F).  
Figure 3.1. Strategy to identify neutrophils and macrophage  
Cells isolated from the lungs of infected mice were stained with various cell 
markers and subject to FACS analysis. The FSC 
mid-hi
 SSC 
mid-hi
 population was 
selected to exclude lymphocyte (A). Within this population, the neutrophils (B) 
were identified as Ly6g
+
 and CD11b
+
 and airway macrophage (C) were defined 
as CD11c+ and CD11b+. FSC is represent forward scatter and SSC is for side 
scatter. 
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3.2.2. TREM-1 expression on myeloid cells during influenza 
infection 
3.2.2.1. The expression of surface TREM-1 during infection 
The TREM-1 expression profile was next examined in a mouse model of influenza 
infection, which is a well-developed experimental system and relevant to the study of 
the immunopathology of human influenza infection. We first characterized a time 
course of infection to correlate TREM-1 expression with disease. The severity of 
illness is monitored by different parameters, including weight loss and the number of 
cells infiltrating the lung. During the course of infection animals were sacrificed at 
intervals and cells from a variety of organs stained with different cell markers to 
determine their number, function and phenotype. Upon intranasal administration of 
influenza A virus (2.6x10
3
 pfu per mouse), weight loss was apparent after 2 days and 
peaked at 5 or 6 days post inoculation with approximately 25% weight loss (Fig 
3.3.A). After day 6, mice gained weight gradually and the last time point measured 
was day 10. This weight loss kinetics is reproducible between infections. The kinetics 
Figure 3.2.  TREM-1 expression in the airway and lung at homeostasis  
Naïve mice were sacrificed to harvest cells from the airway (A-C) and lung (D-F). 
Different cell markers were used to identify macrophage and neutrophils. 
Histogram shows TREM-1 staining (blue line) and isotype matched control in red 
on the cell population shown. This data was representative of 15 mice from three 
independent experiments.  
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of cell accumulation in the airway and lung correlated with weight loss with maximal 
cellularity at time points associated with the peak of weight loss (Fig. 3.3. B&C). This 
expansion continued until day 10 in the lymph nodes (Fig.3.3D).  
 
 
 
 
The TREM-1 expression pattern was characterized in different organs and on 
different myeloid cell populations. During influenza infection, neutrophils in the 
blood expressed high levels of TREM-1 that remained fairly constant throughout 
infection (Fig.3.4A). TREM-1 expression on airway neutrophils was absent of the 
start of infection but increased during infection (Fig.3.4.B-K), whereas expression on 
neutrophils in the lung was similar to those in the blood. It should be appreciated that 
lungs were not perfused to remove the vasculature. Therefore lung samples may 
contain residual blood neutrophils. In contrast, macrophages in the airway and lung 
did not express high levels of TREM-1 at any stages of infection (Fig. 3.5). Airway 
DCs are a very small population lacking TREM-1 expression in this analysis.  
Figure 3.3.  Weight loss and cellularity observed in mice during influenza infection. 
Mice were infected with influenza and body weight expressed as percent of original 
weight (left axis) was monitored every day (A).The cells from the lung (B) airway 
(C), and lymph node (D) were harvested at 6 hr, 1, 2, 3, 6 and 10 days after infection 
and counted at each time point. Results represent mean values ± SEM, n = 5 and 
plots as representative of three independent experiments 
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Figure 3.4. Mouse TREM-1 expression and regulation on neutrophils during 
influenza infection.  
Mice received influenza intranasally (2.6x103 pfu/mouse), and the change in 
TREM-1 expression was monitored at day 1, 2, 4 and 7 post infection. Mice were 
culled and analysed for expression of neutrophils in the blood (left column), 
airway (middle column) and lung (right column). The blue histograms represent 
TREM-1-expression and the red histograms are IgG2 isotype control. The 
fluorescence intensity is measured on the log10 scale, and the y-axis indicates 
event counts per channel on a linear scale.  
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Figure 3.5. Mouse TREM-1 expression on macrophages during influenza 
infection.  
Mice received influenza intranasally (2.6x10
3
 pfu/mouse), and TREM-1 
expression on macrophage was monitored at day 1, 2, 4 and 7 post-infection. In the 
airway (left column) and lung (right panel). The blue histograms represent TREM-
1-expressing cells and the red histograms are IgG2 isotype control. The 
fluorescence intensity is measured on the log10 scale, and the y-axis indicates 
event counts per channel on a linear scale.  
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TREM-1 expression was remarkably consistent between individual mice within each 
time point (Fig 3.6), increasing by three to four fold in the airway and lung reaching a 
maximum after 2 days and then rapidly declining to base line in both sites. In contrast, 
elevated populations of TREM-1
+
 neutrophils were maintained with in blood (Fig.3.6. 
C&D). Analysis of the geometric mean of fluorescence intensity indicated that the 
level of TREM expression on individual neutrophils also increased at day 2. It was 
interesting to note that TREM-1 was expressed on approximately 90% of blood 
neutrophils but only 50% of lung neutrophils and 20% of airway neutrophils even at 
day 2 (Fig.3.6). The increase of TREM-1 may simply reflect the fact that the 
recruitment of neutrophils to the airway peaks at days 1-2 following influenza 
infection. In addition, their increase in the blood most likely represents enhanced 
mobilization form bone marrow. This suggests that specific mechanisms in the lung 
microenvironment caused neutrophils to loss TREM-1 following their recruitment 
from the blood. The strong expression of TREM-1 in the early stage of influenza 
infection, especially on neutrophils recruited to the airway suggested that TREM-1 
may play a role in the acute inflammatory response. It may associate with other 
receptors to trigger release of proinflammatory cytokine and chemokines. TREM-1 
expression peaks at day 2 and precedes maximal weight loss (Fig. 3.7), which 
suggests that the early recruited lung TREM-1
+
 neutrophils may contribute to the 
disease process during influenza infection. 
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Figure 3.6. The kinetics of TREM-1 expression on neutrophils and sTREM-1 during 
influenza infection.  
Mice were infected with influenza and cells were harvested. FACS analysis were used to 
calculate total number of neutrophils in the airway (A), blood (E) and lung (I). In addition, 
the number of TREM-1 expressing neutrophils (Ly6g+) were enumerated by flow 
cytometry in the airway (B), blood (F) and lung (J), which is calculated by multiplying the 
percentage of TREM-1
+
 neutrophils (C, G and K) by the total cell number. The middle 
panel shows the percentage of TREM-1 positive cells in different sites. The right panel 
represent the concentration of sTREM-1 which measured by ELISA in the airway (D), 
blood (H) and lung (L). The right panel shows the number of TREM-1 positive neutrophils 
in the corresponding tissue. Data represent as Mean ± SEM and 4 mice used at each time 
point. 
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3.2.2.2. The secretion TREM-1 during influenza infection 
One of the most intriguing features of TREM-1 is its soluble form, which is already 
used as a diagnostic marker of infectious inflammatory conditions (Gibot et al., 
2004a). To identify the potential involvement of sTREM-1 in vivo during influenza 
infection, lung homogenates, blood serum and BAL fluid were collected at each time 
point through the infection and subjected to measurement of sTREM concentrations 
by ELISA. In uninfected mice, sTREM-1 was detected at low levels in the airspaces, 
lung and serum. Following infection, the concentration of sTREM-1 increased 
significantly from day 1, reaching a peak at day 2 (Fig.3.6.C, G, K). This kinetic 
correlated with the number of surface TREM-1+ neutrophils at each sites. The 
concentration of sTREM-1 in serum was much lower than the lung and airway 
(Fig.3.6.H), despite the fact that TREM-1 was expressed on 90% of neutrophils in this 
site. This may suggest that the cleavage of this surface receptor was inhibited or that 
the mechanisms required for its secretion is inactivated in the blood. 
 
Figure 3.7. The correlation of weight loss and TREM-1 expression on neutrophils.  
Weight loss was expressed as percent of original body weight (red line with closed 
circles on left axis) and the number of TREM-1 positive neutrophils (black line 
with open circles on right axis) was enumerated at 1, 2, 4, 6, 7 days after infection. 
Data represents the Mean ± SEM of n = 4 per time point. 
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3.2.3. TREM-1 expression during influenza and bacterial co-
infection 
3.2.3.1. The expression of surface TREM-1 during influenza and 
bacterial co-infection 
Clinically, influenza infection is often complicated by secondary bacterial infection 
including Haemophilus influenzae, Staphylococcus aureus, and Streptococcus 
pneumoniae leading to increased morbidity and mortality (Morens et al., 2008). To 
facilitate study of the mechanisms that underlay this potentially synergistic interaction 
between influenza virus and bacteria, a relevant animal model of secondary bacterial 
pneumonia following by influenza infection was developed. 
 
In this dual infection model, BALB/C mice were pre-infected with influenza virus for 
6 days and then challenged intranasally with Streptococcus pneumoniae. The mice 
were sacrificed for bacterial culture and cellular counts at various time points post co-
infection and one additional group was carefully monitored for survival. Infected mice 
started to reach the home office regulated end point (loss over 25% of original weight) 
48 hours after bacterial infection and individual mice succumbed thereafter 
(Fig.3.8.A). Mortality was associated with a dramatic raise in bacterial load in the 
blood, lung, nasal cavity and airway over time (Fig.3.8.B-E). An increase of 
cellularity in the airway and lung was also observed (Fig.3.8.F, G) and subjected to 
FACS analysis to profile TREM-1 expression.  
 
During co-infection, as in influenza alone, TREM-1 positive neutrophils and 
macrophages were observed in the airway and lung, both the intensity and proportion 
increased over time (Fig 3.9). Later time points after 48 hours were not analysed due 
to mortality in the co-infected group. TREM-1 mean fluorescent intensity increased 
on macrophages and neutrophils in the airway (Fig.3.9. A&B) and lung (Fig.3.9. 
C&D). This similar pattern was also observed for the percentage of positive 
neutrophils (Fig.3.9 E-H). It is interesting to note that unlike influenza infection alone 
the population of macrophages and neutrophils expressing TREM-1 was much higher 
in the co-infected group. Considering that the expression profile was only analysed up 
to 2 days post bacterial challenge, it is possible that TREM-1 expression in mice 
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survived the co-infection may have returned to the baseline similar to influenza alone 
infected mice.  
 
 
Figure 3.8.The bacterial burden and survival rate in influenza and S. pneumoniae co-
infection model  
Mice were pre-infected with X31 influenza virus for 6 days and then challenged with 
10
6
 cfu of S. pneumoniae. Mice were carefully monitored and the survival rate (A) was 
recorded after infection. Bacterial colony forming units were enumerated in the blood 
(B), lung homogenate (C), nasal wash (D) and BAL fluid (E). Cell count from 
harvested BAL fluid (E) and lung (F) were determined at each time point. Data 
represent as Mean ± SEM and 5 mice used at each time point. 
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Figure 3.9 The expression profile of TREM-1 receptor after influenza and S. 
pneumoniae co-infection.  
Mice were pre-infected with X31 influenza for 6 days then challenged with 10
6
 cfu of 
S. pneumoniae. 6, 24 and 48 hours after the onset of co-infection, mice were harvested 
and the BAL fluid and lungs were collected for FACS analysis. The expression of 
TREM-1 was examined on macrophages (left panel) and neutrophils (right panel). The 
geometric mean fluorescence intensity of TREM-1 expression (A-D) was recorded at 6 
hours (purple line), 24 hours (green line) and 48hours (yellow line).  Representative 
histograms for expression in the airway cells (A, B) and lung cells (C, D) is shown 
with isotype control which is represented as the red line. The percentage of TREM-1+ 
immune cells (E-H) are recorded in the airway (E, F) and lung (G, H) and each point 
represents an individual mouse. The data shown are Mean of n = 5 per time point.  
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3.2.3.2. The secretion of soluble TREM-1 during influenza or co-
infection  
We next examined sTREM-1 levels in mice infected with influenza alone, S. 
pneumoniae alone and a combination of both pathogens as before. During the 
influenza infection alone, sTREM-1 secretion was elevated in line with disease 
severity and reached a peak at day 2, followed by a reduction to day 6. Upon bacterial 
infection of influenza infected mice, a significant amount of sTREM-1 was observed 
in both the BAL fluid (Fig.3.10.A) and lung (Fig.3.10.B) which was seven-fold higher 
than the first peak. In this experiment we included a bacterial alone group, which was 
not sufficient to stimulate such a high level of sTREM-1(Fig.3.10 A&B).  
 
 
 
Figure 3.10.  The kinetics of sTREM-1 during influenza and bacterial co-infection  
Mice were pre-infected with X31 influenza for 6 days then challenged with 10
6
 cfu of 
S. pneumoniae. 6, 24 and 48 hours after the onset of co-infection, mice were harvested 
and the BAL fluid and lungs were collected. The concentration of sTREM-1 was 
measured by ELISA in the airway (A) and lung (B). The black lines represent the level 
of sTREM-1 during co-infection, and the dashed lines indicate the level of sTREM-1 
in bacterial alone infection. Data are represent as Mean ± SEM of n = 5 per time point.  
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3.2.3. The role of TREM-1 in TLR responses  
As we observed elevated expression of TREM-1 on macrophage after co-infection, it 
may play a role in the pulmonary host response to viral and bacterial infection. To 
obtain insights into the function of TREM-1, we assessed the synergistic activity 
between TREM-1 and TLRs on the alveolar macrophage (MH-S) and RAW (264.7) 
cell lines. The TREM-1 stimulation was achieved by culturing cells in a 96 wells plate 
coated with agonist anti-TREM-1 antibody followed by the addition of various TLR 
ligands for additional an 24 hour. TREM-1 engagement alone was enough to enhance 
the production of TNF-α, IL-6 probably as a result of the cross-linking of TREM-1 on 
the cell membrane (Fig 3.11). An additive effect was observed on IL-6 production of 
RAW cells treated with agonist TREM-1 antibody in response to TLR 2 and 3 
stimulation. For TLR4 and 7, we observed a significant increase in IL-6 production 
when TREM-1 was trigged. This effect was even more pronounced for TNF 
production; however it must be considered that cell lines that may display phenotype 
different from primary cell in vivo. Base on previous data, TREM-1 is likely to 
facilitate the inflammatory response caused by TLR ligands and sTREM-1 may blunt 
innate immunity leading bacterial super-infection. 
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Figure 3.11.  TREM-1 synergizes with TLR and NLR ligands.  
MH-S (left panel) and RAW (right panel) cells were incubated in wells coated with anti-
TREM-1 antibodies in the presence of: TLR2= LTA (5 ug/ml), TLR3= poly I:C (5 ug/ml), 
TLR4= LPS (10 ng/ml), TLR7=poly U(1ug/ml) or TLR9= CpG (10 ug/ml).  The 
concentration of IL-6(A, B) and TNF-α (C, D) were measured by ELISA after 24 hr 
stimulation. Closed bars represent the stimulation induced by the combination of the anti-
TREM-1 antibodies with the TLR ligands, and open bars are stimulations with TLR ligands 
alone. Data are presented as means Mean ± SEM of n = 4. 
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3. 3 Discussion 
3.3.1. The expression profile of surface TREM-1 during 
influenza infection 
We investigated, for the first time, the expression pattern of TREM-1 on immune cells 
in homeostasis and infection to extend the findings of previous studies showing that 
TREM-1 is up-regulated by various infectious and inflammatory conditions (Bouchon 
et al., 2001b). Previously elevated expression of TREM-1 has been demonstrated on 
neutrophils and monocytes during bacterial infections such as P. aeruginosa and 
Staphylococcus aureus (Sharif et al., 2008). Furthermore, Marburg and Ebola virus 
activates neutrophils in a TREM-1–dependent manner (Mohamadzadeh et al., 2006). 
The inducible expression of TREM-1 leads further control over innate immunity. Low 
level TLR signalling may occur at homeostasis via recognition of pathogen-associated 
molecular patterns (PAMPs) derived from commensal bacteria, which do not lead to 
overt inflammation without TREM-1. 
 
To support this we show that airway macrophages and DCs express low levels of 
TREM-1 on their surface at homeostasis. In naïve mice, the airway space is constantly 
exposed to various antigens; therefore a reduced TLR response avoids unnecessary 
tissue damage (Wissinger et al., 2009). Taking into account that TREM-1 acts as an 
amplifier of inflammatory responses (Colonna et al., 2003), the downregulation of 
TREM-1 may be employed by host cells to prevent non-specific or over zealous 
inflammation in the airway to common allergens and commencal bacteria. It is also 
possible that the lung microenvironment prevents TREM-1 expression via TGF-β, IL-
10, IL-33 and CD200R, which could be tested in knockout mice or through antibody 
mediated depletion.  
 
During infection, TREM-1 is dominant on neutrophils, where upregulation preceded 
maximal weight loss at day 6 or 7 post challenge. Expression was diminished during 
the resolution phase following viral clearance. TREM-1 enhances the production of 
proinflammatory cytokines such as TNF-α and IL-1β after TLR activation, along with 
rapid neutrophil degranulation and oxidative burst (Radsak et al., 2004).  
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This early induction pattern fits with the need to initiate a fast innate response to 
control viral replication and activate adaptive responses. We and others observe that 
co-ligation of TLRs and TREM-1 results in higher cytokine production than either 
TREM-1 or TLR alone. This finding provides a potential mechanism to modulate 
over zealous innate immunity to influenza virus and subsequent secondary bacterial 
infection. 
 
3.3.2. The regulation of TREM-1 
In this study show that the expression of TREM-1 on neutrophils depends on the 
tissue compartment analysed. The various scenarios that may cause this are show in 
figure 3.14. At homeostasis, neutrophils in the blood express high levels of surface 
TREM-1 constitutively, but only a small proportion of neutrophils express TREM-1 
in the inflamed lung and airway. Before migration into specific tissues, circulating 
neutrophils need undergo further maturation which associated with a regulation of cell 
receptors such as the G-CSF receptor to allow site-specific functions (Shoup et al., 
1998). Thus, the downregulation of TREM-1 may also evolve at a specific 
maturational stage (Fig 3.12-1). When the circulating neutrophils enter specific 
tissues, its phenotype is also likely to be controlled by local microenvironment. Thus 
the site specific factors or proteinases may also lead to inhibition of TREM-1 splicing 
or cleavage of surface TREM-1 (Fig 3.12-2). Finally, TREM-1 may be lost on 
neutrophils that have performed their function and are undergoing apoptosis. The 
latter hypothesis is appealing since it would prevent the potentiation of TLR 
signalling during efferocytosis of apoptotic neutrophils (Fig 3.12-3).  
 
Neutrophils circulating in the blood are less phagocytic than tissue neutrophils 
(Sorensen et al., 2001). The down regulation of TREM-1 may therefore denote 
phagocytic activity. The engagement of TREM-1 by its unknown ligand in the lung 
causes DAP12 dependent production of IL8, MCP-1, MPO, lactoferrin (Radsak et al., 
2004), and reactive oxygen species (ROS), which promotes degranulation and 
phagocytosis (Bouchon et al., 2000). The blood is a relatively sterile environment 
compared with lung tissue; therefore the activity of TREM-1 signalling is limited due 
the apparent lack of ligands for the receptor. Upon neutrophil extravasation into the 
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lung, its expression may be down-regulated by TLR ligands or a cytokine-rich 
environment.  
 
  
 
After 3 or 4 days of influenza infection, the expression TREM-1 is reduced again, 
which may prevent ongoing innate immunity. This downregulation may caused by 
several different mechanisms, including direct interaction between influenza and 
neutrophils, which is supported by a study showing that filoviruses down-regulate 
TREM-1 (Mohamadzadeh et al., 2006). As mentioned before clearance of apoptotic 
neutrophils requires ingestion without inflammation. To facilitate this TREM-1 may 
be downregulated or shed before efferocytosis. Furthermore two peptides present in 
the lung, vasoactive intestinal peptide (VIP) and LL-37 modulate TREM-1 expression 
(Sun et al., 2011 and Amatngalim et al., 2010). VIP is a bioactive neuropeptide and 
its anti-inflammatory properties have been demonstrated in respiratory diseases 
Figure  3.12. The underlying mechanism of TREM-1 down-regulation.  
At present there are three possible mechanisms :( 1) TREM-1 is lost during 
maturation. (2) The site specific factor or proteases such as MMP9 inhibit or cleave 
TREM-1. (3) The apoptotic neutrophils lose the expression of TREM-1 
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(Gürkan et al., 2009). VIP inhibits expression of TREM-1 mRNA in LPS stimulated 
lung cells (Sun et al., 2011). LL-37 is a human cationic host defense peptide of the 
cathelicidin family (Amatngalim et al., 2010) and produced from a precursor protein, 
hCAP-18, by proteolysis (Nijnik et al., 2009). Its production is induced under 
inflammatory conditions (Bals et al., 1999) and suppressed expression of TREM-1 on 
monocytes (Amatngalim et al., 2010). Thus, the downregulation of TREM-1 we 
observed in influenza infection may be caused by the rising levels of these two 
peptides, the correlation of which should be tested.  
 
3.3.3. The correlation between sTREM-1 and infection 
Although the mechanism underlying the production of sTREM-1 remains unknown, 
sTREM-1 levels are monitored in a number of systemic acute inflammatory clinical 
conditions (Haselmayer et al., 2007).  Several studies compare the reliability between 
sTREM-1 and other biomarkers, such as C-reactive protein (CRP) and procalcitonin 
(PCT) to distinguish infectious and non-infectious systemic inflammatory response 
syndrome (SIRS). In a cohort study of 76 patients admitted to an adult medical ICU 
with a suspicion of infection, higher plasma levels of sTREM-1 are detected in 
infectious systemic inflammatory response syndrome than in those without microbial 
infection (Gibot et al., 2004a). The superiority of sTREM-1 as a diagnostic tool is 
supported by the high sensitivity, specificity, positive predictive value and negative 
predictive value at 96%, 89%, 94%, and 93%, respectively (Gibot et al., 2004a). A 
similar result is obtained in pediatric patients by comparing sTREM-1 with CRP or 
ratio of immature versus total neutrophil. Measurement of sTREM-1 exhibited higher 
sensitively and specificity in diagnosing severe bacterial infections. (Chen et al., 
2008). In sepsis, sTREM-1 in plasma is an independent risk factor associated with 
outcome of disease. Comparing to patient that died due to sepsis, the survivors had 
higher baseline level of sTREM-1 in their serum. As the sepsis progressed, the 
concentration of sTREM-1 progressively decreased in survivors, whereas the 
concentration remains high in non-survivors (Gibot et al., 2005). According to these 
studies, the measurement of plasma sTREM-1 concentrations remains promising in 
diagnosing systemic infections. 
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The local measurement of sTREM-1 concentrations has also been tested during a 
variety of pulmonary infections. A study of 148 patients under mechanical ventilation 
defined the alveolar concentration of sTREM-1 as a marker of infectious pneumonia 
that performed better than any other clinical or biologic diagnostic marker (including 
CRP and PCT) in both community-acquired and ventilator-associated pneumonia 
(Gibot et al., 2004b). This conclusion is confirmed by other studies which found that 
sTREM-1 are significantly higher during bacterial or fungal pneumonias, while 
sTREM-1 concentrations remained relatively lower in case of viral infection (Huh et 
al., 2008). This is supported by our observation that sTREM-1 levels were lower 
during primary influenza infection, but increased after secondary bacterial infection. 
This result shows its diagnostic value in influenza and bacterial co-infections, 
particularly to determine whether the patient is presenting with a poly-microbial 
conditions.  
 
Recent studies suggest that sTREM-1 may be induced in biologic fluids from other 
inflammatory conditions, such as COPD where sTREM-1 concentrations inversely 
correlate with disease severity (Radsak et al., 2007). Similar elevations of sTREM-1 
in plasma, with an increase in the expression of monocytic TREM-1 are also detected 
during acute pancreatitis (Ferat-Osorio et al., 2009 and Wang et al., 2004). 
Unexpectedly, the diagnostic value of sTREM-1 has also been explored in a cohort 
study of 54 patients resuscitated from a cardiac arrest (Adib-Conquy et al., 2007). 
60% of the patients presented with elevated plasma sTREM-1 concentrations, 
especially among patients who had multi-organ failure. All these findings suggest that 
the clinical diagnostic value of plasma level of sTREM-1 is not limited to infections.  
 
We demonstrate a rise in sTREM-1 in the airway and blood during influenza 
infection, thus this assay may have prognostic value during pandemic influenza 
infection. Influenza infection is frequently associated with secondary bacterial 
pneumonia (Jonathan et al., 2008) and it is important to differentiate single from dual 
infections. We observed a 10-fold increase of sTREM-1 in BAL fluid from dual 
infected mice compared to either influenza or bacterial alone infection. Thus the 
measurement of sTREM-1 in BAL fluid or serum may help in patient management by 
restricting antibiotic use to those with bacterial pneumonia and reducing the health-
care cost and the emergence of antibiotic resistance. 
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4.1. Introduction 
4.1.1. The origin of soluble triggering receptor expressed on 
myeloid cells-1 (sTREM-1) 
TREM-1 was discovered by Bouchon in 2000 as a cell surface receptor specifically 
expressed on the surfaces of monocytes and neutrophils. In addition, a soluble form, 
which only contains the extracellular domain of the intact TREM-1 molecule, was 
first identified in the serum and bronchoalveolar lavage (BAL) fluid of sepsis patients 
and its diagnostic implications for sepsis was identified (Gibot et al., 2004b).  In an 
extension of this study, sTREM-1 level was correlated with the severity of sepsis 
(Zhang et al., 2011). Other studies have also defined it as valuable marker for several 
inflammatory diseases such as ventilator-associated pneumonia (Wu et al., 2011) and 
influenza A (H1N1)-related pneumoniae (Raftogiannis et al., 2010). Despite its 
diagnostic implication, the mechanisms underlying the production of sTREM-1 
remain unclear. There are two currently proposed theories: sTREM can be produced 
by the translation of an alternative TREM-1 mRNA splice variant or by proteolytic 
cleavage of membrane TREM-1 (Klesney-Tait et al., 2006).  
 
All members of the matrix metalloproteinase (MMP)
 
family are detected within the 
lung tissue and many of them are upregulated
 
during the acute phases of inflammatory 
diseases (Parks et al., 2004). For example, the serum level of MMP-9 from an 
influenza patient were significantly higher than the healthy controls (Ichiyama et al., 
2007) and it could be upregulated by influenza in various organs via MAPK-NFκB 
dependent mechanisms (Wang et al., 2010). In addition, the MMPs can cause 
cleavage of the extracellular domain of membrane receptors such as the insulin 
receptor and the membrane beta2-adrenergic receptor. (Rodrigues et al., 2010). Based 
on these, we hypothesised that specific MMPs present in the lung may induce the 
cleavage of cell surface-anchored TREM-1 into sTREM and that their levels, or its 
activity may be induced during influenza infection.  
 
The presence of proteases in the lung does not rule out the possibility that alternative 
mRNA splicing produces sTREM. Therefore another assumption can be made that the 
translation of an alternative sTREM-1 mRNA splice variant is induced by 
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inflammatory factors in the lung.  A variant has already been detected in human 
monocytes (Gingras et al., 2001), but its predicted molecular mass is lower than that 
of the actual sTREM-1 found in supernatants of monocyte cultures (Gibot et al., 
2004b). Currently, the distribution pattern of splice variants in the lung is unknown, as 
is the exact function and role of sTREM-1. However we can make a rational 
hypothesis, based on the fact that sTREM-1 has the same extracellular domain as 
TREM-1, but no signalling motif. We believe that sTREM-1 may compete with 
TREM-1 for its ligand(s) and act to down-regulate the TREM-1 pathway. Therefore, 
sTREM-1 could be considered to behave as an anti-inflammatory mediator whose 
function could be mimicked by an artificially generated peptide. 
 
4.1.2. The manipulation of TREM-1 signalling 
The involvement of TREM-1 in immune responses during bacterial infection and 
sepsis make it a promising target for modulation to improve the outcome of these 
diseases. Currently, there are many in vivo studies in which TREM-1 signalling is 
interrupted by using a synthetic peptide mimicking a part of the extracellular domain 
of TREM-1 (Luo et al., 2010). This peptide is called LP17 and has the 
complementary determining region 3 (CDR3) and the “F” β strand of the extracellular 
domain of TREM-1, which has been proposed to mediate dimerization of the TREM-
1 receptor (Radaev et al., 2003). It is suggested that this compound either impairs 
TREM-1 dimerization and/or competes with the natural ligand of TREM-1 (Gibot et 
al., 2004b). In vitro, LP17 reduces TNF and IL-1β production from monocytes 
stimulated with LPS alone or with a TREM-1 agonistic antibody (Gibot et al., 2004b). 
This TREM-1 blocking reagent also has significant impact on other in vivo animal 
models of infectious disease (Marc et al., 2010)  
 
In mouse models of LPS-induced septic shock, either pre-treatment of mice with a 
single dose of LP17 before a lethal dose of LPS, or treatment of mice 4 hours after 
disease onset, provided a survival advantage and reduced inflammation compared to 
control mice (Gibot et al., 2004b). This protective effect of LP17 is also seen in other 
models of infection such as during P. aeroginosa pneumonia and Burkholderia 
pseudomallei pneumonia (Gibot et al., 2006; Wiersinga et al., 2007). In P.aeroginosa 
pneumonia, LP17 prevents cellular infiltration, histological damage and decreases 
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levels of TNF, IL-1β and IL-6 in BAL and plasma at 24 h post-infection compared to 
control mice (Gibot et al., 2006). This decrease in cytokine levels correlates with 
previous studies in the sepsis model (Gibot et al., 2004), but not with the model of B. 
pseudomallei pneumonia (Wiersinga et al., 2007), which suggests that regulation of 
the TREM-1 pathway has different effects depending on the infectious model. 
4.1.3. Hypothesis 
TREM-1 is expected to play an important role in regulating immune homeostasis and 
dictating the extent of inflammation in the lung during infection. As we have shown 
in the previous chapter, expression of TREM-1 receptor is upregulated by influenza 
alone or with bacterial co-infection. Moreover, activated TREM-1 can amplify 
infection-induced inflammatory response signals primarily through the augmentation 
of TLR signalling to produce excessive cytokines. sTREM-1, considered an anti-
inflammatory mediator by binding to the TREM-1 agonist (Giamarellos-Bourboulis et 
al., 2006), was also elevated  post infection and followed the same pattern as surface 
TREM-1. The interplay between soluble and surface TREM-1 level may be employed 
by the host to fine-tune the innate immune response. For these reasons, we will test 
whether the blockade of TREM-1 by LP17 during the initial phase of infection will 
result in reduced innate immune activity. We hypothesize that this would potentially 
provide benefit for the host by limiting the innate immune thus preventing bystander 
tissue damage and further secondary bacterial pneumonia. 
4.1.4. Aims 
This chapter is based on the hypothesis that inhibition of surface TREM-1 activity 
during influenza infection will improve outcome of the disease. Therefore, the 
following aims will be investigated to test this hypothesis:  
 Determine the effect of LP17 treatment on influenza alone or bacteria alone 
infection 
 Determine the effect of LP17 treatment on the influenza bacterial co-infection 
 Determine the source of sTREM-1 during influenza infection 
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4.2. Results 
4.2.1. The effect of LP17 on influenza infection 
4.2.1.1. The effect of LP17 on weight loss and cellularity 
LP17 is a synthetic peptide containing a sequence homologous to the extracellular 
domain of TREM-1. It has been used both in vivo and in vitro to compete with the 
natural ligand of TREM-1 and impair the TREM-1 dimerization required for 
proinflammatory signalling (Radaev et al., 2003). Therefore treatment of LP17 could 
reduce influenza induced excessive inflammatory responses and improve the disease 
outcome. An experiment containing two groups of mice was carried out to discover 
whether LP17 could change the immunopathology of influenza infection. Mice were 
injected with 100 μg LP17 or control peptide daily after the influenza X31 infection  
 
No significant difference in weight loss was observed by LP17 treatment (Fig. 4.1 A). 
Six days after challenge, the mice were harvested to check the cellularity in different 
lung compartments.  Cellular infiltration into the airways and lung was reduced by 
30% in the LP17 group compared with controls (Fig. 4.1 B, C) conversely there was a 
three fold increase in cell number in the blood and lymph node (Fig. 4.1 D, E). The 
inhibition of TREM-1 signalling may therefore influence vascular permeability or 
migration of cells from l to effector sites. 
 
  
To further explore the effect of LP17 administration on disease progression, vascular 
permeability, viral titer and proinflammatory cytokine production were assayed (Fig 
4.2). The albumin levels in the BAL fluid, which are widely used as markers of lung 
permeability, were significantly lower in the LP17 treated mice relative to the controls 
at day 6 after influenza instillation (Fig 4.2A). Meanwhile, LP17 treatment had 
reduced the viral titer slightly (Fig 4.2 B), but significantly inhibited the levels of 
interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) (Fig 4.2C, D). 
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Figure 4.1.  LP17 treatment reduces cell recruitment to the lung  
Two groups of female BALB/cmice were infected with 50 HA unit of influenza 
virus. One group were administered LP17 (100μg) daily until 6 day after infection. 
Weight loss (A) was monitored daily (red line represents the influenza + control 
peptide group and green line represents influenza + LP17 group). At 6 day post 
infection, mice were harvested and total cell numbers from airway (B), lung (D), 
blood (C) and lymph node (D) were counted. Statistical analysis was performed by 
Mann Whitney test of variance and data are shown as Mean ± SE. The experiment 
was repeated three times and 4 mice per group were used in single experiments. *P 
<0.05 and **P<0.01 compared with control group at the same time points. 
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Figure 4.2.  LP17 treatment reduces proinflammatory cytokine levels and 
permeability 
The BAL fluids and lung tissue were collected from mice infected with influenza 
for 6 days with LP17 (black bar) or with control peptide (white) treatment. The 
level of albumin was measured by ELISA (A) and a plaque assay was used to 
determine viral titer in the lung homogenate (B). Additionally, the concentrations 
of TNF (C) and IFNγ (D) were also evaluated in the BAL fluid. Statistical analysis 
was performed by Mann Whitney test of variance and data are shown as Mean ± 
SE. The experiment was repeated three times and 4 mice per group were used in 
single experiments. *P <0.05 compared with control group at the same time points. 
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4.2.1.2. The effect of LP17 on the myeloid and T cell compartment 
during infection 
As TREM-1 was mainly expressed on the myeloid populations and they were 
examined in LP17 treated mice during influenza infection. There was no difference in 
the number and proportion of neutrophils in the airway or lung tissue 6 days after 
infection (Fig. 4.3 A-D). However, a significant increase in neutrophils was observed 
in the blood compared with control group (Fig. 4.3 E, F). For macrophages, two 
different subsets were classified: alveolar macrophages (F4/80
medium
, CD11c
 hi
) and 
activated recruited macrophage (F4/80
hi
, CD11c
medium
). No differences in either group 
were observed after LP17 treatment (Fig. 4.4). 
 Chapter 4: Blockade of TREM-1 and Source of sTREM-1 During Infection 
 
100 
Control Flu+LP17
0
5.0×10 4
1.0×10 5
1.5×10 5
2.0×10 5
2.5×10 5
N
u
m
b
e
r 
o
f 
n
e
u
tr
o
p
h
il
s
Control Flu+LP17
0
5
10
15
20
%
 o
f 
N
e
u
tr
o
p
h
il
s
Control Flu+LP17
0
5.0×10 4
1.0×10 5
1.5×10 5
N
u
m
b
e
r 
o
f 
N
e
u
tr
o
p
h
il
s
Control Flu+LP17
0
5
10
15
20
%
 o
f 
N
e
u
tr
o
p
h
il
s
Control Flu+LP17
0
2.5×10 6
5.0×10 6
7.5×10 6
*
N
u
m
b
e
r 
o
f 
n
e
u
tr
o
p
h
il
s
Control Flu+LP17
0
10
20
30
%
 o
f 
N
e
u
tr
o
p
h
il
s
A B
C D
E F
Lung
Airway
Blood
 
 
 
 
 
 
 
Figure 4.3.  The effect of LP17 treatment on neutrophil population.   
Mice were infected with influenza and received LP17 or control treatment daily for 6 days. 
The cells harvested from lung (A, B), airway (C-D) and blood (E-F) were stained for Ly6g, 
CD11c, CD11b and F4/80. The neutrophil population was detected by flow cytometry as 
before. All the left panels (A, C, E) represent the number of neutrophils and the right panels 
(B, D, F) represent the percentage neutrophils. Statistical analysis was done by Mann 
Whitney test of variance and data are shown as Mean ± SE. The experiment was repeated 
three times and 4 mice per group were used in a single experiment. *P <0.05 compared with 
control group at the same time points. 
.  
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Figure  4.4. The effect of LP17 treatment on the macrophage cell population.  
Mice were infected with influenza at day 0 and subsequently administrated LP17 or 
control peptide on a daily basis until day 6. The cells harvested from lung (A-B) and 
airway (C-D) were stained for Ly6g, CD11c, CD11b and F4/80. Two different subsets 
of macrophage were identified. The population with F4/80
hi
, CD11c
medium
 was defined 
as recruited macrophages (RM) and the population with F4/80
medium
, CD11c
hi
 was 
defined as alveolar macrophages (AM). All the left panels (A, C) represent the number 
of different subsets of macrophages and right panels (B, D) represent the precentage. 
Statistical analysis was performed by Mann Whitney test of variance and data are shown 
as Mean ± SE. The experiment was repeated three times and 4 mice per group were used 
in a single experiment.  
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4.2.1.3 The effect of LP17 on T cell responses during influenza 
To determine whether LP17 treatment affected T cell recruitment and activation, the 
numbers of CD4 and CD8 cells were assayed by flow cytometry. The expression 
profile of OX40 has also been analysed as it is increased on activated T cells. OX40 
also plays a critical role in the maintenance of an immune response beyond the first 
few days and onwards to a memory response due to its ability to enhance survival 
(Humphreys et al., 2003). OX40 also plays a crucial role in both Th1 and Th2 
mediated reactions in vivo (Seshasayee et al., 2007).  We also examined CD45RB that 
is present on naive T cells and gradually downregulated upon activation. Therefore 
these two cell markers, OX40 and CD45RB, were used to identify the activated 
effector T cells. 
 
There was no significant difference in the numbers or proportion of CD4+ (Fig 4.5) 
and CD8+ (Fig 4.6) T cells in lung (A, B in Fig. 4.5 and 4.6) and airways (C, D in 
Fig. 4.5 and 4.6) of both groups. Their activation was not affected based on OX40 
levels (right hand two bars in Fig. 4.5 and 4.6) or CD45RB loss (middle two bars in 
Fig. 4.5 and 4.6). The major difference was observed in the blood and lymph node, 
where more CD4+ and CD8+ cell were found in the LP17 group with a 2-3 fold 
increase in the level of OX40 and CD45RB expression (Fig.4.5 and Fig.4.6). This 
difference was observed in cell number but not in their proportion. Thus LP17 
treatment resulted in an increase in the cellularity of the local lymph node and blood. 
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Figure 4.5. The LP17 treatment affects the CD4+ cell population.   
Mice were infected with flu alone or administrated with LP17 treatment for 6 day. The 
cells harvested from lung (A-B), airway (C-D), lymph node (E-F) and blood (G-H) was 
staining for CD4, CD8, CD45RB and OX40. The left panels represent the number of 
different CD4+ population, which is calculated as multiplying the percentage of CD8+ 
(right panels) by total cell number. Statistical analysis was done by Mann Whitney test of 
variance and data are shown as Mean ± SE. The experiment was repeated three times and 
4 mice per group were used in single experiment. *P <0.05 compared with control group.  
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Figure 4.6. The LP17 treatment affects the CD8+ cell population.   
Mice were infected with flu alone or administrated with LP17 treatment for 6 day. The 
cells harvested from lung (A-B), airway (C-D), lymph node (E-F) and blood (G-H) was 
staining for CD4, CD8, CD45RB and OX40. The left panels represent the number of 
different CD8+ population, which is calculated as multiplying the percentage of CD8+ 
(right panels) by total cell number. Statistical analysis was done by Mann Whitney test of 
variance and data are shown as Mean ± SE. The experiment was repeated three times and 
4 mice per group were used in single experiment. *P <0.05 compared with control group.  
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4.2.2. The effect of LP17 on bacterial infection 
4.2.2.1 The effect of LP17 on Streptococcus pneumoniae infection 
Streptococcus pneumoniae is the most common pathogen involved in secondary 
bacterial complications following influenza infection and is associated with increased 
morbidity and mortality during influenza epidemics and pandemics (Morens et al., 
2008). To examine the effect of TREM-1 blockade during bacterial infection alone, 
LP17 was administrated to mice infected with S. pneumoniae. BALB/C mice were 
infected intranasally with 10
6
 colony forming unit (CFU) of S. pneumoniae and 
received one treatment of 100 μg LP17 or saline control at the same time. At 48 hours 
post infection, BAL fluid and lung samples were harvested to assay the bacterial 
burden, cell number and cytokine profile.  
 
In the saline control group, the bacterial colonization is limited to the nasal cavity and 
airway, without contamination of the lung. Under these conditions, leukocytes 
infiltrate to the lung and airways to eliminate the pathogen and mice can survival from 
Streptococcus pneumoniae infection without any weight loss. Treatment with LP17 
peptide did not affect the cell infiltration (Fig 4.7 A and B) or bacterial clearance in 
the nasal cavity and airway (Fig 4.7 C and D). Although macrophages and neutrophils 
recruited into the lung were not affected by LP17 (Fig 4.8 E-H), a marked reduction 
in airway macrophages was seen in LP17 treated group (Fig 4.8 A and B).   
 
We next determined whether LP17 could alter the inflammatory cytokines response 
induced by S.pneumonia. The concentration of TNF-α and IL-6 in the airway were 
significantly decreased in the LP17 group, compared with the control group (Fig 4.9 
A and B). By contrast, there was no difference in the cytokine levels between these 
two groups in the lung homogenate (Fig 4.9 C and D). These data suggest that LP17 
lowers the magnitude of pneumonia-induced inflammatory responses in the airway 
but without any effect on bacterial clearance.  
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Figure.4.7. The effect of LP17 on cellularity and bacterial load  
Mice were infected with 1 x 10
6
 CFU S. pneumoniae and treated with saline or 
100μg LP17. Total cell numbers in the lung (A) and airway (B) were enumerated 
and bacterial outgrowth in the nasal cavity (C) and airway (D) was assessed at 48 
hours post infection. Statistical analysis was performed by Mann Whitney test of 
variance. Data represent as Mean ± SEM and 5 mice used at each group. 
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Figure. 4.8. The effect of LP17 on myeloid cell populations  
The cells were collected from the airways (A-D) and lung (E-H) for flow cytometry 
analysis. The macrophages and neutrophils were identified and compared between control 
and LP-17 group 48 hours after Streptococcus pneumoniae infection. Statistical analysis 
was performed by Mann Whitney test of variance. Data represent as Mean ± SEM and 5 
mice used at each group. 
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Figure. 4.9. The effect of LP17 on cytokine production  
The BAL fluid (A, B) and lung homogenate (C, D) were collected at 48 hours after 
Streptococcus pneumoniae infection. The concentration of TNF-α (A, C) and IL-6 
(B, D) were determinated by ELISA and compared between saline control group 
and LP-17 groups. Statistical analysis was performed by Mann Whitney test of 
variance. **P <0.01 compared with vehicle control group at the same time points. 
Data represent as Mean ± SEM and 5 mice used at each group. 
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4.2.2.3 The effect of LP17 on Haemophilius influenzae infection 
In addition to S. pneumoniae, other common co-infecting bacteria include 
Staphylococcus aureus, Haemophilus influenzae and Streptococcus pyogenes. To 
explore the effect of LP17 after H. influenzae infection, a similar protocal of treatment 
was applied to BAL B/C mice as described in the previous section. LP17 treatment 
demonstrated a trend of reduced cellularity in the airway although this did not reach 
significance (Fig. 4.10 A, B). Furthermore, bacterial loads were assayed in both BAL 
fluid and lung homogenate 48 h after H. influenzae instillation. Despite no difference 
in the nasal cavity, the bacterial load was significantly decreased by LP17 in the 
airway (Fig. 4.10 C, D)..  Interestingly, LP17 had no effect on the number of 
macrophages and neutrophils (Fig 4.11) or concentration of proinflammatory 
cytokines such as TNF-α and IL-6 (Fig 4.12).  
 
Figure.4.10. The effect of LP17 on cellularity and H. influenzae load 
Mice were infected with 1 x 10
7
 CFU Haemophilius influenzae and treated with 
saline or 100μg LP17. Total cell number from the lung (A) and airways (B) were 
enumerated and bacterial outgrowth in the nasal cavity (C) and airway (D) was 
assessed at 48 hours post infection. Data represent as Mean ± SEM and 5 mice 
used at each group. 
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Figure.4.11. The effect of LP17 on myeloid cell populations  
Cells were collected from the airways (A-D) and lung (E-H) for flow cytometry 
analysis. Macrophages and neutrophils were identified and compared in the saline 
control group and the LP-17 group 48 hours after Haemophilius influenzae 
infection. Statistical analysis was performed by Mann Whitney test of variance. 
Data represent as Mean ± SEM and 5 mice used at each group. 
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Figure. 4.12. The effect of LP17 on cytokine production  
The BAL fluids (A, B) and lung homogenate (C, D) were collected at 48 hours after 
Haemophilius influenzae infection. The concentration of TNF-α (A, C) and IL-6 (B, D) were 
determinated by ELISA and compared between saline control group and LP-17 groups. 
Statistical analysis was performed by Mann Whitney test of variance. *P <0.05 compared 
with vehicle control group at the same time points. Data represent as Mean ± SEM and 5 mice 
used at each group. 
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4.2.3. The effect of LP17 on influenza and bacterial co-
infection 
4.2.3.1. The effect of LP17 on influenza and Streptococcus 
pneumoniae co-infection 
The previous section showed that LP17 treatment has mild effect on single bacterial 
infection.  
As we described in the previous chapter, Streptococcus pneumoniae synergized with 
influenza virus to cause more severe disease in BALB/c mice, leading to 100% 
lethality. The mechanism leading to disease exacerbation does not involve T or B 
cells, and thus appears to be mediated by innate immunity. In our co-infection model, 
BALB/c mice were exposed to 50 HA X31 influenza virus for 7 days, and then 
challenged with a non-lethal dose (10
6
 CFUs) of Streptococcus pneumoniae. Bacterial 
replication in the respiratory tract was enhanced 24 hours after infection and detected 
in the blood stream, which caused systematic sepsis. Meanwhile the motility rate was 
significantly increased and reached 100% within a few days. We hypothesized that 
the lethal outcomes observed with secondary pneumococcal pneumonia following 
influenza could be due to immunopathology engendered by excess proinflammatory 
cytokine and hyperactivated macrophages or neutrophils. To determine whether the 
immunosuppressive properties of LP17 could translate into survival improvement, 
LP17 treatment was introduced during the primary influenza phase of the co-infection 
model. An additional group of mice were treated with control peptide, which 
contained the same amino acids, but in a totally different sequence order. 
 
Prophylactic treatment with LP17, which mean the peptide was given to mice daily 
throughout the entire primary influenza infection, significantly protected the mice 
from the death usually caused by secondary bacterial infection compared to the 
control group (Fig 4.13. A). All the mice that received LP17 were able to recover 
from co-infection. This improvement correlated with reduced cell infiltration and 
reduction of bacterial titres (Fig. 4.14). In the airway and lung, the cell infiltration was 
reduced by LP17 at 48 hours post co-infection (Fig 4.12. B, C), which was primarily 
associated with decreased neutrophils and macrophages (Fig 4.13.E-H) that are 
essential in phagocytosis and in coordinating the innate immune response. Overall, 
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LP17 treated mice recruited significantly less macrophages and neutrophils in the 
airway, with a tendency of a decrease observed in the lung (Fig 4.13.E-H).  
 
To further highlight the influence of LP17 treatment on progression of bacteraemia, S. 
pneumoniae burden was measured in the nasal cavity, airway, lung and blood. No 
significant differences were observed on number of bacterial colonized in the lung 
(Fig 4.14. B). However, LP17 significantly reduced the bacterial burden in the airway 
and nasal cavity (Fig 4.14.C, D). Interesting, no bacteria were recovered from the 
blood of LP17 treated mice (Fig 4.14 A). Moreover, the secretion of proinflammatory 
cytokines, TNF-α and IL-6, were reduced by LP17 in the BAL fluid (Fig 4.14. E, F).  
 
These results suggest that daily LP17 treatment during the primary viral infection 
prevented the complication that usually arises upon secondary bacterial infection. 
This is interesting since only mild effects were observed during single infections with 
influenza virus or S. pneumoniae. 
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Figure. 4.13. LP17 treatment improves the survival of influenza and Streptococcus 
pneumoniae co-infection and reduces cell infiltration.   
Groups of five female BALB/c mice were infected intranasally with 50 HA of influenza 
X31 in PBS and challenged with 1 x 10
6
 CFU S. pneumoniae on day 6. Mice received 
daily administration of LP17 or control peptide during flu infection with an additional 
group of mice treated with normal saline. The mice were carefully monitored for survival 
rate (A) and harvested 6, 24 and 48 hours after onset of co-infection. The cells were 
collected from the airway (B) and lung (C), and total viable cells counted. Neutrophils (D, 
E) and Macrophages (F, G) were identified.  Statistical analysis was performed by Mann 
Whitney test of variance. **P <0.01 compared with the vehicle control group at the same 
time point. Data represent as Mean ± SEM and 5 mice used at each group. 
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We next tested two alternate strategies including changing the length and time course 
of the treatment. To assay whether the delayed treatment could still have the 
protective effect, LP17 was give two days after influenza infection for therapeutic 
purpose or only one dosage coinciding with bacterial challenge (Fig. 4.15.A). In terms 
of survival, delayed LP17 treatment still improves the outcomes of infection, 
Figure.4.14. LP17 treatment enhanced bacterial clearance and reduced cytokine 
secretion.  
Groups of five female BALB/c mice were infected intranasally with 50 HA of 
influenza X31 (Flu) in PBS and challenged with 1 x 10
6
 CFU S. pneumoniae. Mice 
received daily administration of LP17 or control peptide during the flu infection with 
an additional group of mice treated with normal saline. The mice were harvested 6, 
24 and 48 hours after onset of co-infection to assay the bacteria burden in the blood 
(A), lung (B), nasal cavity (C) and airway (D). The concentrations of TNF (E) and 
IL-6 (F) in the BAL fluid were determined by ELISA. Statistical analysis was done 
by Mann Whitney test of variance. *P <0.05 compared with vehicle control group at 
the same time point. Data represent as Mean ± SEM and 5 mice used at each group. 
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conferring 90% protection from fatality (Fig. 4.15.B). In the airways, neutrophil 
recruitment was inhibited by LP17 with no delayed bacterial clearance (Fig. 4.15.C).. 
The spread of bacteria was limited in the lung cavity without reaching the blood 
stream (Fig. 4.16.A-D). Furthermore therapeutic LP17 treatment continued to cause a 
reduction in airway levels of TNF-α and IL-6 (Fig. 4.16.E-F). 
 
By contrast, initiation of LP17 treatment to coincide with bacterial infection failed to 
protect the mice and all died within a few days. In addition, this treatment had no 
effect on cell infiltration; bacteria growth and cytokine production (Fig.4.15 and 
4.16). Overall the therapeutic treatment was superior to coinciding treatment as a 
means of improving the outcome of co-infection. Both prophylactic and therapeutic 
LP17 administration can provide the survival advantage for the host, which can be 
explained by the abolished systematic bacteraemia and diminished innate immune 
response. This abolishment was indicated by absence of bacteria in the blood, was 
critical for the host to avoid sepsis and organize appropriated immune response.  
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Figure. 4.15. Delayed LP17 treatment can still improve the survival rate in co-infected mice 
Groups of mice were infected with influenza virus then challenged 6 days later with S. 
pneumoniae. Treatment with LP17 was initiated 2 days after influenza infection (therapeutic 
group) or coinciding with bacterial challenge. Mock treatments with normal saline were 
included as control group.  The mice were carefully monitored for survival (B) and 
harvested 48 hours after onset of co-infection. The cells were collected from the airways (C) 
and lung (D), and total viable cell enumerated. Neutrophils (E, F) and macrophages (G, H) 
were identified.  Statistical analysis was performed by Mann Whitney test of variance. *P 
<0.05 compared with vehicle control group at the same time points. Data represent as Mean 
± SEM and 5 mice used at each group. 
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Figure. 4.16. The effect of LP17 treatment on bacterial load and cytokine production  
Mice received LP17 treatment as before (Fig. 4.16) and were harvested 48 hour after 
co-infection. The bacterial load was determined in the lung (A), blood (B), airway (C) 
and nasal cavity (D). The concentrations of TNF-α (E) and IL-6 (F) in the BAL fluid 
were determined by ELISA. Statistical analysis was done by Mann Whitney test of 
variance. **P <0.01 compared with vehicle control group at the same time point. Data 
represent as Mean ± SEM and 5 mice used at each group. 
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4.2.3.2. The affect of TREM-1 on influenza and Haemophilius 
influenzae co-infection 
We previously described that Haemophilus influenzae synergized with influenza virus 
to cause more severe disease in BALB/c mice, leading to delayed bacterial clearance 
from the lung. To further explore the potential of TREM-1 blockade, LP17 peptide 
was also administrated during the influenza and H. influenzae co-infection model. 
Prophylactic and therapeutic administrations of LP17, similar to the previous section, 
were tested (Fig.4.17.A). 
 
Both strategies had an inhibitory effect on cellularity and cell populations in the 
airway and lung (Fig 4.17.B-C). Airway neutrophils were significantly decreased at 
12 and 48 hours after bacterial infection in LP17 treated mice compared to the saline 
control group (Fig.4.17.D-E). On the other hand, the recruitment of macrophages to 
the airway was not significantly affected by treatment in both airway and lung 
(Fig.4.17.E-H).  
 
In addition, the bacterial loads were assayed in the lung, airway and nasal cavity 12 
and 48 hours after bacterial inoculation. LP17 limited bacterial load in the airway and 
lung at the early phase (12 hours), which may provided host advantage to clear the 
infection faster (Fig.4.18.A-C). In this model, we never recovered any bacteria from 
the blood as described in the previous chapter. Meanwhile, IL-6 and TNF-α 
production were inhibited as we have seen previously by LP17 treatment. Overall, 
these results suggest that LP17 can either enhance bacterial clearance or prevent 
bacterial replication.  
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Figure.4.17. LP17 treatment reduces cell infiltration in the airway of mice co-infected 
with influenza and H. influenzae  
Groups of mice were infected with 50 HA influenza virus and then challenged 6 days later 
with 1 x 10
6
 CFU H. influenzae. Treatment with LP17 was initiated at the same day as 
influenza infection (prophylactic) or 2 days after primary infection (therapeutic). A mock 
treatment with normal saline was included as a control.  Mice were harvested 48 hours 
after onset of co-infection. The cells were collected from the airway (B) and lung (C), and 
total viable cells enumerated. Neutrophils (D, E) and macrophages (F, G) were identified.  
Statistical analysis was performed by Mann Whitney test of variance. *P <0.05 compared 
with vehicle control group at the same time point. Data represent as Mean ± SEM and 5 
mice used at each group. 
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Figure. 4.18. The effect of LP17 treatment on bacterial load and cytokine secretion 
Mice received LP17 treatment as described in Fig. 4.17 and were harvested 48 hour after 
co-infection. The bacterial load was assayed in the airway (A), nasal cavity (B) and lung 
(C). The concentrations of TNF (D) and IL-6 (E) in the BAL fluid were determined by 
ELISA. Statistical analysis was performed by Mann Whitney test of variance. *P <0.05 
compared with vehicle control group at the same time point. Data represent as Mean ± 
SEM and 5 mice used at each group. 
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4.2.4 The mechanism of enhanced generation of sTREM-1  
4.2.4.1. The sTREM-1 levels are enhanced by a soluble in the BAL 
fluid from influenza infection  
We observed in the previous chapter that levels of sTREM-1 in BAL fluid were 
significantly induced during influenza infection with its concentration peaking 2 days 
after infection. We hypothesised that influenza viruses may cause shedding of the 
extracellular domain of TREM-1 from the surface of target cell, or that enzymatic 
activity in the airway may mediate its release. During influenza infection, large 
amounts of proteinases and matrix metalloproteinase (MMP) are released into the 
airway and lung (Wang et al., 2010), which may be the mediators of sTREM-1 
generation.     
 
To further explore the mechanism of sTREM-1 production, RAW and MH-S cell line 
were incubated with 50 HA unit influenza viruses or 2-folds diluted BAL fluid from 
the influenza infected mice (Fig 4.19 A). MH-S cell lines were chosen to represent 
murine alveolar macrophage cells as they shared morphological, cytochemical, and 
functional characteristics (Mbawuike et al., 1989). Incubation of both cell types with 
influenza virus had no effect on sTREM-1 production (Fig 4.19 B, C). In contrast, 
BAL fluids from a day 1 or day 2 influenza infection contained elevated amounts of 
active MMP-9 and significantly enhanced the production of sTREM-1(Fig 4.19 B-D). 
Furthermore, the levels of MMP-9 during infection exhibit similar pattern as sTREM-
1 in BAL fluid in vivo (Fig 4.19 D). These results suggested that the influenza viruses 
could not directly stimulate the release of sTREM-1, but that a constituent of BAL 
fluid may be the cause for the elevated level of sTREM-1 during infection.     
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Figure. 4.19. BAL fluid from influenza infected mice can enhance the production of 
sTREM-1  
The mouse RAW 264.7 (B) and MH-S cell lines (C) were plated at 2 x 10
5
/ well and 
triplicate wells exposed to 50HA influenza virus, diluted BAL fluid from infected 
mice or left untreated. Following 4, 24 and 48 hours incubation, supernatants were 
removed and the concentration of sTREM-1 was detected by ELISA. The in inactive 
pro-MMP-9 and active MMP-9 were measured by ELISA in the BAL fluids from 
various time point post influenza infection (D). Statistical analysis was performed by 
Mann Whitney test of variance. **P <0.01 compared with untreated control group at 
the same time point. Data represent as Mean ± SEM and n = 3. 
   
.  
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4.2.4.2. BAL fluid induced generation of sTREM-1 is suppressed by 
an MMP-9 inhibitor 
Soluble factors present in the BAL fluid can significantly enhance the production of 
sTREM-1 from RAW and MH-S cells. One possible factor is MMP-9, whose active 
form is detected at elevated levels in the airway during the early phase of infection 
(Pan HY et al., 2011). To confirm that the presence of MMP-9 in BAL fluid is 
essential for production of sTREM-1, an MMP-9 inhibitor was used.  
 
The BAL fluid from mice 1 or 2 days post infection, were used to stimulate cells to 
release sTREM-1. At the same time, an MMP-9 inhibitor was added to examine its 
effect on sTREM-1 production. The figure 4.20 has showed that the inhibition of 
MMP-9 suppressed BAL fluid induced production of sTREM-1. 
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Figure.4.20. An MMP-9 inhibitor can abolish the generation of sTREM-1 from 
cell line by influenza BAL fluid  
Mouse RAW 264.7 (A, C) and MH-S cells (B, D) were plated at 2 x 10
5
/ well and 
triplicate wells exposed to diluted BAL fluid from influenza infected mice with or 
without MMP-9 inhibitor. Following 4, 24 and 48 hours, cells were harvested for 
FACS analysis of TREM-1 expression. The supernatants were removed and the 
concentration of sTREM-1 was detected by ELISA. **P <0.01 compared with 
untreated control group at the same time point. Data represent as Mean ± SEM and 
n = 3 for each time point in all groups. 
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4.2.4.3 MMP-9 can enhance the production of sTREM-1 in vitro 
During influenza infection, the virus infects the respiratory mucosal surface and 
induces release of various host factors into the airway, such as pro-inflammatory 
cytokines and matrix metalloproteinases (MMPs). The activated MMPs, such as 
MMP-2 and MMP-9, promote endothelial hyperpermeability and assist inflammatory 
cell migration through the breakdown of vascular basement membranes and 
extracellular matrix (Westermann et al., 2010). MMP-9 is found at significantly 
higher levels in the serum of influenza patients (Ichiyama et al., 2007) and it was 
upregulated in the airway and lung by influenza via MAPK-NFκB dependent 
mechanisms (Pan et al., 2011). There are theoretical cleavage sites for MMP-9 in the 
sequence of surface TREM-1 molecule; therefore MMP-9 may cleave the 
extracellular domain of TREM-1 from the cell membrane. In addition, the 
catalytically activated viral factor, neuraminidase, facilitates release of newly formed 
virions and prevents them from self-aggregating after budding from the infected cells 
(Gillian et al., 1989). This also makes influenza neuraminidase a potential enzyme to 
shed TREM-1 from cell surface.  
 
We tested the effects of purified MMP-9 and neuraminidase on sTREM-1 generation 
in an in vitro culture system. MH-S cells and RAW cells were cultured for 2 days 
with different doses of MMP-9 or neuraminidase, and compared to cells only cultured 
with medium as a control. The released sTREM-1 in the medium was monitored 2, 4, 
6, 24 and 48 hour after treatment. In the control group, only approximately 15 pg/ml 
of sTREM-1 was detected and this level did not increase significantly increase with 
time (Fig. 4.21.A, B). The addition of MMP-9 resulted in an enhancement of sTREM-
1 secretion in a dose dependent manner, as evidenced by a consistently increased level 
of sTREM-1 (Fig.4.21.A, B). This effect on sTREM-1 release by MMP-9 was 
observed at MMP-9 concentrations as low as 100ng/ml, and release was higher at 400 
ng/ml of MMP-9. Identical results were obtained in repeat experiment (Fig. 2.22A-C). 
Additionally, staining for surface TREM-1 expression revealed a down-regulation of 
TREM-1 on the cell surface in MMP-9 treated cells (Fig. 4.22. B). In contrast, both 
level of surface TREM-1 and sTREM-1 was not affected by addition of 
neuraminidase at even 1000 ng/ml (Fig. 4.21.C, D and Fig. 4.22. D).  
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Figure. 4.21. MMP-9 can enhance the production of sTREM-1 in a dose-
dependent manner  
The mouse RAW 264.7 (A,C) and MH-S cell lines (B,D) were plated at 2 x 10
5
/ 
well and triplicate wells exposed to different doses of MMP-9 (A,B), 
neuraminidase (C,D) or left untreated (black line). Following 2, 6, 24 and 48 hours 
incubation, supernatants were removed and the concentration of sTREM-1 was 
detected by ELISA. **P <0.01 compared with untreated control group at the same 
time point. Data represent as Mean ± SEM and n = 3 for each time point in all 
groups. 
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Figure.4.22 MMP-9 can enhance the production of sTREM-1  
The mouse RAW 264.7 (A,B) and MH-S cell lines (C,D) were plated at 2 x 10
5
/ 
well and triplicate wells exposed to 200ng MMP-9 (red line), 500ng 
neuraminidase (green line) or left untreated (black line). Following 2, 6, 24 and 48 
hours incubation, cells were harvested for FACS analysis of TREM-1 expression 
(B and D). The supernatants were removed and the concentration of sTREM-1 was 
detected by ELISA (A and C). **P <0.01 compared with untreated control group 
at the same time point. Data represent as Mean ± SEM and n = 3 for each time 
point in all groups. 
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4.2.4.4. The MMP-9 induced generation of sTREM-1 is independent 
of intracellular protein synthesis  
To eliminate the possibility that enhanced sTREM-1 in response to MMP-9 was 
dependent on translation of an alternative mRNA splice variant of TREM-1, 
intracellular protein transport was inhibited by Brefeldin A. Incubation of cells in 
culture with Brefeldin A leads to blockade of protein transport to the Golgi complex 
and accumulation of proteins in the endoplasmic reticulum (Misumi et al., 1986). If 
the MMP-9 induced production of sTREM-1 was dependent on the intracellular 
protein synthesis, a reduction of sTREM-1 in the supernatant treated with Brefeldin A 
would be observed.  
 
MH-S cells were cultured with MMP-9 and neuraminidase as previous described and 
harvested 4, 8 and 24 hours later. Brefeldin A was added to the medium 4 hours 
before harvest and medium were kept for sTREM-1 ELISA (Fig.4.23.A). The 
inhibition of protein transport did not effect sTREM-1 release by MMP-9 
(Fig.4.23.B), suggesting that MMP-9 did not promote intracellular sTREM-1 
synthesis. In addition, Brefeldin A treatment significantly reduced surface TREM-1 in 
medium controls (Fig.4.23.C, E).    
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Figure.4.23. MMP-9 driven sTREM-1 generation is not depended on de novo 
protein synthesis 
Mouse RAW 264.7 cells were plated at 2 x 10
5
/ well and triplicate wells exposed 
to MMP-9, neuraminidase and medium (RM) with or without addition Brefeldin 
A. Following 4, 8 and 24 hours incubation, cells were harvested for FACS analysis 
of TREM-1 expression (C and E). The supernatants were removed and the 
concentration of sTREM-1 was detected by ELISA. **P <0.01 compared with 
medium control group at the same time point. Data represent as Mean ± SEM n = 
3 for each time point in all groups. 
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4.3 Discussion 
4.3.1. The protective effect of LP17 on viral-bacterial co-
infection 
In the present chapter we explored the role of TREM-1 in a well-established murine 
models of influenza alone or influenza-bacterial co-infection. TREM-1 plays a critical 
regulatory role in immune responses during acute infection (Dower et al., 2008) and 
inflammation in multiple tissues, including the lung (Gibot et al., 2004b). To 
modulate TREM-1 activity, a peptide (LP17) was constructed with similar structure to 
the ligand binding sequence in the extracellular domain of the TREM-1 protein. LP17 
competitively inhibits TREM-1 interaction with its ligand and impairs TREM-1 
dimerization necessary for its engagement (Gibot et al., 2006). The blockade of 
TREM-1 activity with this synthetic peptide exerts an anti-inflammatory effect with 
survival benefits in systemic inflammatory disorders, such as experimental sepsis 
(Gibot et al., 2004b) and Pseudomonas aeruginosa-induced pneumonia (Gibot et al., 
2006). The influence of this peptide on a viral infection has not been investigated yet. 
 
Administration of LP17 during influenza infection resulted in reduced cellularity, 
production of pro-inflammatory cytokines and decreased lung permeability as 
determinated by the presence of albumin in the airway. These may provide 
advantages for the host in fighting an infection with a subsequent pathogen. TREM-1 
amplifies TLR2 and TLR4 signalling and results in enhanced production of pro-
inflammatory cytokines (TNF-α, IL-1β, granulocyte-macrophage colony stimulating 
factor) and inhibits release of IL-10 (Bouchon et al., 2001b). The expression of 
TREM-1 in turn is upregulated by activation of these TLRs (Bouchon et al., 2000). 
TREM-1 and TLRs seem to cooperate to control inflammatory responses. 
Accordingly, LP17 blocked the amplification of TLR signalling to reduce the levels 
of TNF-α, resulting in a dampened cytokine storm (Wang et al., 2010). Another 
possible outcome of LP17 treatment is an increased level of IL-10, whose protective 
effect is demonstrated in high-dose influenza challenge (McKinstry et al., 2009). 
Despite extensive work on extracellular TLRs, no reports state the role of TREM-1 
has in potentiating intracellular TLRs. The limited effect of LP17 on influenza alone 
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infection may due to the lack of an effect on intracellular TLRs. Furthermore, we only 
use intraperitoneal injection to deliver LP17 in all our experiments, which has been 
extensively used in many mouse models. To achieve higher concentrations of the drug 
delivered to airway, the intranasal rate should be tested in the future.  
To investigate the potential effect of LP17 treatment on subsequent infection 
following influenza, we administrated LP17 during influenza and super infected with 
S. pneumoniae. LP17 treatment significantly improved the survival rate of mice and 
abolished detectable systemic bacteraemia. The reduced lung permeability and 
inflammation in mice previously treated with LP17 during the influenza stage may 
retain an effective physical barrier to prevent bacterial dissemination. Another 
possible mechanism that may improve secondary bacterial clearance is based on the 
effect of TREM-1 on neutrophils. TREM-1 activates neutrophils, inducing respiratory 
burst and expression of chemokines. Thus, treatment with LP17 during influenza 
infection may reduce their migration and ROS production resulting in less lung 
damage. The blockade of TREM-1 signalling may also result in increased availability 
of LL-37, which suppresses the expression of TREM-1 (Amatngalim et al., 2010). 
LL-37 is a cationic anti-microbial and upregulated together with TREM-1 in response 
to a Vitamin D and contributed to enhanced innate immunity (Amatngalim et al., 
2010). This peptide disrupts the integrity of the bacterial membrane causing lysis and 
has high anti-staphylococcal activity (Lehrer., et al 1993), which may contribute to 
the improved bacterial clearance in LP17 treated mice. Despite the fact that the half 
life of LP17 is unknown, we suggest that residual LP17 does not remain during the 
bacterial co-infection stage as administration daily is required. The later beneficial 
effect may rely on subtle dampening of the inflammatory environment during 
influenza infection. The dampening of TREM-1 signalling by LP17 may provide 
significant benefits by not totally abrogating the inflammatory response allowing 
sufficient immunity to clear the infection without bystander immunopathology. In 
addition, its potential effect on anti-microbial peptides may provide an advantage for 
the host to fight a secondary bacterial infection. This peptide may provide a new 
immunomodulatory strategy in viral and bacterial co-infections.  
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4.3.2. The mechanism of releasing sTREM-1. 
Although sTREM-1 is used as a biomarker for disease, the underlining mechanisms 
mediating its release are still unclear. Recent evidence suggests that sTREM-1 is 
generated through the proteolytic cleavage of membrane-bound TREM-1 via matrix 
metalloproteinase (MMP) activity rather than the translation of a gene splice variant 
(Gomez-Pina, 2007). We also observed that elevated levels of sTREM-1 coincided 
with markedly increased levels of MMP-9 in the lung during influenza and co-
infection. Membrane-anchored TREM-1 was detected on the surface of neutrophils 
and macrophages, which makes them possible cellular sources of sTREM-1. Thus we 
propose that sTREM-1 is produced from proteolytic cleavage of membrane TREM-1 
by MMP-9 in the lung. 
 
Metalloproteinases (MMP) are produced by inflammatory cells, such as neutrophils, 
mast cells and macrophages (Taggart et al., 2005). All members of MMP
 
family are 
detected within the lung tissue and play critical roles in lung
 
organogenesis. Many of 
them are up-regulated
 
during the acute phases of inflammatory diseases (Parks et al., 
2004) and are increasingly associated with the release of membrane-anchored 
signalling molecules in response to different stimuli. One example is MMP-9, which 
sheds the active form of TGF-β through proteolytic degradation of the latent TGF beta 
complex (Yu et al., 2000). There is a potential cleavage site for MMP-9 within the 
sequence of the intact TREM-1 protein (Fig.4.24) and previous studies (Gomez-Pina 
et al., 2007) demonstrate that the metalloproteinases can be used to shed TREM-1 
from cell surface. We hypothesises that MMP-9 present in the lung is responsible for 
shedding the cell surface-anchored TREM-1 and accounts for the source of sTREM 
(Fig.3.15-2). It is also possible that viral neuraminidase on influenza-infected cells, 
which functions to cleave the cellular receptor sialic acid residues to release newly 
formed viruses (Moscona et al.,  2005), may cause release of sTREM-1. Furthermore 
the activities and levels of both of these enzymes are induced during influenza 
infection, thus the precise mechanism may involve activation of multiply proteinases. 
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MRKAGLWGLL CVFFVSEVKA AIVLEEERTD LVEQTLTVK
CPFNIMKYAN SQKAWQRLPD GKEPLTLVVT QRPFTRPSEV
HMGKFTLKHD PSEAMLQVQM TDLQVTDSGL YRCVIYHPPN
DPVVLFHPVR LVVTKGSSDV FTPVIIPITR ITERPILITT
KYSPSDTTTT RSLPKPTAVV SSPGLGVTII NGTDADSVST
SSVTISVICG IISKSLVFII LFIVTKRTFG  
 
 
 
Our in vitro studies confirm this hypothesis by showing that BAL fluid induced the 
production of sTREM-1 from macrophages that was abolished by treatment with 
MMP-9 inhibitor. More direct evidence was provided by treating macrophages with 
MMP-9, which resulted in significantly elevated levels of sTREM-1. This result was 
not altered by Brefeldin A, which blocks protein transport. Therefore, MMP-9 
induced production of sTREM-1 is most likely due to proteolytic cleavage.  
 
MMP-9 is known play an important role in influenza infection. Serum MMP-9 
concentrations are significantly higher in patients with influenza-associated 
encephalopathy compared to patients with uncomplicated influenza or in healthy 
controls (Ichiyama et al., 2007). This phenomenon is consistent with Dr Robert 
Snelgrove’s observation that MMP-9 levels in the murine lung are elevated after 
influenza virus infection. Influenza induced MMP-9 is mediated through MAPK-NF-
kB- and/or AP-1-dependent mechanisms (Siye et al., 2010). Other extracellular 
proinflammatory cytokines such as TNF-α (Moon et al., 2004) and IL-1β (Yokoo et 
al., 1996) can also upregulate MMP-9. Thus we propose a model of MMP-9 
regulating sTREM-1 production, whereas influenza-induced production of cytokines 
and the activation of intracellular signalling, leads to increased levels of MMP-9 and 
surface TREM-1. This may be a advantageous sequence of events that resolves in 
inflammation once distinctive proteases have reached a specific level. 
 
Figure 4.24. The sequence of TREM-1 protein 
The possible sequence for MMP-9 cleavage site is P-X-X-H-T, where X is any 
amino acid and H is hydrophobic. The potential cleavage site within TREM-1 is 
showing in red. 
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We show that influenza BAL fluid can induce quiescent macrophages to produce 
sTREM-1. Other proteases induced by influenza may also cleave surface molecules 
such as TREM-1, including ectopic trypsin (Le et al., 2006) and epitheliasin (Eva 
Böttcher-Friebertshäuser et al., 2010). Ectopic trypsin mediates the post-translational 
proteolytic cleavage of the viral envelope hemagglutinin (Klenk et al., 1975), which is 
crucial for viral entry and replication (Kido et al., 2008) and subsequent tissue 
damage in various organs (Kido et al., 2007). It also efficiently converts pro-MMP-9 
to active MMP-9, which may release TREM-1. Epitheliasin is involved in the 
regulation of epithelial sodium channels (Donaldson et al., 2002) and may cleave 
newly synthesized HA within the influenza infected cell (Eva Böttcher-
Friebertshäuser et al., 2010). In addition to their direct activating effect on surface 
viral proteins, proteases may also act on cellular functions (Riteau et al., 2006). Both 
proteases induced by influenza infection could be involved in the shedding of surface 
TREM-1. It would be interesting to study additional proteases likely to be present in 
the airway by performing the blocking studies we described for MMP-9 
 
Although the ligands for TREM-1 have not been fully identified, TREM-1 on the 
neutrophil surface can directly interact with Ebola virus leading down-regulation of 
TREM-1 (Mohamadzadeh et al., 2006). This finding suggests the possibility that 
influenza viruses may bind to membrane bound TREM-1 and then cleave it to 
produce sTREM-1 by other protease. To check if TREM-1 binds influenza, U937 
cells, which ectopically express TREM-1 could be used (Tessarz et al., 2007). These 
cells would be incubated with recombinant influenza A virus expressing green 
fluorescence protein to score the number of cells bound by virus via 
immunofluorescence. Another approach would be to transfect cell lines with influenza 
glycoproteins or nucleoproteins and then incubate them with recombinant TREM-1 
protein labelled with florescence dye. Both approaches require further optimisation 
and investigation.  
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5.1. Introduction 
5.1.1. TREM-2 signalling 
TREM-2 is a member of the Ig-superfamily characterized by a single V-type 
extracellular domain, a transmembrane region with a charged residue of lysine and a 
short cytoplasmic tail with no signaling motifs (Bouchon et al., 2000). The ligation of 
TREM-2 receptor by its agonistic antibody signals though the DAP12 adaptor and 
causes phosphorylation of ERK1/2 and increases intracellular calcium (Bouchon et 
al., 2001).  In DCs, activation of TREM-2 causes upregulation of CCR7, CD40, 
CD86, MHC class II and dendritic cell maturation (Bouchon et al., 2001b), whereas 
only ERK1/2 phosphorylation and CCR7 are induced in microglia (Takahashi et al., 
2005). These suggest that there is a cell type specific difference in TREM-2 
signalling. Despite the fact that TREM-2 shares signalling adapter DAP12 with 
TREM-1, the degradation of IkB-α and translocation of NF-kB are not induced, which 
may account for their different roles in immunoregulation (Bouchon et al., 2001b). In 
addition, bone marrow derived macrophages from TREM-2 knock out mice display 
hyperactivated cytokine production in response to TLR ligation (Hamerman et al., 
2006), which suggests that TREM-2 is a inhibitor of inflammatory response. 
 
5.1.2. The function of TREM-2   
The function of TREM-2 is exemplified in Nasu-Hakola disease, which caused by a 
genetic mutation in the TREM-2 gene. The symptoms are a presenile dementia and 
bone cyst, which suggests involvement of TREM-2 in immunological regulation in 
brain and in bone modelling (Kondo et al., 2002). Further studies show that inhibited 
TREM-2 expression leads to defective osteoclastogenesis in vitro (Humphrey et al., 
2007). In microglia, over-expression of TREM-2 leads to less TNF and inducible 
nitric oxide (iNOS) mRNA after culture of these cells with apoptotic neurons 
(Takahashi et al., 2005). In addition, bone marrow derived macrophage from TREM-
2 knockout mice produce more TNF and IL-6 in response to LPS, compared to wild-
type controls (Turnbull et al., 2006).These results are confirmed by inhibition of 
TREM-2 by shRNAi where secretion of TNF in response to the TLR2/6 ligand 
zymosan and the TLR9 ligand CpG is enhanced (Hamerman et al., 2006). All these 
data imply that TREM-2 negatively regulates cytokine synthesis in macrophages in 
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response to different TLR ligands and has potential utility in modulating host immune 
responses in various immune disorders and infections.  
 
More recently, TREM-2 has also been associated with regulation of classical (M1) or 
alternative (M2) macrophage activation. The expression of TREM-2 is induced in 
vitro by culture of resident peritoneal macrophages with IL-4, which is a Th2 
cytokines known to stimulate alternative activation (Turnbull et al., 2006). More 
conclusive evidence comes from comparing the level of markers associated with 
classical or alternative macrophage in TREM-2 knock out and wild type mice. In the 
Trem-2
-
/
-
 mice, the mRNA level of alternative macrophage markers such as arginase-
1, Ym-1 and mannose receptor is remarkably decreased, whereas classical 
macrophage markers such as inducible nitric oxide synthase is induced (Hiroshi et al., 
2008).   
 
5.1.3. Hypothesis 
Resolution of inflammation following influenza infection leads to a de-sensitisation of 
alveolar macrophage to TLR agoinsts (Didierlaurent et al., 2008). We hypothesises 
that TREM-2 will be upregulated during the resolution phase of influenza and 
responsible for post-flu TLR desensitization. 
 
5.1.4. Aims 
The goal of this chapter is to characterisation the role of TREM-2 expressing 
macrophages in the resolution phase of influenza infection by achieving following 
aims: 
 To compare the TLR responses of TREM-2 positive and negative airway 
macrophages from post influenza mice.  
 To determine the profile of classical and alternative macrophage markers in 
TREM-2 positive macrophages  
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5.2. Results 
5.2.1. Characterization of TREM-2 positive macrophages 
during influenza infection 
5.2.1.1. Characterization of TREM-2 positive macrophages during 
PR/8 influenza infection 
To investigate the phenotype of macrophages migrating into and differentiating within 
the airway and lung tissue during the resolution phase of infection, the different 
signature markers of CD11c and CD11b were analysed and the expression of TREM-
2 were examined by flow cytometry. Infected mice consistently lost weight and 
reached the peak at 8-9 days, after which time they regained weight by day 17 (Fig 
5.1A) 
 
The macrophage population expressed low levels of TREM-2 at naïve state (Fig 5.5) 
and was categorized into two subsets: CD11c
+
 CD11b
hi
 and CD11c
+ 
CD11b
low
 cells 
(as described in Chapter 3 section 3.2.1). On both populations, TREM-2 expression 
was elevated at day 4 post infection following by a decrease of expression at 8 days 
after infection (Fig 5.1). In addition, the levels of TREM-2 were increased and 
exceeded pre-infection level at day 16 (Fig 5.1). This trend was observed in both 
airway and lung. This reduction in TREM2
+ 
macrophage occurs at the peak of 
inflammation and may be due to the influx of other cell types or downregulation of 
TREM-2 in the presence of high level of inflammatory cytokines.  
 
Since TREM-2 has been postulated to be a marker of alternative activation, we next 
investigated the expression of resistin-like molecule (RELM-α) and Ym-1. Unlike 
classically activated (M1) macrophage, which are important for killing intracellular 
pathogens by producing nitric oxide and pro-inflammatory cytokines, the alternatively 
activated macrophage produce RELM-α, Ym-1 and other pro-fibrotic factors to kill 
extracellular parasites and promote tissue healing (Patel  et al., 2004).  
 
RELM-α, which belongs to a family of small cysteine-rich secreted proteins (Nair et 
al., 2005), negatively regulates Th2 cytokine-mediated inflammation in the lung 
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(Holcomb et al., 2000). Ym-1 is a member of a family of mammalian proteins that 
share homology to chitinases of lower organisms (Raes et al., 2002). The level of 
Ym-1 was high on TREM-2 expressing macrophage at day 4 and declined afterword 
(Fig 5.2). However, it expression was upregulated again at day 16. The proportion of 
cells producing RELM-α increased during infection particularly of CD11c+ cells in 
the airway (Fig5.3). The RELM-α staining in the lung emitted less fluorescence than 
isotype control and was unreliable to analysis. The upregulation of TREM-2 
coincided with high level of M2 macrophage marker suggests that TREM-2 may be 
involved in the immune regulation during later resolution and resolved phase.   
 
 
 
Chapter 5: Role of TREM-2 in Influenza Infection 
140 
Airway
Lung
CD11b+
B
E
H
K
C D
F G
I J
L M
TREM-2
TREM-2
TREM-2
TREM-2
CD11c+
CD11b+
CD11c
Day 8 Day 16Isotype Day 4
A
Day 4 Day 8 Day 16
0
25
50
75
%
 o
f 
 t
o
ta
l 
m
a
c
ro
p
h
a
g
e
Day 4 Day 8 Day 16
1750
2250
2750
3250
3750
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
Day 4 Day 8 Day 16
0
15
30
45
60
%
 o
f 
 t
o
ta
l 
m
a
c
ro
p
h
a
g
e
Day 4 Day 8 Day 16
1350
1450
1550
1650
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
25
50
75
%
 o
f 
 t
o
ta
l 
m
a
c
ro
p
h
a
g
e
Day 4 Day 8 Day 16
2000
2500
3000
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
Day 4 Day 8 Day 16
0
10
20
30
%
 o
f 
 t
o
ta
l 
m
a
c
ro
p
h
a
g
e
Day 4 Day 8 Day 16
750
1000
1250
1500
1750
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
70
80
90
100
110
Day post infection
%
o
f 
O
ri
g
in
a
l 
W
e
ig
h
t
Day 4 Day 8 Day 16
%
 o
f 
 t
o
ta
l 
m
a
c
ro
p
h
a
g
e
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
%
 o
f 
 t
o
ta
l 
m
a
c
ro
p
h
a
g
e
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
%
 o
f 
 t
o
ta
l 
m
a
c
ro
p
h
a
g
e
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
%
 o
f 
 t
o
ta
l 
m
a
c
ro
p
h
a
g
e
In
te
n
s
it
y
 o
f 
fl
u
o
re
s
c
e
n
c
e
%
o
f 
O
ri
g
in
a
l 
W
e
ig
h
t
%
o
f 
O
ri
g
in
a
l 
W
e
ig
h
t
 
 
Figure 5.1. The surface expression of TREM-2 during PR8 influenza infection.  
Mice were infected with APR8 influenza and weight loss was monitored daily (A). The 
cells were harvested from the BAL (B-G) and lung (H-M) at 4, 8 and 16 days after 
infection.  The left panel represents the histograms of TREM-2 expression on CD11b+ or 
CD11c+ macrophage. Middle panel shows individual percent of TREM-2 expressing 
macrophages and their mean at each time point. The right panel shows the geometric mean 
fluorescence of TREM-2 staining and their mean. Data represent as mean and five mice 
were harvested at each time point.   
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Figure 5.2.Ym-1 staining on TREM-2 expressing macrophages 
The level of Ym-1 on TREM-2 expressing macrophage is detected in the airway (A-F) 
and lung (G-L) at different time point after A PR8 infection. The left panel is 
representative histograms for fluorescence of Ym-1
+ 
TREM-2
+
 macrophage at each time 
point is shown (red line is the isotype control and other colour is Ym-1
+
 at different time 
point). The middle panel show the percentage of Ym-1 producing TREM-2
+
macrophage 
and right panel represent the geometric mean fluorescence intensity of Ym-1 on TREM-2
+ 
macrophage. Data represent as mean and five mice were harvested at each time point.  
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Figure 5.3. RELM-α staining on TREM-2 expressing macrophages 
The level of RELM-α on TREM-2 expressing macrophage is detected in the airway at 
different time point after A/PR8 infection. Representative histograms (A-F) for 
fluorescence of RELM-α + TREM2+macrophage at each time point is shown (red line 
is the isotype control and blue colour is RELM-α). The percentage of RELM-α 
producing TREM-2
+
macrophage (G, I) and the geometric mean fluorescence intensity 
(H, J) of Relm-α were determinated by FACS analysis.  Data represent as mean and 
five mice were harvested at each time point.  
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5.2.1.2. Characterization of TREM-2 positive macrophages during 
X31 influenza infection 
To further explore TREM-2 in influenza infection of a different serotype, mice were 
infected with X31 (H3N2) and at day 2, 4, 7, 14, 21 post-infection the lung and BAL 
were sampled. The flow cytometry was performed to determine the percentage and 
fluorescence intensity of TREM-2 in various macrophage populations (as described in 
Chapter 3 section 3.2.1). 
 
Similar to the PR8 (H1N1) infection, early induction of TREM-2 expressing 
macrophages was observed 2 and 4 days after infection, followed in same case by a 
downregulation at the peak of inflammation in both airway and lung (Fig 5.4). In 
addition, TREM-2 expressing macrophage did not return to the pre-infection levels at 
day 21 and over 30% of airway macrophages were expressing TREM-2 (Fig 5.4). The 
expression profile between X31 and PR8 influenza infection is consistent with 
induction of TREM-2 during innate stage. This early upregulation may be mediated 
by TLR signalling or other immune cells recruited by chemokines. The resolution 
from peak inflammation is possibly mediated by desensitization of TLR or apoptosis 
of immune cells and TREM-2 was persisted above baseline following viral resolution.  
 
Co-expression of several other cell markers was then assessed, including the negative 
regulatory markers, CD200 receptor, Glucocorticoid Receptor (GR) and AXL, and 
M2 markers Ym-1, RELM-α. Consistent with previous findings, the TREM-2 positive 
macrophage produced high level of Ym-1 and RELM-α after 4 days (Fig 5.5 and Fig 
5.6).  Once again the expression intensity of these markers reduced at peak 
inflammation followed by elevated level, which was significant higher than naïve 
states and remained even 21 day after infection.  
 
CD200 receptor (CD200R) is an important inhibitory immune receptor for influenza 
infection in the airway (Snelgrove et al., 2008). AXL is a member of the TAM 
receptor family (Yanagita et al., 2001), that also had an inhibitory effect in 
macrophage regulation (Correll et al., 2004). Moreover, GR is another negative 
modulator, where glucocorticoid treatment leads to a M2 anti-inflammatory 
phenotype of human monocyte derived macrophages (Ehrchen et al., 2007). The 
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expression intensity of all these markers were significantly elevated on TREM-2 
positive macrophages during the later phase of influenza infection (Fig 5.7- Fig 5.9) 
and their levels at resolution were much higher than at uninfected states.  
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Figure 5.4. The surface expression of TREM-2 during X31 influenza infection.  
Mice were infected with X31 influenza and the cells were harvested from the airway and 
lung at 0, 2, 4, 7, 14 and 21 days after infection. TREM-2 on CD11c+ and CD11b+ 
macrophages was examined in the airway (A-D) and lung (E-H). The left panels represent 
the percentage of TREM-2 expressing macrophage and the right panels represent the 
geometric mean fluorescence intensity of macrophage TREM-2 expression. Data 
represent as mean and 4 mice were used in each time point.  
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Figure 5.5. The expression profile of Ym-1 on TREM-2 macrophage during X31 influenza 
infection.  
Cells were harvested from the airway (A-C) and lung (D-F) of mice infected with influenza 
X31 for 2, 4, 7, 14 or 21 days. The flow cytometry was used to identify the TREM-2 
expressing CD11 b and CD11c macrophages and co-expression of Ym-1. The figure A and 
D represent histograms for Ym-1 on TREM-2 + macrophage at each time point (red is the 
isotype control and blue is Ym-1 staining). The geometric mean fluorescence intensity of 
Ym-1 was assayed in the airway (B, C) and lung (E, F). Data represent as mean and 4 mice 
were used in each time point.  
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Figure 5.6. The expression profile of RELM-α on TREM-2 macrophage during X31 
influenza infection.  
Cells were harvested from the airway (A-C) and lung (D-F) of mice infected with 
influenza X31 for 2, 4, 7, 14 or 21 days. The flow cytometry was used to identify the 
TREM-2 expressing CD11 b and CD11c macrophages and co-expression of RELM-α. 
The figure A and D represent histograms for RELM-α on TREM-2 + macrophage at each 
time point (red is the isotype control and blue is RELM-α staining). The geometric mean 
fluorescence intensity of RELM-α was assayed in the airway (B, C) and lung (E, F). Data 
represent as mean and 4 mice were used in each time point.  
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Figure 5.7. The expression profile of GR on TREM-2 macrophage during X31 influenza 
infection.  
Cells were harvested from the airway (A-C) and lung (D-F) of mice infected with influenza 
X31 for 2, 4, 7, 14 or 21 days. The flow cytometry was used to identify the TREM-2 
expressing CD11 b and CD11c macrophages and co-expression of GR. The figure A and D 
represent histograms for GR on TREM-2 + macrophage at each time point (red is the isotype 
control and blue is GR staining). The geometric mean fluorescence intensity of GR was 
assayed in the airway (B, C) and lung (E, F). Data represent as mean and 4 mice were used in 
each time point.  
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Figure 5.8. The expression profile of AXL on TREM-2 macrophage during X31 
influenza infection.  
Cells were harvested from the airway (A-C) and lung (D-F) of mice infected with 
influenza X31 for 2, 4, 7, 14 or 21 days. The flow cytometry was used to identify the 
TREM-2 expressing CD11 b and CD11c macrophages and co-expression of AXL. The 
figure A and D represent histograms for AXL on TREM-2 + macrophage at each time 
point (red is the isotype control and blue is AXL staining). The geometric mean 
fluorescence intensity of AXL was assayed in the airway (B, C) and lung (E, F). Data 
represent as mean and 4 mice were used in each time point.  
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Figure 5.9. The expression profile of CD200R on TREM-2 macrophage during X31 
influenza infection.  
Cells were harvested from the airway (A-C) and lung (D-F) of mice infected with 
influenza X31 for 2, 4, 7, 14 or 21 days. The flow cytometry was used to identify the 
TREM-2 expressing CD11 b and CD11c macrophages and co-expression of CD200R. 
The figure A and D represent histograms for CD200R on TREM-2 + macrophage at each 
time point (red is the isotype control and blue is CD200R staining). The geometric mean 
fluorescence intensity of CD200R was assayed in the airway (B, C) and lung (E, F). Data 
represent as mean and 4 mice were used in each time point.  
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5.2.1.3. The expression profile of TREM-2 on macrophage after 
resolution of X31 influenza infection 
It is interesting to notice that the expression of TREM-2 is high at resolution and we 
next examined how long this elevated level persisted. Mice were sacrificed at 4, 5 and 
6 weeks post influenza X31 infection and cells from the lung and airway were 
examined for TREM-2 expression with other negative regulator marker or M2 
marker.  
 
In both the lung and airway, a significant proportion of CD11c+ macrophage 
expressed TREM-2 at 4, 5 and 6 weeks post infection. During later phase of infection, 
the number of CD11b+ macrophage was very low and TREM-2 expression was 
absent in the lung at 5 weeks and airway (Fig 5.10).  
 
The examination of M2 markers revealed Ym-1 and RELM-α were co-expressed in 
TREM-2 positive macrophages related to naïve state (Fig 5.11 and Fig 5.12), and the 
TAM receptor AXL but not GR (Fig 5.13- Fig 5.14). In all cases, the longevity of 
alterations was more evident in CD11c+ macrophages than CD11b+ macrophage. It 
should be noted that CD11c+ macrophages in the lung probably represent residual 
airway macrophage that are not removed by lavage. This implies a level of site 
specific alteration by factors that dominate in the airway to which CD11b+ 
parenchymal macrophage are not exposed. This hypothesis is supported by the high 
expression of CD200R that remain on CD11c+ macrophage that dominated in the 
airway (Fig 5.15).   
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Figure 5.10. The surface expression of TREM-2 during resolution phase of X31 influenza 
infection.  
Mice were infected with X31 influenza and the cells were harvested from the airway and 
lung at 4, 5, 6 weeks after infection.  The TREM-2 on CD11b hi/low macrophage is 
detected in the airway (A-C) and lung (D-F). The figure A and D are represented 
histograms for TREM-2 on macrophage at each time point (red line is the isotype control 
and blue colour is TREM-2 staining). The geometric mean fluorescence intensity of 
TREM-2 expression was assayed in the airway (B, C) and lung (E, F). Data represent as 
mean and 5 mice were used in each time point.  
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Figure 5.11. The co-expression of TREM-2 and Ym-1 during resolution phase of X31 
influenza infection.  
Mice infected with X31 influenza (50 HA intranasally) were harvested 4, 5, 6 weeks after 
infection.  TREM-2 expressing CD11b/c and CD11c macrophage population were 
identified by flow cytometry. Representative staining of Ym-1 (blue line) and its isotype 
control (red line) are shown for cell isolated from airway(A-C) and lung(D-F), and 
geometric mean fluorescence plotted for CD11b (B, E) and  CD11c (C, F) macrophage 
population. Data represent as mean and 5 mice were used in each time point.  
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Figure 5.12. The co-expression of TREM-2 and RELM-α during resolution phase of X31 
influenza infection.  
Mice infected with X31 influenza (50 HA intranasally) were harvested 4, 5, 6 weeks after 
infection. TREM-2 expressing CD11b/c and CD11c macrophage population were 
identified by flow cytometry. Representative staining of RELM-α (blue line) and its 
isotype control (red line) are shown for cell isolated from airway(A-C) and lung (D-F), 
and geometric mean fluorescence plotted for CD11b (B, E) and  CD11c (C, F) 
macrophage population. Data represent as mean and 5 mice were used in each time point.  
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Figure 5.13. The co-expression of TREM-2 and GR during resolution phase of X31 
influenza infection.  
Mice infected with X31 influenza (50 HA intranasally) were harvested 4, 5, 6 weeks after 
infection.  TREM-2 expressing CD11b/c and CD11c macrophage population were 
identified by flow cytometry. Representative staining of GR (blue line) and its isotype 
control (red line) are shown for cell isolated from airway(A-C) and lung (D-F), and 
geometric mean fluorescence plotted for CD11b (B, E) and  CD11c (C, F) macrophage 
population. Data represent as mean and 5 mice were used in each time point.  
 
Chapter 5: Role of TREM-2 in Influenza Infection 
155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14. The co-expression of TREM-2 and AXL during resolution phase of X31 
influenza infection.  
Mice infected with X31 influenza (50 HA intranasally) were harvested 4, 5, 6 weeks after 
infection.  TREM-2 expressing CD11b/c and CD11c macrophage population were 
identified by flow cytometry. Representative staining of AXL (blue line) and its isotype 
control (red line) are shown for cell isolated from airway(A-C) and lung (D-F), and 
geometric mean fluorescence plotted for CD11b (B, E) and  CD11c (C, F) macrophage 
population. Data represent as mean and 5 mice were used in each time point.  
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Figure 5.15. The co-expression of TREM-2 and CD200R during resolution phase of 
X31 influenza infection.  
Mice infected with X31 influenza (50 HA intranasally) were harvested 4, 5, 6 weeks 
after infection.  TREM-2 expressing CD11b/c and CD11c macrophage population were 
identified by flow cytometry. Representative staining of CD200R (blue line) and its 
isotype control (red line) are shown for cell isolated from airway(A-C) and lung(D-F), 
and geometric mean fluorescence plotted for CD11b (B, E) and  CD11c (C, 
F)macrophage population. Data represent as mean and 5 mice were used in each time 
point.  
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5.2.2. TREM-2 positive alveolar macrophage exhibit an 
immunosuppressed phenotype 
5.2.2.1. TREM-2 positive macrophages exhibit suppressed 
responses to TLR stimulation 
To determine the role of TREM-2 expressing macrophages following influenza 
infection, airway cells were harvested by BAL from mice four weeks post infection. 
Macrophage populations were identified by flow cytometry analysis as described 
previously and stained with CD11c, F4/80 and TREM-2. TREM-2 positive and 
negative macrophage were then sorted (dot plots shown in Fig 5.16). The percentage 
of TREM-2 positive CD11c
+
 macrophage was 28% in total CD11c+ population and 
the purity was 91%, whereas the TREM-2 negative CD11c
+
 constituted 72% of total 
CD11c+ population and purity 89% was achieved.  
 
The TLR responsiveness of these two macrophage populations was compared to 
investigate whether the expression of TREM-2 was associated with altered functional 
properties as determined by cytokine secretion. After 24 hours, TREM-2 positive 
macrophages secreted significantly less IL-6 and TNF in response to TLR-2, TLR-4 
and a lesser extent TLR-3, TLR-7 ligands (Fig.5.16.F.G). These results suggest that 
TREM-2 expressing macrophage account for TLR desensitization post influenza 
infection (Didierlaurent et al., 2008). This reduction was observed even though the 
TLR expression levels were the same on both populations of macrophage (Fig.5.17.A-
C).  
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Figure 5.16. TLR responsiveness of TREM-2 expressing macrophage from resolving lung is 
suppressed. 
Cells were collected by bronchoalveolar lavage (BAL) from mice 4 weeks post infection with 
X31 influenza. Airway cells were immunostained with CD11c to identify macrophage. 
Lymphocytes (R1) were excluded based on their sizes and granularity defined in the forward 
light scatters (FSC) and side light scatter (SSC) plots (A). Cell populations were sorted based 
on their TREM-2/CD11c profiles (B-E). Equal number of TREM-2 positive and negative 
macrophages were incubated with different TLR stimuli (concentration were described in 
method) and supernatants collected after 24 hours. In addition, some cells were incubated 
with medium only as control. The concentration of TNF and IL-6 were determined in the 
medium from stimulation by ELISA (F-G). The results are expressed as the mean ± SEM. 
Statistical analysis was done by Mann Whitney test of variance and significantly difference 
was defined at p < 0.05.  
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5.2.2.2. TREM-2 positive macrophages remained following 
influenza infection have high expression of M2 markers and low 
M1 markers 
As I showed in the previous section, markers associated with negative regulation of 
macrophage activity (CD200R, AXL, and GR) were co-expressed on TREM-2 
positive macrophages, whereas markers for classical activation (CD86, CD69 and 
MHC-II), were down-regulated (Fig 5.17 G-L). All data suggest that TREM-2 + 
macrophage resemble alternatively activated (M2) or regulatory macrophages. In 
order to address this, further phenotyping of TREM-2 positive macrophage was 
carried out by comparing the expressions of various surface markers.  
 
The level of C-C chemokine receptors (CCR) and interleukin (IL) receptors were also 
determined by flow cytometry. CCR-2 involved in emigration of inflammatory 
monocytes from bone marrow to blood (Serbina et al., 2006) and recruitment of 
monocytes/macrophages (Kurihara et al., 1997). CCR-5 has been shown to contribute 
to the survival of macrophages during inflammation and infection (Tyner et al., 
2005). Both of them were upregulated on TREM-2+ve macrophage compared to 
TREM-2-ve macrophage, whereas CCR-7 expression was reduced (Fig 5.18 A-F). 
This suggested that this TREM-2+ macrophage may be originally recruited from 
blood and can retain in the airway. The expression of IL-4 receptors was also 
significantly higher than the TREM-2 + macrophage (Fig 5.18 H).  
 
To check whether transcriptional regulators are differentially expressed in TREM-2+ 
versus TREM-2 population, TREM-2 positive and negative macrophages were sorted 
for RNA extraction. As shown in Figure 5.19, there was a significantly enhanced 
expression for M2 macrophage-related transcripts argunase-1, Ym-1 as well as 
negative regulators of TLR signalling such as Toll interacting protein (TOLLIP), 
NFκB negative regulator (A20) and IRAK-M. These results suggested that the 
phenotype of TREM-2+ macrophages is consistent with M2 macrophages phenotype. 
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Figure 5.17. Comparing the expression of TLR and other receptors between TREM-2 
positive and negative macrophages isolated from late resolving phase. 
Cells were collected by BAL of the mice infected with influenza for 4 weeks. TREM-
2 expressing macrophages were sorted based on their TREM-2/CD11c profiles. The 
cells were also were immunostained with CD86, CD11b, MHC II and TLR receptor 
(TLR3, TLR4, and TLR7), followed by multiparameter flow cytometry analysis. In 
the histogram (A-C and G-I), blue line represent the TREM-2 negative macrophage, 
whereas red line represent the positive cells and black ling is unstaining control.  The 
results are expressed as the mean ± SEM. Statistical analysis used done by Mann 
Whitney test of variance and significantly difference was defined at **p < 0.01.  
 
 
 
Lymphocytes and macrophages were gated according to their sizes and granularity 
defined in the forward light scatter (FSC) and side light scatter (SSC) plot. Cell 
populations were sorted based on their CD11b/CD11c profiles 
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Figure 5.18. Comparing the expression of chemokine and other receptors between TREM-
2 positive and negative macrophages isolated from late resolving phase. 
Cells were collected by BAL of the mice infected with influenza for 4 weeks. TREM-2 
expressing macrophages were sorted based on their TREM-2/CD11c profiles. The cells 
were also were immunostained with CD69, chemokine receptor (CCR5, CCR2, and 
CCR7), IL-4 receptor and IL-10 receptor, followed by multiparameter flow cytometry 
analysis. In the histogram (A-C and G-I), blue line represent the TREM-2 negative 
macrophage, whereas red line represent the positive one and black ling is unstaining 
control.  The results are expressed as the mean ± SEM. Statistical analysis was done by 
Mann Whitney test of variance and significantly difference was defined at **p < 0.01. 
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Figure 5.19. Comparing of mRNA expression profile of macrophage activity markers 
from TREM-2 +/- macrophages isolated from infected mice. 
The airway macrophages were isolated from influenza-infected mice and subjected to 
FACS sorting to separate TREM-2 expressing and non-expressing cells. The mRNA 
levels in cells were quantitated by real-time PCR. Data represents the mean ± SEM results 
from three sample mice per value and only one experiment was performed. **p < 0.01. 
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5.2.2.3. IL-4 driven airway macrophage has the same 
responsiveness as influenza resolved macrophage  
As we observed that high levels of IL-4R expressed on TREM-2+ macrophage in the 
post-influenza lung (Fig 5.18), when the concentration of IL-4 also increased at same 
time (Fig 5.20). In addition, since IL-4 upregulates the expression of TREM-2 
(Turnbull et al., 2006), we ascertained whether naïve macrophage could be altered by 
incubation with IL-4. Airway macrophages were harvested from naïve mice and 
incubated with IL-4 for 72 hours (Fig 5.21. A). TREM-2 expression was increased 
with nearly 70% of cells expressed TREM-2 after incubation, compared with naïve 
macrophage. TREM-2 positive and negative macrophages were then sorted from 
these cultures and the productions of inflammatory cytokines in response to various 
TLR agonists examined 24 hours later. As we saw previously in TREM-2+ 
macrophage from the resolved lung, there was a significant decrease in the production 
of IL-6 and TNF by IL-4 induced TREM-2+ macrophages compared to negative ones 
(Fig 5.21. C, D).  
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Figure 5.20. The concentration of IL-4 in the BAL fluid during influenza infection.  
Mice were infected with X31 influenza and the BAL fluid was collected at different time 
points post infection (n=5 per time point). The amounts of IL-4 were measured using the 
ELISA kit (mean ± SEM). 
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5.2.2.4. IL-4 induced TREM-2 positive macrophage have high 
expression of M2 and low M1 markers 
Consistent with TREM-2+ cells isolated from the influenza resolved lung, those IL-4 
induced TREM-2 expressing macrophage were stained with the same panel of 
macrophage markers as previously applied. In addition, there is no significant 
difference in TLR expression (Fig 5.22 A-F) and markers of classical activation were 
low on TREM-2 + macrophage (Fig 5.22 G-L). Consistent with our finding in 
resolved macrophage, the striking induction were found on level of CCR 5, 2 IL-4 
receptor in TREM-2 expressing cells, whereas remarkable reduced level of CD86, 
MHC II and CCR-7, compared to the TREM2+ macrophage negative cells(Fig 5.22 
Figure 5.21. The suppressed TLR responsiveness of IL-4 induced TREM-2 expressing 
macrophage. 
Airway macrophages were collected from naïve mice followed by sorting and incubating 
with IL-4 for 72 hours (A). Then the cells were immunostained with CD11c and TREM-2 
and sorted into TREM-2 positive and negative (B). Both populations were incubated with 
different TLR agonistes for 24 hours. The concentration of TNF (C) and IL-6 (D) was 
determined in by ELISA. Statistical analysis was done by Mann Whitney test of variance 
and significant difference defined as *p<0.05 and **p < 0.01. The results are expressed as 
the mean ± SEM 
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and 5.23). Taken together, these results further suggest that the phenotype and 
responsiveness of IL-4 driven TREM-2+ macrophage was similar to TREM-2+ 
macrophage taken from the influenza resolved lung.  
 
 
Figure 5.22. The phenotype of IL-4 driven airway macrophage  
IL-4 induced TREM-2+ macrophages were sorted based on their TREM-2/CD11c profiles 
and immunostained with CD86, CD11b, MHC II and TLR receptors (TLR3, TLR4, and 
TLR7), followed by multiparameter flow cytometric analysis. In the histogram (A-C and G-
I), the blue line represent the TREM-2 positive macrophage, whereas red line represent the 
negative one and black ling is unstaining control. Statistical analysis was done by Mann 
Whitney test of variance and significance defined as *p<0.05 and **p < 0.01. The results 
are expressed as the mean ± SEM 
Chapter 5: Role of TREM-2 in Influenza Infection 
166 
 
 
 
 
 
 
 
 
Figure 5.23. The phenotype of IL-4 driven airway macrophage  
IL-4 induced TREM-2+ macrophages were sorted and immunostained with CD69, 
chemokine receptors (CCR5, CCR2, and CCR7), IL-4 receptor and IL-10 receptor, followed 
by multiparameter flow cytometry analysis. In the histogram (A-C and G-I), blue line 
represent the TREM-2 positive macrophage, whereas red line represent the negative one and 
black ling is unstaining control. Statistical analysis was done by Mann Whitney test of 
variance and significance defined as *p<0.05 and **p < 0.01. The results are expressed as 
the mean ± SEM 
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5.2.2.5. The TREM-2 positive cells regulate the TLR 
responsiveness of naïve macrophage  
As we previously revealed that both resolved and IL-4 driven TREM-2+ macrophages 
display an M2 or regulatory phenotype, therefore it is possible they may have 
suppressive effect on other immune cells. To assess their ability to regulate other 
macrophages, naïve macrophages were co-cultured with them for LPS stimulation and 
the production of pro-inflammatory cytokine were compared.  
 
Naïve macrophages were sorted from lavage based on CD11c expression and 
incubated with IL-4 to generate TREM-2 expressing macrophage. After 72 hours, 
cells were re-sorted for TREM-2 expressing macrophage which were then co-cultured 
with naïve macrophage or the TREM-2 negative macrophage.  100ng/ml of LPS was 
added to the medium and production of pro-inflammatory cytokine was quantified by 
ELISA at 24 hours later. Naïve airway macrophage produced significant amounts of 
TNF (Fig. 5.24 B) and IL-6 (Fig. 5.24C) comparing to medium alone. TREM-2 
negative macrophage from the IL-4 culture produced less TNF and IL-6 than naïve 
macrophage, but still addition of TREM-2+ macrophage blunted their response. Two 
controls are shown on the right hand side of each graph TREM-2+ and TREM-2- 
macrophage alone at the concentration they were used in the co-culture. It is 
interesting that TREM-2- cells displayed a blunted response. This is likely due to the 
influence of TREM-2+ cells in the culture prior to the second sort. It would be 
interesting to see if this effect wanes with time. It is possible that IL-4 in the original 
cultures affected not only TREM-2+ cells but also TREM-2- macrophages, which do 
express IL-4R but to a lower extent than TREM-2+ cells  
 
The suppressive effect of TREM-2 expressing macrophages from the influenza 
resolved lung was also assessed. TREM-2+ cells were isolated 4 weeks after influenza 
infection and much fewer cells are available compared to the IL-4 driven one.  Even 
though lower ration (1:10) of TREM-2+ macrophage was used; the LPS-induced 
proinflammatory cytokine production was inhibited by co-culture with TREM-2+ 
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cells. The amount of TNF and IL-6 was further reduced by doubling the number of 
TREM-2+ macrophage (Fig5.25 B, C) 
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Figure 5.24. IL-4–activated TREM-2 positive macrophages suppress the TLR response of 
naïve alveolar macrophage 
FACS Aria-sorted naïve BALB/c alveolar macrophages (CD11high) were incubated with 
500ng/ml IL-4 for 72 hours (A) followed by further sorting based on the expression of 
TREM-2. TREM-2+ cells were cultured alone, with naïve macrophages or TREM-2- cells 
from the IL-4 cultures in the presence of 100ng/ml LPS. 2 x10
5
 TREM-2
+
 cells were co-
cultured with either 5 x10
5 
TREM-2
–
 cells (ratio = 2: 5) or 5 x10
5 
naïve cells (ratio = 2: 5). 
After 24 hours, the concentration of pro-inflammatory cytokines was assayed by ELISA 
(B, C).  The results are expressed as the mean. Statistical analysis was done by Mann 
Whitney test of variance and significance defined as *p<0.05 and **p < 0.01. The results 
are expressed as the mean ±SEM 
 
. 
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Figure 5.25. The resolved TREM-2 positive macrophage suppress the TLR 
response of naïve alveolar macrophage 
FACS Aria-sorted resolved TREM-2 expressing macrophages were cultured alone 
or with naïve macrophage or TREM-2 negative cells in the presence of LPS. 2 
x10
5
 TREM-2
+
 cells were co-cultured with either 1 x10
6 
naïve cells (ratio = 2: 10) 
or 2 x10
5 
naïve cells (ratio = 1: 10) and relevant amount of cells were cultured 
alone. After 24 hours, the concentration of pro-inflammatory cytokine was assayed 
by ELISA. Statistical analysis was done by Mann Whitney test of variance and 
significance defined as *p<0.05 and **p < 0.01. The results are expressed as the 
mean ± SEM.  
. 
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5.2.3. The transfer of TREM-2+ macrophages improved the 
disease progression of influenza infection  
5.2.3.1. Transfer of TREM-2+ macrophage to influenza infected 
mice reduce the weight loss   
The preceding data suggests that the TREM-2+ macrophages display regulatory 
activity; therefore we transferred IL-4 induced TREM-2+ macrophages prior to 
influenza infection to assess their effect in innate immunity and disease progression.  
 
TREM-2 expressing macrophages were generated by culturing naïve airway 
macrophage with IL-4 for 72 hours. These cells were then washed to remove IL-4 and 
1 × 10
5
 TREM-2 +ve cells or freshly isolated alveolar macrophages transferred 
intranasally to the recipient naïve mice (Fig 5.26 A). A further control group of mice 
only received medium and influenza was introduced into all mice one day later. The 
transfer of TREM-2 + cell reduced influenza induced weight loss at day 2, 3 and 5, 
whereas the transfer of naïve macrophage had no effect (Fig 5.26 B).  
 
On day 0, 3 and 7 days after infection, lung tissue and BAL fluid were recovered from 
mice to assay viral load and commensal bacteria. At day 3, the viral load in mice that 
received TREM-2+ macrophage was higher than control group (Fig 5.27 A). 
However, one outlier in mice that received naïve macrophages meant there was no 
significant difference with this group compared to mice that received TREM-2+ 
macrophage. This difference was disappeared at day 7 when all groups had similar 
viral titres in the lung (Fig 5.27 B). We next analysed commensal bacteria in the 
airway which previously noted their expression correlated with disease severity and 
progression. Low levels of bacteria were observed in the mice that received naïve 
macrophage or medium and one mouse from TREM-2+ group. Three days after the 
infection, we cannot recover any bacteria from TREM-2+ group (Fig 5.27 D) and no 
bacteria were recovered from the airway at 7 days.  
 
One day after transfer of TREM-2+ or naïve macrophages, the cell count in airway of 
both recipient groups was significant higher than the medium control, which 
demonstrated successful installation (Fig 5.28 A and B). Three days later, less cells 
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were onserved in mice that received TREM-2+ macrophage compared to both control 
groups (Fig 5.28 C and D). However at day 7, there was no difference in cellularity 
between any groups (Fig 5.28 E and F). This suggests that TREM-2+ macrophages 
reduced cellularity and weight loss whilst increased the early viral titre.  
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Figure 5.26. The weight loss of TREM-2+ cells reduced early weight loss during influenza 
infection.    
BALB/C mice received equal amounts of (10
5
) IL-4 induced TREM-2
+
 macrophages 
(group A), naïve macrophages (group B) or medium alone (group C). Weight loss was 
recorded daily to monitor the disease progression (B). Statistical analysis was done by one 
way ANOVA test of variance and significance difference (*) defined at p < 0.05. The date 
was expressed as mean ± SEM and 5 mice per group were used in the experiment.  
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Figure 5.27. Transfer of TREM-2+ macrophages reduce commensal bacterial load in 
airway but increase early viral load  
Mice were sacrificed at 0, 3 and 7 day post influenza infection for collection of BAL fluid 
and lung tissue. Plaque assay was carried on the lung homogenates for viral titre (A, B). 
BAL fluids were incubated on blood agar plates and assay for colonies (C, D). Statistical 
analysis was done by Mann Whitney test of variance. * was defined as p < 0.05 and ** is 
p<0.01. The data is expressed as mean and 5 mice per group were used in the experiment.  
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Figure 5.28. Transfer of TREM-2 macrophages reduced T cells early cell infiltration. 
The mice were sacrificed at 0, 3 and 7 day post influenza infection for collection of BAL 
fluid and lung tissue. Cellularity was determined in the airway (A, C, E) and lung (B, D, F) 
by trypan blue exclusion. Statistical analysis was done by Mann Whitney test of variance 
and significantly difference was defined at p < 0.05(**). The data is expressed as Mean ± 
SEM and 5 mice per group were used in the experiment.  
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5.2.3.2. Transfer of TREM-2+ macrophages modulate recipient 
macrophage activity  
To explore the effect of introducing TREM-2 positive macrophages on innate 
immunity, a detailed profile of macrophage phenotype was determined by flow 
cytometry. The percentage of macrophages expressing TREM-2 was higher in the 
airway of mice receiving it compared to the other two control groups (Fig 5.29 A-C). 
This suggested successful installation into the airway of mice or that transferred 
TREM-2+ cells may induce expression of TREM-2 on other cells. Elevated 
proportions of TREM-2 + macrophages were observed at day 3 post infection (Fig 
5.29 A-C). By 7 days after infection, no difference was observed in the proportion of 
TREM-2 macrophages between the groups (Fig 5.29 A-C). Next we enumerated 
actual cell numbers and less macrophage were observed in the TREM-2 transfer 
group only at day 3, which reflect the overall decrease in cell number in early time 
point (Fig 5.29 D-E). Therefore the cell proportion was more relevant to represent the 
profile of TREM-2. 
 
We examined the profile the phenotype of macrophages for Ym-1 (M2 markers) and 
CD200R (negative regulator). There significant differences were observed in the 
airway (Fig 5.30) of lung (Fig 5.31). In addition, elevated expression of IL-10 and 
significantly reduced levels of TNF were observed in mice that received TREM-2+ 
macrophage compared to the other two groups.  
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Figure 5.29. Analysis of TREM-2 expression during influenza infection  
TREM-2+ macrophages were identified by flow cytometry at day 0, 3 and 7 days after 
infection. Fig A shows representative flow cytometry plots and gated based on isotype 
control. The proportion of TREM-2+ macrophage in total macrophage (B, C) and total 
number of macrophage (D, E) in the airway and lung are recorded at each time point. 
The data was expressed as mean ± SEM and 5 mice per group were used in the 
experiment.  
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Figure 5.30. The effect of TREM-2+ macrophages transfer on the phenotype of 
macrophage during influenza infection 
TREM-2+ airway macrophages were identified by flow cytometry at day 0, 3 
and 7 days after infection. The cells were also were immunostained with IL-10 
(A), TNF (B), CD200R (C), IFNγ (D) and Ym-1 (E) followed by multiparameter 
flow cytometry analysis. The data is expressed as mean ± SEM and 5 mice per 
group were used in the experiment.  
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Figure 5.31. The effect of TREM-2+ macrophages transfer on the phenotype of 
macrophage during influenza infection 
TREM-2+ macrophages were identified by flow cytometry at day 0, 3 and 7 
days after infection. The cells were also were immunostained with IL-10 (A), 
TNF (B), CD200R (C), IFNγ (D) and Ym-1 (E) followed by multiparameter 
flow cytometry analysis. The data is expressed as mean ± SEM and 5 mice per 
group were used in the experiment.  
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5.2.3.3 Transfer of TREM-2 macrophage has no effect on T cells 
We next examined the influence of TREM-2+ macrophage transfer on adaptive 
immunity. Cells harvested from airway and lung at day 3 and 7 were stained with anti 
CD4 and CD8 antibodies. In addition, two additional markers, CD200 and OX40 
were used to analyse T cell activation. CD200 is a type 1 membrane glycoprotein, 
delivering immunoregulatory signals through binding to its receptors (Boudakov et 
al., 2007). OX40 is a co-stimulatory signal in the TNF receptor (TNFR) superfamily 
that can be expressed on T cells (Croft M., et al  2009).  
 
There was no consistent difference in CD4 or CD8+ T cells, or their expression of 
CD200 or OX40 in either the airway (Fig 5.32) or lung (Fig 5.33). The transferring of 
TREM-2+ cells also had limited effect on T cell activation, only percent of CD200+ 
CD4+ cells was elevated in the lung at day 7 (Fig 5.33). Collecting with preceding 
results, it was suggested that the instillation of TREM-2 had suppressive effect on the 
macrophage with only mild influence on T cell mediated immunity.   
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Figure 5.32. The effect of TREM-2 transfer on the phenotype of T cells in the airway 
The airway cells were harvested from mice suffered 3 and 7 days of influenza infection. 
The differential T cells count were represented as present of CD4 (A) and CD8 (B) 
positive cell and additional immunoassaying with CD200 (C,D) and OX40 (E,F) were 
used to analysis the T cell activation. The date was expressed as mean ± SEM and 5 
mice per group were used in the experiment.  
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Figure 5.33. The effect of TREM-2 transfer on the phenotype of T cells in the lung 
The lung cells were harvested from mice suffered 3 and 7 days of influenza infection. The 
differential T cells count were represented as present of CD4 (A) and CD8 (B) positive 
cell and additional immunoassaying with CD200 (C,D) and OX40 (E,F) were used to 
analysis the T cell activation. The date was expressed as mean ± SEM and 5 mice per 
group were used in the experiment.  
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5.3. Discussion 
5.3.1. The regulation of TREM-2 expression during influenza 
infection  
Influenza infection and secondary bacterial pneumonia following influenza are 
associated with significant mortality and morbidity, particularly following highly 
pathogenic strains including the (H1N1) 2009 influenza pandemic (Dunning et al., 
2010). Influenza induced pathology is not only attributed to viral replication, but also 
the excessive host immune response (Openshaw et al., 2010). Therefore, it is 
desirable to indentify pathways to counter-act this phenomenon and improve the 
outcome of the disease.  
 
TREM-2 is a novel immune regulatory molecule expressed primarily on 
macrophages, where it suppresses TNF and IL-6 production and promotes an anti-
inflammatory state (Turnbull et al., 2006). The regulation of its expression and role in 
viral infection is poorly understood. For the first time, we have demonstrated that 
TREM-2 expression is upregulated in a biphasic manner, during the early stage and 
resolved phase of infection. Naïve alveolar macrophages showed low expression of 
TREM-2, whereas greater levels were observed in the influenza resolved lung. Such a 
persistence of TREM-2 either reflect on ongoing function in the lung or persistence of 
expression indirectly via changes in other pathways. It is difficult to ascertain whether 
the early peak of TREM-2 at 4 days post influenza infection has any function 
consequences. The downregulation from peak on macrophages occur at a time when 
innate immunity is at its peak 
 
Several studies reveal that expression of TREM-2 is regulated by several cytokines 
and TLR signalling pathway. In the murine macrophage cell line RAW 264.7, 
BMDM and microglia, TLR-4 engagement by LPS downregulated the cell surface 
expression of TREM-2 (Bouchon et al., 2001b) and in vivo blockade of IL-23 also 
resulted in a 100-fold reduction of TREM-2 transcripts in macrophages (Yi Chen et 
al., 2006), whereas IL-4/IL13 treatment enhanced TREM-2 expression (Turnbull et 
al., 2006). In human osteoclast precursors, IL-10 inhibits their development of by 
suppressing the TREM-2 gene transcription. During early phase of influenza 
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infection, the elevated level of TLR antigens, TNF and IL-10 play a dominant role in 
inhibiting TREM-2 expression. At the same time, IL-23 and IL-4 (Fig.5.34) may 
serve as opposing factors in the regulation of TREM-2 expression. 
  
After 7 days of infection, the level of TREM-2+ macrophages increased again and 
was maintained at 30% during remaining period of study. This coincided with 
enhanced levels of IL-4 and enhanced expression of IL-4 receptor on TREM-2+ 
macrophages. Thus we hypothesise that IL-4/IL-4R levels could be responsible for 
second induction phase of TREM-2 expression and it overwhelm the inhibitory effect 
by IL-10 and remaining TLR antigens.    
 
This could be tested by IL-4 neutralisation during resolution though it woud be 
difficult to ascertain a direct effect from an alternation in other aspects of influenza 
infection or the inflammatory responses. However, we showed a high similarity 
between IL-4-driven TREM-2 macrophages and resolved TREM-2 macrophages in 
vitro with respect to phenotype and function. We proposed that TREM-2 expression is 
therefore regulated by the balance of inhibitors and stimulatory signals at different 
phases of infection (Fig 5.34). It is interesting to note that TREM-2 expressing 
macrophages inhibit cytokine production by TREM-2- macrophages in response to 
several toll-like receptor ligands. At present we cannot attribute this to TREM-2 
directly. We have initiated collaboration with Dr William E. Seaman, who has a 
TREM-2 agonist antibody to address this question (Humphrey et al., 2007). It would 
also be interesting to define whether cell to cell contacts or secretory molecules are 
required for TREM-2 mediated suppression by using transwell culture system. If 
significant separation of two cell types can reduce the cytokine production, the direct 
cell contact is not required for the inhibitory effect.  
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5.3.2. The phenotype of TREM-2+ macrophage  
In the resolved airway, more than 30% of macrophages expressed TREM-2. These 
TREM-2+ macrophages exhibited reduced responses to TLR stimulation compared to 
naïve macrophages and TREM-2- macrophages in vitro. As the surface expression of 
TLRs was the same on both TREM2 positive and negative macrophages, this 
suppressive effect was not due to reduced receptors for TLR signalling. Although the 
exact mechanism of regulation is unknown, TREM-2 receptor ligation does not 
induce the degradation of IκB-α and the subsequent nuclear translocation of NF-κB 
(Bouchon et al., 2001), which are important to upregulate the transcription of pro-
inflammatory genes. The stable expression of TREM-2 on resolved macrophages may 
therefore contribute to the post influenza TLR desensitization we described befrore 
(Didierlaurent et al., 2008). 
 
Many studies show that macrophages have a high degree of plasticity and they adapt 
to different cytokine environments to behave in a pro-inflammatory (M1) or tissue 
repair manner (M2) (Gordon et al., 2003). To address this, we examined expression of 
markers of M1 and M2 macrophages and other known negative regulators of 
Figure. 5.34. Potential parameters to control TREM-2 expression during influenza 
infection. 
In the resting lung high levels of IL23 and IL-4 may maintain a small portion of TREM2+ 
macrophage that counter harmless response to innocuous antigens. During the innate 
immune phase following influenza infection, TLR agonists and innate cytokine reduce the 
TREM-2 expression on the macrophage. At the resolution phase, when the homeostasis is 
restoring, elevated levels of IL-4, IL-33 may induce the TREM-2 expression.  
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inflammation and immune signalling. TREM-2+ macrophages exhibited an apparent 
alternative activation profile, include relatively high levels of Relm-α and Ym-1. 
Negative feedback inhibitors of TLR signalling, A20 and IRAK-M were elevated. 
Similarly markers related to inhibition (AXL and GR) and immune modulation 
(CD200R) were upregulated. Taken together, these data suggest that TREM-2+ 
macrophages not only exhibit an M2 phenotype, but may promote immune 
suppression.  
 
IL-4 induces TREM-2 expression in resident peritoneal macrophages (Turnbull et al., 
2006). We confirmed that IL-4 induces TREM-2 expression on naïve alveolar 
macrophages. These IL-4 driven TREM-2+ macrophages displayed not only similar 
expression profiles of macrophage markers and regulatory molecules to resolved 
macrophages, but also suppressed TLR responses by TREM-2- macrophages. When 
co-cultured with naive macrophages, both resolved and IL-4 induced TREM-2+ 
macrophages inhibited pro-inflammatory cytokine production in response to LPS. 
Autoregulation of other macrophages within pockets of inflammation in the lung is an 
attractive idea (Hamerman et al., 2006).  
 
TREM-2+ macrophage also co-expressed other negative regulators such as CD200R, 
GR and Axl. The high expression of CD200R on TREM-2+ is may be driven by IL-
10 in the resolved lung (Snelgrove et al., 2008) and the IL-10 has been reported 
highly produced by TREM-2 expressing myeloid cells (Takahashi et al., 2007). Thus 
TREM-2+ macrophage may secrete IL-10 to upregulated CD200R. In addition, the 
expression of CD200 on epithelium may exert a profound regulatory effect on these 
TREM-2+ macrophages. On other hand the high levels of TAM receptor AXL 
confirm the role of TREM-2 in apoptosis, which suggested by showing the TREM2 
expression in microglia increases phagocytosis in response to apoptotic neurons 
(Takahashi et al., 2005). The AXL binds to externalised phosphatidylserine on 
apoptotic cells using bridging molecule Gas6 and protein S to induce apoptosis 
(Hafizi et al., 2006). Thus the repopulation of TREM-2 expressing cell may be driven 
by efferocytosis of apoptotic cells. The activated TAM receptors interact with the type 
I interferon receptor to induce the suppressor of cytokine signalling (SOCS) 1 and 3, 
that suppress of TLR-driven cytokine production (Rothlin et al., 2007). This may 
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contribute to the reduced cytokine levels of TREM-2+ macrophage in response to 
TLR stimulation.  
 
  
5.3.3. The suppressive effect of TREM-2+ macrophages on 
other cell types 
TREM-2+ macrophages have an immunosuppressive phenotype and a modulatory 
effect on macrophage activity. These characteristic imply that TREM-2+ 
macrophages regulate inflammatory responses to influenza infection. To investigate 
this, we intranasally transferred IL-4 induced TREM2+ macrophages into mice prior 
to influenza infection that lead to reduced weight loss and cellularity, but higher viral 
loads were detectable in the lung. The macrophages from treated mice produce more 
anti-inflammatory cytokine (IL-10) and M2 associated Ym-1, and less pro-
inflammatory cytokine (TNF-α). The fact that viral loads were higher does not 
suggest that a phagocytic environment in the airway is enhanced. 
 
TNF-α is an important component of cytokine storm, which is general elevated in 
severe influenza infection (Kobasa et al., 2006). The viral replication within lung 
epithelial cells is strongly inhibited by TNF-α (Seo et al., 2002). Its implication in 
lung immunopathology would suggest that anti-TNF treatment might actually be 
beneficial (Hussell et al., 2001). Our data show that the production of TNF-α is 
inhibited by TREM-2+ macrophages, which account for delayed viral clearance 
during early phase of infection. The reduction of TNF may be also account for 
reduced cellularity since TNF activate endothelium to enhance cell recruitment. 
Taken together with higher levels of IL-10 would also impede cell expansion within 
the airway.  
 
 
The exact role of M2 macrophages in an influenza infection is unknown, but their 
induction in RSV infection is beneficial for tissue repair and reduced host pathology 
(Shirey et al., 2010). Induction of Arg1 by IL-4 and IL-13 is also implicated in 
collagen deposition (Hesse et al., 2001) and degradation (Wilson et al., 2009), which 
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are essential steps in wound healing. M2 macrophages promote excessive fibrosis by 
producing growth factors and chemokines to recruit fibroblasts (Daley et al., 2010). A 
recent study demonstrated that TREM-2 signalling is essential for colonic mucosal 
wound repair (Hiroshi et al., 2009). After colonic biopsy injury, TREM-2 knock out 
mice exhibited significantly slowed and incomplete mucosal healing. They also found 
that TREM2 promoted efficient wound healing by inhibiting cytokines that can 
enhance M1 macrophage activation. At the same time, the cytokines that can promote 
M2 macrophage activation were also enhanced by TREM-2 in the wound bed 
(Hiroshi et al., 2009). We hypothesise that boosting TREM-2+ macrophages at the 
initial stage of infection may enhance the would healing and reduce the tissue damage 
caused by immunopathology. 
 
In this chapter, we have shown that intranasally applied TREM2+ macrophages prior 
infection reduces influenza induced weight loss and inflammation, despite slightly 
higher viral titers, which suggests that the viral load is not the dormant factor in 
disease severity in this model. This is similar toTLR3-deficient mice (Le Goffic et al., 
2006) and IL-17RA knockout mice with the highly virulent strain A/PR8 influenza 
(Christopher et al., 2009), where delayed viral clearance is also observed with an 
improvement in disease severity. It is worth considering that such a strategy may 
increase the susceptibility for secondary bacterial complication. However, most data 
suggest that reducing cellularity at the beginning of influenza is beneficial with 
reduced collateral damage and abolished bacterial colonisation.  
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6. Discussion 
Knowledge of events leading to excessive immunity to influenza infection is critical 
for the development of alternative treatment since anti-viral or vaccination strategies 
have many limitations. The early host responses against highly pathogenic influenza 
are usually over-activated, causing pulmonary pathology that contributes to the 
severity of disease and incidence of secondary bacterial complications (de Jong et al., 
2006). Therefore the activity of immune cells needs to be regulated to control the 
magnitude and duration of the immune response. Increasing evidence implies that 
complications may occur long after the infection has resolved. Repair of damaged 
lung tissue is necessary, but may impede responses to unrelated microorganism.   
The hypothesis underlying this thesis stems from animal studies which have shown 
that TREM-1 and TREM-2 play vital roles in immune regulation during various 
infections. Although they share the same signalling adaptor, TREM-1 is positive 
regulator of the immune responses, whilst TREM-2 is an inhibitor (Murakami et al., 
2009 and Turnbull IR et al., 2007). It was thus assumed that the dynamic signal ratio 
of TREM-1/TREM-2 may account for early excessive inflammation and drive the 
immunosuppressed state observed in the lung after viral resolution. This discussion 
will focus on where we believe the state of understanding lies based on the results 
presented in the thesis.   
 
6.1. The role of TREM proteins in early innate response 
In steady-state conditions, the respiratory tract is consistently exposed to 
environmental antigens and commensal bacteria. Therefore, the activity of TLR 
responses must be modulated to avoid constant unnecessary inflammation to 
innocuous stimuli. Consistent with this, naïve alveolar macrophages are in a relatively 
quiescent state in the lungs, producing only low levels of inflammatory cytokines and 
have reduced phagocytic activity (Holt et al., 1978). We show that naïve alveolar 
macrophages express low levels of TREM-1 and TREM-2, similarly sTREM-1 is also 
low. As TREM-1 and TREM-2 have opposite effects on TLR signalling, this may 
contribute to the immunosuppressive environment during homeostasis. Once the 
threat exceeds a certain level, the balance of TREM-1/ TREM-2 must be overcome to 
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trigger an immune response. Thus at high inflammatory loads, or once the regulatory 
influence of the epithelium has been lost, TREM-1 is upregulated and overcomes 
regulation by TREM-2.   
 
This idea is supported by studies into the interaction between the host and commensal 
bacteria in another mucosal environment, the gut. Over 10 
13–14
 resident bacterial 
microorganisms colonize the gut and other mucosal surfaces (Ley et al., 2006); the 
immune system must tolerate this to avoid damaging inflammatory responses. 
Tolerance is achieved by modulation of both the magnitude and duration of TLR 
signalling. For example TLR2 enhances the production of both proinflammatory and 
anti-inflammatory cytokines upon activation. Other regulatory strategies employed in 
mucosal tissue includes high levels of interleukin-10 (IL-10) (Steidler et al., 2000), 
the deubiquitinating enzyme A20 (Boone et al., 2004), CD200 (Snelgrove et al., 
2008), and the IL-33/ST2 pathway (Brint et al., 2004). The inhibitory effect of 
TREM-2 was demonstrated by administration of TREM-2+ macrophages into naïve 
lung which lessens immunopathology to subsequent viral infection, even though viral 
clearance is delayed (Chapter 5). To test whether TREM-2 expression simply reflects 
an association with a regulated environment it will be necessary to administer a 
blocking antibody during the resolution phase of influenza infection.  We have 
acquired this from Professor Bill Seaman, USA but time did not permit analysis for 
this thesis.  If TREM-2 is contributing to the suppressed environment then a blocking 
TREM-2 antibody would prolong inflammation and may even lead to mortality. 
Furthermore, in the future a cleaner way to test whether transferred TREM-2+ 
macrophages dominate during infection of the recipient mice would be to derive them 
from Thy 1.1 mice and transfer them into congenic Thy 1.2 mice. TREM-2 deficient 
macrophages produce excessive cytokines (Hamerman et al., 2006) and 
administration of artificial soluble TREM-1 in inflammatory bowel disease also 
reduces the exacerbated local immune responses (Schenk et al., 2007). Therefore, a 
precise dynamic equilibrium exists between TREM-1, TREM-2 and sTREM-1 that 
are relevant to the initiation of inflammation, controlling the magnitude of the 
immune response and its resolution. We believe this dynamic is influenced by 
epithelial integrity and the inflammatory environment. 
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An interesting question is whether we are born with the TREM dynamic in place or 
that it is acquired through interaction with the environment. This question relates to 
the ‘hygiene hypothesis’, which states that reduced environmental education may lead 
to allergy and/or autoimmunity (Strachan et al., 1989). It is based on the observation 
that people with improved hygiene in their childhood are more likely to develop to 
allergy. In this case, the threshold of immune reactivity is set too low by a lack of 
education leading to inflammation to innocuous or self antigens that are usually 
ignored (Okada et al., 2010).  
 
The evidence supporting this comes from germ-free mice, which have an uneducated 
mucosal immune system. In these mice, the gene-expression profile of intestinal 
epithelial cells are changed and the number of IgA-producing plasma cells and lamina 
propria CD4+ T cells are reduced (Hooper et al., 2001; Macpherson et al., 2001 and 
2003). This immature immune system is ‘educated’ after several weeks of colonizing 
germ-free animals with commensal bacteria, a normal event in neonates within days 
of birth (Mackie et al., 1999). This education process continues throughout lifetime; 
prior exposure to influenza virus infection protects mice from subsequent airway 
hyperresponsiveness (Marsland et al., 2004) and pathology due to RSV infection 
(Walzl et al., 2000). The expression of TREM-1/2 and sTREM-1 is likely to be 
involved in adjusting the threshold of immune reactivity in mucosal sites and would 
be interesting to study in neonatal and germ free mice. 
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6.2. The role of TREM proteins in acute inflammation  
Once the threshold of activation is achieved either due to high pathogen load, loss of 
integrity of epithelium, positive regulators of TLRs, such as TREM-1, ensure 
sufficient signalling to produce inflammatory cytokines and chemokines. However, 
this may be excessive in the case of highly virulent infections. Enhanced expression 
of TREM-1 is evident in many infectious models including Streptococcus 
pneumoniae infection in mice (Lagler et al., 2009) where they show that treatment 
with an anti-TREM-1 agonist antibody resulted in sufficient bacterial elimination, 
accelerated resolution of inflammation and reduced morbidity rates. We also observed 
reduced cytokine production after blocking TREM-1 in a similar infectious model, 
without significant detrimental effect. This may suggest that in a bacterial alone 
infection, TREM-1 engagement is facilitative but not essential for bacterial clearance.  
 
During viral infection we observed delayed viral clearance but a reduced risk of 
subsequent bacterial complications in mice where TREM-1 was blocked by the 
sTREM-1 mimic peptide, LP17. This effect may be associated with neutrophils, 
which express high levels of TREM-1 and an overexuberant neutrophil response may 
Figure. 6.1. The proposed mode of TREM-1/2 and sTREM-1 is regulating immune 
activation  
The ratio of activator (TREM-1) and inhibitor (sTREM-1 and TREM-2) is used to regulate 
TLRs in different conditions. At homeostasis, this ratio represses TLRs to avoid 
inflammation to commencal bacteria. Once infectious pathogens appear, activators will be 
upregulated to overcome negative regulators to activate immune responses. After infection, 
inflammation must resolve and this may contribute susceptibility to secondary infection.  
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contribute to lung injury in influenza infection (Egan et al., 2008). TREM-1 activation 
in neutrophils results in augmented TLR responses, including production of 
inflammatory mediators such as IL-8, MCP-1 and myeloperoxidase, degranulation, 
phagocytosis and the oxidative burst (El Mezayen et al., 2007). We show that 
administration of LP17 during influenza infection inhibits production of pro-
inflammatory cytokines and improves the outcome of a secondary bacterial 
complication. Prior influenza induces epithelial cell loss and excessive neutrophil 
responses contribute to uncontrolled spread of bacteria and the cytokine storm. LP17 
reduced these effect to improve the tissue damage and the requirement for extensive 
repair, both process usually contribute to bacterial colorization and invasion. Our 
findings are consistent with LP17 treatment in a rat model of Pseudomonas 
aeruginosa pneumonia, where reduced lung damage and improved survival is also 
observed (Gibot et al., 2006). We have only examined one influenza viral strain 
(x31). It would be interesting to examine TREM-1, TREM-2 and sTREM-1 in a more 
pathogenic infection such as the A/PR8, H1N1 stain and compare it role in a less 
cytopathic viral infection such as RSV.  
 
6.2. The mechanism of sTREM-1 production and its diagnostic 
value 
We are the first to identify elevated levels of sTREM-1 during influenza infection 
alone and viral-bacterial co-infection in chapter 4. The performance of sTREM-1 as 
an indicator of bacterial infection still needs to be further validated. However, only 
low levels of sTREM-1 were present in viral infection. In order for sTREM-1 to 
provide clinically relevant information, studies should examine sTREM-1 in patients 
with defined bacteria and viral infection alone to see if different ranges of sTREM-1 
levels correlate in each case. It is possible that combined measurements of sTREM-1, 
TREM-3 or TREM-6 provide better diagnostic value than each marker alone (Kofoed 
et al., 2007) and these other TREM family members should be examined in our 
models. Eventually it may be possible to design a panel of markers which hold great 
promise in clinical practice. Beyond the use of sTREM-1 as a diagnostic marker, the 
determination of its concentration is being investigated as a prognostic indicator for 
the outcome of a sepsis (Gibot et al., 2005) 
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It is presumed that sTREM-1 competes with the membrane bound form for its ligand, 
limiting TREM-1 amplified cytokine production. The two hypothesised mechanism of 
sTREM-1 production is debated. sTREM-1 is either synthesised directly from a 
mRNA splice variant or by proteolytic cleavage of the membrane bound form 
(Klesney-Tait et al., 2006). Our data support the latter theory, as treatment with 
MMP-9 enhanced the production of sTREM-1. To investigate further, we could 
measure sTREM-1 production in MMP-9 knockout mice or mice treated with a 
MMP-9 inhibitor. If MMP-9 is solely responsible for cleaving the TREM-1 molecule, 
the secretion of sTREM-1 would be completely abolished. However, proteolytic 
cleavage may be mediated by additional proteases such as epitheliasin and human 
airway trypsin-like protease, activities of which are highly elevated in influenza 
infection (Bahgat et al., 2011). Furthermore, it would be interesting to examine the 
release of sTREM in a less inflammatory environment such as during RSV infection, 
house dust mite-induced allergy or influenza infected mice treated with immune 
modulators. 
 
6.3. Macrophages regulate the resolution of influenza 
infection  
Once the virus is cleared, activated macrophages need to be switched off to avoid 
unnecessary tissue damage and to reset immune homeostasis in the airway (Taut et 
al., 2008). The inhibitory effect of TREM-2 on TLR responses of macrophages is well 
known and we observed a post-flu upregulation of TREM-2 on macrophages. These 
cells exhibited an immunosuppressive phenotype and inhibited proinflammatory 
cytokine production of classically activated (M1) macrophages when co-cultured 
together. The regulatory mechanism of TREM-2+ macrophages is still unknown but it 
may be associated with the elevated expression of negative regulators such as Tollip, 
IRAK-M, A20 and CD200R. These negative regulators dampen the production of 
proinflammatory cytokines, which is detrimental to the host at resolution. To test if 
the expression of TREM-2 is essential for inflammatory resolution after influenza, we 
have instigated a collaboration to provide TREM-2 blocking antibody. This antibody 
would be administrated one day after peak weight loss and the phenotype of 
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macrophages and their cytokine levels in the lung would be assayed. If inflammation 
continues, this would indicate that TREM-2 signalling is crucial to terminate 
inflammation. An alternative approach would be to investigate if TREM-2 knockout 
mice fail to resolve inflammation.  
 
Another important task post infection is to repair tissue damage, which is also linked 
to TREM-2. Activation of TREM-2 enhance phagocytosis of apoptotic neurons with 
reduced transcription of inflammatory genes including TNF-α, IL-1 and nitric oxide 
synthase- 2 (Takahashi et al., 2005). Furthermore, TREM-2 deficient mice exhibit 
slower and incomplete mucosal healing post injury and the underling mechanism may 
be a TREM-2 promotion of alternatively activated macrophages (Hiroshi et al., 2008). 
In our study, TREM-2+ macrophages contained higher levels of Ym-1 and Relm-α 
and therefore may fulfil the same function. Taken together, TREM-2 may participate 
in tissue repair by both clearance of apoptotic cells and the activation of the healing 
process.  
 
One important question is what upregulates TREM-2 at the later stage of infection to 
limit TLR signalling and assist in lung repair? In chapter 5, we show that IL-4 
induced the expression of TREM-2 on macrophages. In addition, we also show 
elevated co-expression of TREM-2 and the IL-4 receptor on macrophages and 
increased levels of IL-4 in the BAL fluid from mice in resolution. Taken together, 
these observations suggest that IL-4 may regulate the expression of TREM-2 during 
influenza.  The source of IL-4 may come from epithelial damage, which is reported to 
cause IL-4 production (Sandra et al., 2002). M2 macrophages themselves can also 
produce IL-4 and may upregulate TREM-2 in a positive autocrine manner. Future 
studies will be required to test this hypothesis. One approach would be to treat mice 
with IL-4 blocking antibody after viral clearance, which is day 6 or 7 post infection, 
and examine TREM-2 expression, TLR responses and susceptibility to bacterial 
invasion. IL-4 knockout mice would probably harbour developmental defects and 
experience greater inflammation to influenza infection, thus would confound any 
observation on TREM-2. 
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Another important issue is the source of TREM-2+ macrophages. These cells may 
represent a distinct cell subset or an alteration of TREM-1+ macrophage by the local 
environment. We observed that macrophage numbers return to pre-infection levels 
during resolution, which supports the latter theory. To confirm that original alveolar 
macrophages persist once highly inflammatory infiltrating macrophage have been 
cleared to instigate tissue repair, a fluorescence dye would be used to label naive 
airway macrophages. The intranasal administration of this dye would allow us to track 
the movement and phenotype of these macrophages. 
  
The regulatory effect of TREM-2+ macrophages was clearly evident by transferring 
them into naive mice prior to influenza infection, which reduced weight loss, 
inflammation and accelerated resolution of inflammation. Despite delayed viral 
clearance, we anticipate that this would also reduce susceptibility to secondary 
bacterial super-infection due to reduced bystander tissue damage. This is an exciting 
finding and the mechanism of TREM-2+ macrophage suppression will be investigated 
further to determine whether it is contact dependent or via soluble factors. 
 
6.4. Concluing remarks  
The data presented herein are the first to characterize TREM-1, TREM-2 and 
sTREM-1 expression and function in influenza infection. The TREM-1 blocking 
reagent, LP17 may provide the means to dampen excessive inflammation even after 
peak viral responses. This would reduce the longevity of TLR signalling and may also 
provide a signal for TREM-2 macrophage development.  
 
 Important concepts  Remaining Questions 
1 sTREM-1 limits inflammation 
and is cleaved by MMP-9 
Do other lung proteases cleave TREM-1? 
Do MMP inhibitors block sTREM release? 
2 The balance of TREM-1/2 and 
sTREM-1 is set by environment 
Does this balance require development after 
birth? (neonatal mice and germ-free mice) 
3 sTREM-1 is released following 
significant respiratory disease 
Does the release of sTREM-1 occur in less 
pathogenic infections? 
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4 IL-4 induces the expression of 
TREM-2 
Do other Th2 cytokines (IL-33, IL-13) also 
cause upregulation of TREM-2? Is TREM-2 
dominant in allergic conditions? 
5 TREM-2+ macrophages regulate 
TREM-2- macrophages 
Is this contact dependent or via soluble 
factors? Do TREM-2+ macrophage affect T 
cell differentiation? 
6 sTREM-1 production is lower in 
viral infection than bacterial 
infection 
Can we determine a profile of TREM 
proteins that define viral, bacterial or co-
infection  
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